Kaare, A.
2188 - Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT
4942 - Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party
4942 - Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party
Kaatz, S.
Kabage, A.
Kaban, K.
Kabatabaazi, M.
Kabbani, L. E.
Kabir, S.
Kabir, S.
655 - Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
3179 - Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
3179 - Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
Kabiri, A.
Kabumoto, Y.
Kaçar, D.
Kachhwaha, A.
Kaczmarek, R.
Kaczmarski, R.
Kaczorowski, D.
Kadauke, S.
Kaddi, C.
128 - Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A and B on Fitusiran Antithrombin-Based Dosing Regimen: ATLAS-OLE
2590 - Mechanistic Modeling to Support Hemostatic Equivalency of Antithrombin Lowering in People with Hemophilia A or B
2590 - Mechanistic Modeling to Support Hemostatic Equivalency of Antithrombin Lowering in People with Hemophilia A or B
Kaddis, N. E.
Kaddoura, M.
249 - Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
932 - Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab
1607 - Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy
2389 - Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
932 - Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab
1607 - Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy
2389 - Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis
Kaddoura, M.
Kaddu-Mulindwa, D.
Kadel, S. K.
Kadia, T. M.
56 - Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
216 - Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML
219 - A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update
220 - Long-Term Survival Outcomes and Cytogenetic/Molecular Patterns of Relapse in Adults with FLT3-Mutated AML Receiving Frontline Triplet Therapy with a Hypomethylating Agent, Venetoclax and FLT3 Inhibitor
446 - Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine
642 - Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1-Mutated Myeloid Malignancies
728 - Older Age and TP53 Mutations Are Predictors for the Development of Therapy-Related Myeloid Neoplasms in Adults Undergoing Frontline Therapy for Acute Lymphoblastic Leukemia
734 - A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
735 - Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse
837 - Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse
841 - Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3-Tyrosine Kinase Domain (TKD) Mutations
999 - A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib
1007 - Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML
1011 - Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
1349 - ASXL1 Mutations in AML Are Associated with a Distinct Epigenetic State Which Highlights Vulnerabilities to Specific Epigenetic-Targeted Agents
1373 - Identifying ‘Druggable’ Targets and Preclinically Overcoming Non-Genetic/Adaptive Resistance to Menin Inhibitors in AML with MLL1r or mtNPM1
1427 - Evaluating the Safety of Tyrosine Kinase Inhibitor Discontinuation in Adult Patients with Ph+ ALL Not Undergoing Allogeneic Transplant
1439 - Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
1441 - Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update
1442 - Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia
1461 - Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens
1465 - Clearance of Very Low Levels of Measurable Residual Disease with Blinatumomab Significantly Improves Outcomes in B-Cell Acute Lymphoblastic Leukemia
1472 - Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax
1511 - Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia
1513 - Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up
1572 - Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy
1800 - Adolescents and Young Adults (AYA) with Myeloproliferative Neoplasms (MPNs): Analysis of Patient Outcomes and Impact of High-Molecular Risk Mutations
1816 - Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
2124 - Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial
2191 - Primary Induction Failure Acute Myeloid Leukemia: Immediate Use of Allogeneic Stem Cell Transplantation Vs. Further Induction Chemotherapy
2438 - Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds
2811 - Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed/Refractory B-Cell ALL
2851 - Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease
2853 - Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML
2857 - Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT-Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic Mastocytosis
2861 - Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission
2877 - Phase 2a Study of SLS009, a Highly Selective CDK9 Inhibitor, in Combination with Azacitidine and Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia after Prior Venetoclax Treatment
2883 - Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials
2896 - Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy
2901 - A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
2903 - Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
2912 - Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker
2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
3142 - Evaluation of the Lethal Activity and Its Mechanism of Tasquinimod in Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase
3204 - Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia
3209 - Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML
3212 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome
3572 - Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax
3817 - Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods
4194 - Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update
4207 - Combination Therapy with Nelarabine, Peg-Asparaginase and Venetoclax for Adults Patients with Relapsed/Refractory T-Cell ALL
4251 - Outcomes of Patients with Treated Secondary AML: A High Risk Subtype of AML Arising from Previously Treated Myeloid Neoplasms That Warrants an Independent Prognostic Designation
4262 - Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
4271 - Interim Results of the Phase II Study Investigating CPX-351 in Combination with Ivosidenib for Patients with IDH1-Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
4272 - Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
4277 - Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission
4293 - Patterns of Relapse Following Venetoclax-Based Therapies of Differing Intensity in Acute Myeloid Leukemia
4306 - Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy
4336 - Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1-mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease
4373 - Generation of a Patient Derived T-Cell Prolymphocytic Leukemia Xenograft Model to Evaluate Pre-Clinical Treatment with Small Molecule Inhibitors In Vivo
4584 - Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis
4601 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
1527.2 - Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation
4265.5 - A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML
4288.1 - A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Trial in Progress
- Medical Educators in Hematology
216 - Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML
219 - A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update
220 - Long-Term Survival Outcomes and Cytogenetic/Molecular Patterns of Relapse in Adults with FLT3-Mutated AML Receiving Frontline Triplet Therapy with a Hypomethylating Agent, Venetoclax and FLT3 Inhibitor
446 - Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine
642 - Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1-Mutated Myeloid Malignancies
728 - Older Age and TP53 Mutations Are Predictors for the Development of Therapy-Related Myeloid Neoplasms in Adults Undergoing Frontline Therapy for Acute Lymphoblastic Leukemia
734 - A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
735 - Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse
837 - Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse
841 - Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3-Tyrosine Kinase Domain (TKD) Mutations
999 - A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib
1007 - Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML
1011 - Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
1349 - ASXL1 Mutations in AML Are Associated with a Distinct Epigenetic State Which Highlights Vulnerabilities to Specific Epigenetic-Targeted Agents
1373 - Identifying ‘Druggable’ Targets and Preclinically Overcoming Non-Genetic/Adaptive Resistance to Menin Inhibitors in AML with MLL1r or mtNPM1
1427 - Evaluating the Safety of Tyrosine Kinase Inhibitor Discontinuation in Adult Patients with Ph+ ALL Not Undergoing Allogeneic Transplant
1439 - Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
1441 - Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update
1442 - Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia
1461 - Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens
1465 - Clearance of Very Low Levels of Measurable Residual Disease with Blinatumomab Significantly Improves Outcomes in B-Cell Acute Lymphoblastic Leukemia
1472 - Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax
1511 - Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia
1513 - Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up
1572 - Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy
1800 - Adolescents and Young Adults (AYA) with Myeloproliferative Neoplasms (MPNs): Analysis of Patient Outcomes and Impact of High-Molecular Risk Mutations
1816 - Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
2124 - Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial
2191 - Primary Induction Failure Acute Myeloid Leukemia: Immediate Use of Allogeneic Stem Cell Transplantation Vs. Further Induction Chemotherapy
2438 - Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds
2811 - Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed/Refractory B-Cell ALL
2851 - Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease
2853 - Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML
2857 - Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT-Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic Mastocytosis
2861 - Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission
2877 - Phase 2a Study of SLS009, a Highly Selective CDK9 Inhibitor, in Combination with Azacitidine and Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia after Prior Venetoclax Treatment
2883 - Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials
2896 - Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy
2901 - A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
2903 - Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
2912 - Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker
2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
3142 - Evaluation of the Lethal Activity and Its Mechanism of Tasquinimod in Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase
3204 - Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia
3209 - Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML
3212 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome
3572 - Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax
3817 - Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods
4194 - Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update
4207 - Combination Therapy with Nelarabine, Peg-Asparaginase and Venetoclax for Adults Patients with Relapsed/Refractory T-Cell ALL
4251 - Outcomes of Patients with Treated Secondary AML: A High Risk Subtype of AML Arising from Previously Treated Myeloid Neoplasms That Warrants an Independent Prognostic Designation
4262 - Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
4271 - Interim Results of the Phase II Study Investigating CPX-351 in Combination with Ivosidenib for Patients with IDH1-Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
4272 - Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
4277 - Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission
4293 - Patterns of Relapse Following Venetoclax-Based Therapies of Differing Intensity in Acute Myeloid Leukemia
4306 - Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy
4336 - Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1-mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease
4373 - Generation of a Patient Derived T-Cell Prolymphocytic Leukemia Xenograft Model to Evaluate Pre-Clinical Treatment with Small Molecule Inhibitors In Vivo
4584 - Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis
4601 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
1527.2 - Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation
4265.5 - A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML
4288.1 - A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Trial in Progress
- Medical Educators in Hematology
Kadir, B.
Kadkhoda, H.
2445 - Educational Impact of Live and Online Enduring CME Activities Presented at the 65th ASH Annual Meeting on Hematology/Oncology Specialists Evaluated Using Pre-/Post-Education Assessments
2446 - The Effects of an Online Curriculum Based Approach to CME on Hematologist/Oncologists’ Ability to Treat Patients with BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
2446 - The Effects of an Online Curriculum Based Approach to CME on Hematologist/Oncologists’ Ability to Treat Patients with BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
Kadosh, S.
Kadowaki, N.
Kaduluri, V. P. S.
Kaedbey, R.
1021 - Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies
2291 - Using the Serious Illness Conversation Guide (SICG) in Patients with Hematological Malignancies As a Tool to Address Their Perspectives on Palliative Care
3670 - The Serious Illness Conversation Guide Is Meaningful to Patients with Hematologic Malignancies and Impacts Death in Acute Care
2291 - Using the Serious Illness Conversation Guide (SICG) in Patients with Hematological Malignancies As a Tool to Address Their Perspectives on Palliative Care
3670 - The Serious Illness Conversation Guide Is Meaningful to Patients with Hematologic Malignancies and Impacts Death in Acute Care
Kaeding, A. J.
922 - Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)
2069 - BMS-986393, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1–3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results
2069 - BMS-986393, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1–3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results
Kaempf, A.
62 - Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML
1498 - Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients
1566 - Combination with Palbociclib Overcomes Venetoclax Resistance Mechanisms and Outperforms Single Agent Efficacy in Acute Myeloid Leukemia
2859 - NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia
4314 - Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML
1498 - Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients
1566 - Combination with Palbociclib Overcomes Venetoclax Resistance Mechanisms and Outperforms Single Agent Efficacy in Acute Myeloid Leukemia
2859 - NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia
4314 - Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML
Kaestner, L.
Kagawa, K.
Kageyama, K.
2189 - Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL
3485 - What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes
3508 - Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation
4920 - Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status
4933 - Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms
3485 - What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes
3508 - Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation
4920 - Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status
4933 - Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms
Kahl, B.
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
3736 - Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
1718.1 - SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)
3736 - Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
1718.1 - SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)
Kahl, B. S.
110 - Representation of Minorities in Therapeutic Clinical Trials – a 15-Year Review of Lymphoma Cooperative Group Studies (Alliance A152123)
224 - Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial
236 - Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181
570 - Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma
985 - Phase I Results of Acalabrutinib in Combination with Durvalumab in Primary Central Nervous System Lymphoma: Safety, Efficacy, and Central Nervous System Penetration
1652 - Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
2974 - The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study
3007 - Frontline R-CHOP and BR Have Similar Outcomes By SUVmax in Follicular Lymphoma
3093 - Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study
3249 - Sustained Superiority of Zanubrutinib vs Bendamustine + Rituximab in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN CLL): 5-Year Follow-Up of Cohort 1 from the SEQUOIA Study
3754 - Real-World Predictors of Financial Toxicity in Patients with Lymphoma
4387 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up
4409 - Long-Term Follow-up of Bendamustine/Rituximab – Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)
4414 - Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma
4427 - Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)
1661.3 - Trial in Progress – Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma
224 - Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial
236 - Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181
570 - Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma
985 - Phase I Results of Acalabrutinib in Combination with Durvalumab in Primary Central Nervous System Lymphoma: Safety, Efficacy, and Central Nervous System Penetration
1652 - Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
2974 - The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study
3007 - Frontline R-CHOP and BR Have Similar Outcomes By SUVmax in Follicular Lymphoma
3093 - Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study
3249 - Sustained Superiority of Zanubrutinib vs Bendamustine + Rituximab in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN CLL): 5-Year Follow-Up of Cohort 1 from the SEQUOIA Study
3754 - Real-World Predictors of Financial Toxicity in Patients with Lymphoma
4387 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up
4409 - Long-Term Follow-up of Bendamustine/Rituximab – Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)
4414 - Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma
4427 - Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)
1661.3 - Trial in Progress – Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma
Kahn, J. E.
Kahn, J. M.
307 - Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001
311 - Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001
3649 - Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001
3750 - Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies
5042 - Association between Food Insecurity, Financial Toxicity, and Healthcare Utilization in Patients with Lymphoma
5183 - Clinical Presentation and Induction Outcomes Among Hispanic and Non-Hispanic Patients with Acute Promyelocytic Leukemia
311 - Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001
3649 - Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001
3750 - Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies
5042 - Association between Food Insecurity, Financial Toxicity, and Healthcare Utilization in Patients with Lymphoma
5183 - Clinical Presentation and Induction Outcomes Among Hispanic and Non-Hispanic Patients with Acute Promyelocytic Leukemia
Kahn, M.
Kai, G.
Kaicker, S.
709 - Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
1186 - Variation in Diagnostic Evaluation Patterns for Pediatric Evans Syndrome: Survey Results from the Pediatric ITP Consortium of North America (ICON)
1186 - Variation in Diagnostic Evaluation Patterns for Pediatric Evans Syndrome: Survey Results from the Pediatric ITP Consortium of North America (ICON)
Kaila, S.
Kaila, S.
2280 - Life Years Gained from the FDA Accelerated Approval Program in Hematology: A Portfolio Model
2381 - Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma Retreated with Daratumumab in Real-World Clinical Practice in the USA
2395 - Frontline Treatment Patterns in Patients with Newly Diagnosed Multiple Myeloma - Real-World Evidence from a Large Community-Based Oncology Practice Network in the US
3760 - Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study
5157 - Patient Characteristics, Treatment Patterns and Early Outcomes of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Initiated on Talquetamab: An Electronic Medical Record and Chart Review Study
2381 - Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma Retreated with Daratumumab in Real-World Clinical Practice in the USA
2395 - Frontline Treatment Patterns in Patients with Newly Diagnosed Multiple Myeloma - Real-World Evidence from a Large Community-Based Oncology Practice Network in the US
3760 - Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study
5157 - Patient Characteristics, Treatment Patterns and Early Outcomes of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Initiated on Talquetamab: An Electronic Medical Record and Chart Review Study
Kaimal, V.
Kain, B. N.
Kainat, S.
Kairalla, J. A.
1 - Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731
315 - Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children’s Oncology Group (COG) Protocols
2797 - Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
2813 - Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
4195 - Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131
315 - Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children’s Oncology Group (COG) Protocols
2797 - Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
2813 - Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
4195 - Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131
Kaiser, L.
859 - Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First – Line Treatment for Waldenström’s Macroglobulinemia: Results of the Multicenter Phase II trial (ECWM-2) of the European Consortium for Waldenström’s Macroglobulinemia
4352 - Determining the Mutational Landscape of Waldenström’s Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström’s Macroglobulinemia
4352 - Determining the Mutational Landscape of Waldenström’s Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström’s Macroglobulinemia
Kaiser, M. F.
385 - Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma – an Economic Evaluation of the Fitness Trial
673 - IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial
771 - Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients
898 - Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients
1909 - A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data
1984 - Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial
1987 - Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients – Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial
2061 - Polb 001, an Oral p38 MAPK Inhibitor, Reduces Cytokine Release Syndrome (CRS) in a Mouse Model of Immunotherapy-Induced CRS
2226 - Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform
3333 - Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
3354 - Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome – Long-Term Follow-up of the Ukmra Optimum/Muknine Trial
3375 - MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation
3659 - Global Access to Chimeric Antigen Receptor (CAR) T-Cell Therapies: Health Technology Assessment (HTA) of CAR T in G7 Countries and Australia
3788 - Frontiers in Myeloma: Barriers to Clinical Trial Participation in Multiple Myeloma
3792b - Evaluating Barriers to Enrolment into Multiple Myeloma (MM) Clinical Trials: Results from Health Care Professionals and Patient Survey from the UK Myeloma Research Alliance Equity, Diversity and Inclusivity (EDI) Working Group
3792f - Venetoclax in Patients with Multiple Myeloma with or without t(11;14): A Real-World Analysis
673 - IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial
771 - Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients
898 - Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients
1909 - A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data
1984 - Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial
1987 - Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients – Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial
2061 - Polb 001, an Oral p38 MAPK Inhibitor, Reduces Cytokine Release Syndrome (CRS) in a Mouse Model of Immunotherapy-Induced CRS
2226 - Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform
3333 - Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
3354 - Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome – Long-Term Follow-up of the Ukmra Optimum/Muknine Trial
3375 - MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation
3659 - Global Access to Chimeric Antigen Receptor (CAR) T-Cell Therapies: Health Technology Assessment (HTA) of CAR T in G7 Countries and Australia
3788 - Frontiers in Myeloma: Barriers to Clinical Trial Participation in Multiple Myeloma
3792b - Evaluating Barriers to Enrolment into Multiple Myeloma (MM) Clinical Trials: Results from Health Care Professionals and Patient Survey from the UK Myeloma Research Alliance Equity, Diversity and Inclusivity (EDI) Working Group
3792f - Venetoclax in Patients with Multiple Myeloma with or without t(11;14): A Real-World Analysis
Kaiser, R.
Kaisermann, M. C.
497 - Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis
1974 - Population Pharmacokinetics and Exposure-Response Analyses for Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma from Dreamm-9
1974 - Population Pharmacokinetics and Exposure-Response Analyses for Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma from Dreamm-9
Kaito, S.
Kajdic, A.
Kajdic Hodzic, R.
Kaji, D.
741 - Spatially Resolved Single-Cell Transcriptomics of T Cells in Follicular Lymphoma Reveals Distinct Immune Ecosystems
2162 - Novel Insights into Predictors, Optimized Treatments, and Prognosis Factors for Virus-Induced Hemorrhagic Cystitis Post-Hematopoietic Stem Cell Transplantation: A Single-Institution Study of 427 Japanese Patients
2189 - Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL
3485 - What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes
3508 - Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation
4920 - Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status
4926 - Single Cord Blood Transplantation with Fludarabine, Busulfan and Melphalan Is Crucial Therapeutic Strategy for AML Not in Remission: A Single-Center Retrospective Study of 286 Patients Including Prognostic Factor Analysis
4933 - Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms
2162 - Novel Insights into Predictors, Optimized Treatments, and Prognosis Factors for Virus-Induced Hemorrhagic Cystitis Post-Hematopoietic Stem Cell Transplantation: A Single-Institution Study of 427 Japanese Patients
2189 - Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL
3485 - What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes
3508 - Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation
4920 - Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status
4926 - Single Cord Blood Transplantation with Fludarabine, Busulfan and Melphalan Is Crucial Therapeutic Strategy for AML Not in Remission: A Single-Center Retrospective Study of 286 Patients Including Prognostic Factor Analysis
4933 - Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms
Kajigaya, S.
Kakadia, P. M.
Kakalou, C.
Kakiuchi, N.
Kako, S.
2166 - Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma with Stable or Progressive Disease
3541 - Treatment Outcomes of Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed after Allogeneic Stem Cell Transplant in the Era of Novel Immunochemotherapeutic Agents
4472 - Trends and Outcomes of Hematopoietic Stem Cell Transplantation for Malignant Lymphoma in Japan between 2006 and 2021
4870 - Appropriate Threshold of Quantitative Cytomegalovirus DNA Polymerase Chain Reaction for Preemptive Treatment in Stem Cell Transplant Recipients
3541 - Treatment Outcomes of Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed after Allogeneic Stem Cell Transplant in the Era of Novel Immunochemotherapeutic Agents
4472 - Trends and Outcomes of Hematopoietic Stem Cell Transplantation for Malignant Lymphoma in Japan between 2006 and 2021
4870 - Appropriate Threshold of Quantitative Cytomegalovirus DNA Polymerase Chain Reaction for Preemptive Treatment in Stem Cell Transplant Recipients
Kal, N.
Kalafati, E.
Kalafut, T.
Kalandadze, V.
Kalantari, K.
Kalantarov, G.
Kalariya, N.
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
Kalashnikova, T.
Kalavros, N.
Kalaycio, M.
1777 - Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study
2145 - Prevalence and Outcomes of Opportunistic Infections in Steroid Refractory Graft Versus Host Disease Patients Treated with Ruxolitinib, Ibrutinib, and Belumosudil
3153 - Impact of Non-ABL1 Mutations on Outcomes in Patients with Chronic Myeloid Leukemia
3488 - Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation
2145 - Prevalence and Outcomes of Opportunistic Infections in Steroid Refractory Graft Versus Host Disease Patients Treated with Ruxolitinib, Ibrutinib, and Belumosudil
3153 - Impact of Non-ABL1 Mutations on Outcomes in Patients with Chronic Myeloid Leukemia
3488 - Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation
Kalayoglu Besisik, S.
Kalb, R.
Kalcheim, L.
Kaldas, D.
3021 - Clinical Characteristics and Outcomes of Patients with MYD88 Positive Waldenström Macroglobulinemia: A Single Center Retrospective Analysis
4392 - Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis
4392 - Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis
Kalds, M. M.
Kalfa, T. A.
163 - Heterogeneity of the Erythromyeloblastic Island (EMBI) Niche during Baseline and Stress Erythropoiesis
1071 - Inducible, Erythroid-Specific Knockout of Codanin-1 in Adult Mice Replicates Congenital Dyserythropoietic Anemia Type-Ia
1084 - Loss of ATG5 in Humans Causes Syndromic Congenital Dyserythropoietic Anemia with Impaired Mitophagy in Late Stages of Terminal Erythropoiesis
2458 - The Dominant Negative Acting VPS4AE228Q Mutation Causes Dyserythropoiesis in Human iPSC-Derived Erythroblast Cultures That Phenocopies Cimdag Syndrome-Associated Anemia
1071 - Inducible, Erythroid-Specific Knockout of Codanin-1 in Adult Mice Replicates Congenital Dyserythropoietic Anemia Type-Ia
1084 - Loss of ATG5 in Humans Causes Syndromic Congenital Dyserythropoietic Anemia with Impaired Mitophagy in Late Stages of Terminal Erythropoiesis
2458 - The Dominant Negative Acting VPS4AE228Q Mutation Causes Dyserythropoiesis in Human iPSC-Derived Erythroblast Cultures That Phenocopies Cimdag Syndrome-Associated Anemia
Kalia, A.
Kalibala, D.
Kalina, T.
Kalish, Y.
Kalkan, F. N.
Kallal, L.
Kallam, A.
472 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
1742.1 - A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
1742.1 - A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Kallemeijn, M.
2373 - Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data
5132 - Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study
5132 - Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study
Kallioniemi, O.
Kallioniemi, O.
Källström, J.
Kalmus, G.
Kalpatthi, R.
Kalra, D.
Kalro, A.
Kalter, J.
Kalwak, Sr., K.
112 - “Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
965 - Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
2182 - Analysis of Outcomes after Second Allogeneic Stem Cell Transplant in Relapsed Acute Myeloid Leukaemia in Children: A Study from the EBMT Pediatric Diseases Working Party
2333 - Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT
3540 - Total Body Irradiation Versus Chemotherapy Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia Patients Aged 2 to 4 Years: A Retrospective Study of the EBMT Pediatric Diseases Working Party
305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
965 - Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
2182 - Analysis of Outcomes after Second Allogeneic Stem Cell Transplant in Relapsed Acute Myeloid Leukaemia in Children: A Study from the EBMT Pediatric Diseases Working Party
2333 - Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT
3540 - Total Body Irradiation Versus Chemotherapy Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia Patients Aged 2 to 4 Years: A Retrospective Study of the EBMT Pediatric Diseases Working Party
Kam, A.
Kamachi, K.
Kamada, Y.
Kamalakar, R.
Kamath, P. S.
Kamble, D.
Kamboj, I.
2411b - Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial
5040 - Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns
5040 - Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns
Kamdar, M.
72 - Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
3125 - Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
3130 - Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up
4387 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up
5097 - Impact of Novel Therapies (NTs) on Real-World (RW) Clinical Outcomes of Patients (pts) with Relapsed/Refractory (RR) Mantle-Cell Lymphoma (MCL) By Race/Ethnicity and TP53 Mutation Status
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
3125 - Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
3130 - Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up
4387 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up
5097 - Impact of Novel Therapies (NTs) on Real-World (RW) Clinical Outcomes of Patients (pts) with Relapsed/Refractory (RR) Mantle-Cell Lymphoma (MCL) By Race/Ethnicity and TP53 Mutation Status
Kamdar, M. K.
238 - Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis
2377 - Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
4510 - Preliminary Safety and Tolerability of CD19x22 CAR-T Cell Therapy in Adolescent and Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
2377 - Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
4510 - Preliminary Safety and Tolerability of CD19x22 CAR-T Cell Therapy in Adolescent and Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Kamden, A.
Kameda, T.
Kamija, M.
Kamijo, K.
Kamil, R.
689 - Characteristics and Risk Factors for BK Virus-Associated Cystitis after Post-Transplant Cyclophosphamide (PTCy) -Based Allogeneic Hematopoietic Cell Transplants (HCT)
2429 - Understanding Barriers to Hematopoietic Cell Transplant (HCT) Access: Socio-Demographic Characteristics and Area Deprivation Index (ADI) of Patients Referred to the National Institutes of Health (NIH) for HCT
2429 - Understanding Barriers to Hematopoietic Cell Transplant (HCT) Access: Socio-Demographic Characteristics and Area Deprivation Index (ADI) of Patients Referred to the National Institutes of Health (NIH) for HCT
Kamili, A.
Kamimura, S.
1113 - Short-Term Fostamatinib Treatment Impacts Hematopoiesis and Downregulates Thromboinflammation in Townes Sickle Mice
2485 - Acquired Mutations in the Mitochondrial Genome As Prognostic Markers in Sickle Cell Disease
2490 - 8-Oxoguanine DNA Glycosylase 1 Recruits Transcription Factor STAT1 to Promote the Inflammatory Responses in Sickle Cell Disease
2485 - Acquired Mutations in the Mitochondrial Genome As Prognostic Markers in Sickle Cell Disease
2490 - 8-Oxoguanine DNA Glycosylase 1 Recruits Transcription Factor STAT1 to Promote the Inflammatory Responses in Sickle Cell Disease
Kaminetzky, D.
Kaminetzsky, D.
Kaminski, T.
Kaminsky, A.
Kamiunten, A.
Kammer, C.
Kammerer, B.
Kampfenkel, T.
493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
495 - Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm‑2 Studies
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
4653 - Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
495 - Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm‑2 Studies
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
4653 - Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
Kampmann, P.
Kamradt, M.
Kamysheva, A.
Kanaan, S. B.
Kanack, A.
Kanade, S.
Kanagal-Shamanna, R.
50 - A Single-Cell T-Cell Reference Map Delineates the Biological Landscape of CD4+ T Cells in Myelodysplastic Syndromes Under Venetoclax Therapy
346 - Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant
1301 - Spatial Analysis of Human p53 Mutated AML Bone Marrow Reveals Novel MRD Clusters and Spatial Microenvironmental Features of p53 Mutated AML
1427 - Evaluating the Safety of Tyrosine Kinase Inhibitor Discontinuation in Adult Patients with Ph+ ALL Not Undergoing Allogeneic Transplant
1820 - Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)
3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma
3204 - Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia
3212 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome
3246 - Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53-Mutated Chronic Lymphocytic Leukemia
4224 - Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory
4584 - Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis
4593 - Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)
4601 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
346 - Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant
1301 - Spatial Analysis of Human p53 Mutated AML Bone Marrow Reveals Novel MRD Clusters and Spatial Microenvironmental Features of p53 Mutated AML
1427 - Evaluating the Safety of Tyrosine Kinase Inhibitor Discontinuation in Adult Patients with Ph+ ALL Not Undergoing Allogeneic Transplant
1820 - Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)
3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma
3204 - Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia
3212 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome
3246 - Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53-Mutated Chronic Lymphocytic Leukemia
4224 - Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory
4584 - Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis
4593 - Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)
4601 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
Kanai, A.
Kanakaveti, V.
Kanakry, C. G.
689 - Characteristics and Risk Factors for BK Virus-Associated Cystitis after Post-Transplant Cyclophosphamide (PTCy) -Based Allogeneic Hematopoietic Cell Transplants (HCT)
1040 - Pharmacokinetic (PK) Exposure of 4-Hydroxycyclophosphamide Associates with Clinical Benefits of Reduced-Dose Post-Transplantation Cyclophosphamide: Results of a Completed Phase I/II Trial to De-Escalate Post-Transplantation Cyclophosphamide for HLA-Haploidentical Myeloablative Bone Marrow Transplantation
2429 - Understanding Barriers to Hematopoietic Cell Transplant (HCT) Access: Socio-Demographic Characteristics and Area Deprivation Index (ADI) of Patients Referred to the National Institutes of Health (NIH) for HCT
1040 - Pharmacokinetic (PK) Exposure of 4-Hydroxycyclophosphamide Associates with Clinical Benefits of Reduced-Dose Post-Transplantation Cyclophosphamide: Results of a Completed Phase I/II Trial to De-Escalate Post-Transplantation Cyclophosphamide for HLA-Haploidentical Myeloablative Bone Marrow Transplantation
2429 - Understanding Barriers to Hematopoietic Cell Transplant (HCT) Access: Socio-Demographic Characteristics and Area Deprivation Index (ADI) of Patients Referred to the National Institutes of Health (NIH) for HCT
Kanakry, J. A.
689 - Characteristics and Risk Factors for BK Virus-Associated Cystitis after Post-Transplant Cyclophosphamide (PTCy) -Based Allogeneic Hematopoietic Cell Transplants (HCT)
1040 - Pharmacokinetic (PK) Exposure of 4-Hydroxycyclophosphamide Associates with Clinical Benefits of Reduced-Dose Post-Transplantation Cyclophosphamide: Results of a Completed Phase I/II Trial to De-Escalate Post-Transplantation Cyclophosphamide for HLA-Haploidentical Myeloablative Bone Marrow Transplantation
2429 - Understanding Barriers to Hematopoietic Cell Transplant (HCT) Access: Socio-Demographic Characteristics and Area Deprivation Index (ADI) of Patients Referred to the National Institutes of Health (NIH) for HCT
1040 - Pharmacokinetic (PK) Exposure of 4-Hydroxycyclophosphamide Associates with Clinical Benefits of Reduced-Dose Post-Transplantation Cyclophosphamide: Results of a Completed Phase I/II Trial to De-Escalate Post-Transplantation Cyclophosphamide for HLA-Haploidentical Myeloablative Bone Marrow Transplantation
2429 - Understanding Barriers to Hematopoietic Cell Transplant (HCT) Access: Socio-Demographic Characteristics and Area Deprivation Index (ADI) of Patients Referred to the National Institutes of Health (NIH) for HCT
Kanakura, Y.
Kanamaru, E.
Kanamori, T.
Kanamu, M. H.
Kanangat, S.
Kanannejad, S.
Kanapari, A.
Kanarfogel, T.
Kanate, A. S.
Kanaujiya, J. K.
Kanbur, Ş. M.
Kancharla, P.
Kanda, J.
384 - Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC
639 - Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling
2121 - Kinetics of Recipients with Thrombocytopenia and Its Impact on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study
2166 - Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma with Stable or Progressive Disease
4472 - Trends and Outcomes of Hematopoietic Stem Cell Transplantation for Malignant Lymphoma in Japan between 2006 and 2021
4548 - Optimal Procedures of Allogeneic Transplantation for BCR::ABL1-Negative Atypical Chronic Myeloid Leukemia
639 - Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling
2121 - Kinetics of Recipients with Thrombocytopenia and Its Impact on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study
2166 - Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma with Stable or Progressive Disease
4472 - Trends and Outcomes of Hematopoietic Stem Cell Transplantation for Malignant Lymphoma in Japan between 2006 and 2021
4548 - Optimal Procedures of Allogeneic Transplantation for BCR::ABL1-Negative Atypical Chronic Myeloid Leukemia
Kanda, Y.
384 - Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC
3203 - Molecular Taxonomy Classification for Transplant Decision Making of Myelodysplastic Syndromes
3541 - Treatment Outcomes of Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed after Allogeneic Stem Cell Transplant in the Era of Novel Immunochemotherapeutic Agents
4472 - Trends and Outcomes of Hematopoietic Stem Cell Transplantation for Malignant Lymphoma in Japan between 2006 and 2021
4870 - Appropriate Threshold of Quantitative Cytomegalovirus DNA Polymerase Chain Reaction for Preemptive Treatment in Stem Cell Transplant Recipients
4925 - The Outcome of Fertility Preservation Strategy in Female Hematopoietic Stem Cell Transplant Recipients of Reproductive Age. Retrospective Study from the Kanto Study Group for Cell Therapy
3203 - Molecular Taxonomy Classification for Transplant Decision Making of Myelodysplastic Syndromes
3541 - Treatment Outcomes of Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed after Allogeneic Stem Cell Transplant in the Era of Novel Immunochemotherapeutic Agents
4472 - Trends and Outcomes of Hematopoietic Stem Cell Transplantation for Malignant Lymphoma in Japan between 2006 and 2021
4870 - Appropriate Threshold of Quantitative Cytomegalovirus DNA Polymerase Chain Reaction for Preemptive Treatment in Stem Cell Transplant Recipients
4925 - The Outcome of Fertility Preservation Strategy in Female Hematopoietic Stem Cell Transplant Recipients of Reproductive Age. Retrospective Study from the Kanto Study Group for Cell Therapy
Kanda, Y.
Kandabarau, S.
Kandarp, J.
Kandarpa, M.
Kandasamy, R. K.
Kandathilparambil Sasi, B.
Kandiah, J.
Kandula, M.
Kane, C.
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
3357 - Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study
4653 - Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
4757.1 - Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1–4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody
3357 - Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study
4653 - Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
4757.1 - Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1–4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody
Kane, M.
Kane, M. J.
Kanefsky, J.
Kanellias, N.
361 - Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study
490 - A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma
1020 - Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
1948 - Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients
1991 - Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group
3361 - Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
4397 - Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom’s Macroglobulinemia Treated with Different Regimens in the Real-World Setting
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
4674 - Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis
4675 - Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging
4715 - Sequential Whole Body Low Dose CTs in Patients with Smoldering Multiple Myeloma Identify Early Progression and May Improve Patient Outcomes
4724 - Early Treatment Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma
490 - A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma
1020 - Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
1948 - Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients
1991 - Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group
3361 - Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
4397 - Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom’s Macroglobulinemia Treated with Different Regimens in the Real-World Setting
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
4674 - Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis
4675 - Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging
4715 - Sequential Whole Body Low Dose CTs in Patients with Smoldering Multiple Myeloma Identify Early Progression and May Improve Patient Outcomes
4724 - Early Treatment Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma
Kanellopoulou, C.
Kanellou, P.
Kanemura, N.
639 - Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling
1332 - A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41-Mutant Myeloid Neoplasia
3030 - Treatment and Outcomes of Stage I-II Pulmonary MALT Lymphoma: A Multi-Institutional Observational Study in Japan
3089 - Real-World Experience of Pola-R-CHP Therapy in Diffuse Large B-Cell Lymphoma Aged 80 or Older
1332 - A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41-Mutant Myeloid Neoplasia
3030 - Treatment and Outcomes of Stage I-II Pulmonary MALT Lymphoma: A Multi-Institutional Observational Study in Japan
3089 - Real-World Experience of Pola-R-CHP Therapy in Diffuse Large B-Cell Lymphoma Aged 80 or Older
Kaner, J. D.
970 - A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) – Topline Results
1576 - Opening Pandora’s Box: Ultra-Deep Duplex Sequencing in Long Survivors with Acute Myeloid Leukemia
2867 - Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia
1576 - Opening Pandora’s Box: Ultra-Deep Duplex Sequencing in Long Survivors with Acute Myeloid Leukemia
2867 - Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia
Kanestrom, G. N.
Kaneunyenye, L.
Kanfer, E.
Kang, A. S.
Kang, C. K.
Kang, G.
803 - Sickle Cell Genotype and Biomarkers of Endothelial Dysfunction Predict Early Kidney Disease in Patients with APOL1 High Risk Variants
1065 - Sickle Cell Disease-Related Worry and Associations with Healthcare Utilization in Youth with Sickle Cell Disease
1129 - Impact of Duffy-Null Phenotype on Neutrophil Counts and Clinical Outcomes in Patients with Sickle Cell Disease and without Hydroxyurea
3688 - Health-Related Communication in Adolescents and Young Adults with Sickle Cell Disease
3886 - The Natural History of Glomerular Hyperfiltration in Sickle Cell Disease
3900 - Low Bone Density Associates with Severe Outcomes in Young Adults with Sickle Cell Disease
5063 - Vaso-Occlusive Crisis in Patients with Sickle Cell Anemia with Elevated Fetal Hemoglobin
1065 - Sickle Cell Disease-Related Worry and Associations with Healthcare Utilization in Youth with Sickle Cell Disease
1129 - Impact of Duffy-Null Phenotype on Neutrophil Counts and Clinical Outcomes in Patients with Sickle Cell Disease and without Hydroxyurea
3688 - Health-Related Communication in Adolescents and Young Adults with Sickle Cell Disease
3886 - The Natural History of Glomerular Hyperfiltration in Sickle Cell Disease
3900 - Low Bone Density Associates with Severe Outcomes in Young Adults with Sickle Cell Disease
5063 - Vaso-Occlusive Crisis in Patients with Sickle Cell Anemia with Elevated Fetal Hemoglobin
Kang, H.
Kang, H.
Kang, H. J.
1636 - Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry
4698 - Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment
4698 - Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment
Kang, H. J.
Kang, H. M.
Kang, H.
Kang, J. R. W.
Kang, K. W.
1636 - Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry
3942 - Impact of Platelet Transfusion and Bleeding Risk Stratification in Patients with Immune Thrombocytopenia before Procedures: A Nationwide Population-Based Cohort Study
3942 - Impact of Platelet Transfusion and Bleeding Risk Stratification in Patients with Immune Thrombocytopenia before Procedures: A Nationwide Population-Based Cohort Study
Kang, L.
495 - Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm‑2 Studies
4753 - Optec: A Phase 2 Study to Evaluate Outpatient Step-up Administration of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results
4753 - Optec: A Phase 2 Study to Evaluate Outpatient Step-up Administration of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results
Kang, L.
683 - Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness
3384 - Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial
3447 - Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)
4197 - Chemotherapy-Free Induction with Venetoclax and Azacitidine, Followed By Tandem CD19/CD22 CAR-T Cell Therapy As First-Line Treatment in Newly Diagnosed High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Prospective, Single-Center, Single-Arm, Phase 2 Trial
4766 - 5-Year Follow-up of Combined Infusion of Anti-CD19 and Anti-BCMA CAR-T after ASCT for High-Risk Newly Diagnosed Multiple Myeloma
4794 - Target Antigen-Expressing T Cells Facilitate CAR-T Cell Eradication of Residual CD19+ B Malignant Cells
4836 - Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial
4840 - Safety and Efficacy of CD22/ CD19 CAR-T and Auto-HSCT “Sandwich”Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia
3384 - Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial
3447 - Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)
4197 - Chemotherapy-Free Induction with Venetoclax and Azacitidine, Followed By Tandem CD19/CD22 CAR-T Cell Therapy As First-Line Treatment in Newly Diagnosed High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Prospective, Single-Center, Single-Arm, Phase 2 Trial
4766 - 5-Year Follow-up of Combined Infusion of Anti-CD19 and Anti-BCMA CAR-T after ASCT for High-Risk Newly Diagnosed Multiple Myeloma
4794 - Target Antigen-Expressing T Cells Facilitate CAR-T Cell Eradication of Residual CD19+ B Malignant Cells
4836 - Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial
4840 - Safety and Efficacy of CD22/ CD19 CAR-T and Auto-HSCT “Sandwich”Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia
Kang, S.
Kang, S.
Kang, T.
Kang, W.
Kang, X.
96 - Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
454 - Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas
565 - Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma
648 - Non-Invasive Characterization and Early Detection of Post-Transplant Lymphoproliferative Disorders
853 - Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling
1157 - Acquired Immunodeficiency Landscapes Via Integrated Noninvasive Viral & Immune Profiling in HIV-Associated Lymphoproliferative Disease
2223 - Direct Method for Estimating the Fraction of T and B/Plasma Cell-Derived DNA
3410 - Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study
454 - Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas
565 - Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma
648 - Non-Invasive Characterization and Early Detection of Post-Transplant Lymphoproliferative Disorders
853 - Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling
1157 - Acquired Immunodeficiency Landscapes Via Integrated Noninvasive Viral & Immune Profiling in HIV-Associated Lymphoproliferative Disease
2223 - Direct Method for Estimating the Fraction of T and B/Plasma Cell-Derived DNA
3410 - Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study
Kang, X.
Kang, Y.
2001 - Characterizing and Risk Stratifying Musculoskeletal Toxicities after BCMA CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
2295 - Understanding Sociodemographic Barriers in Hematopoietic Stem Cell Transplantation Among Patients with Hematologic Malignancies: Insights from a North Carolina Cohort
5044 - Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina
2000.1 - MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial
2295 - Understanding Sociodemographic Barriers in Hematopoietic Stem Cell Transplantation Among Patients with Hematologic Malignancies: Insights from a North Carolina Cohort
5044 - Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina
2000.1 - MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial
Kaniskan, H.
Kankeu Fonkoua, L. A.
Kankeu Fonkoua, L. A.
Kannan, B.
Kannan, K.
Kannan, K. K.
Kannan, K.
Kannan, P.
Kannengiesser, C.
Kanno, H.
Kanodia, J.
Kanold, J.
1592 - Circulating Cell-Free DNA in Classical Hodgkin Lymphoma in Children, Adolescents and Young Adults. Results from the Holy Study, a French Ancillary Study of Euronet PHL-C2 Protocol
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)
Kanoun, S.
Kanouni, T.
Kansu, E.
Kantarcioglu, B.
Kantarjian, H. M.
56 - Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
212 - Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
213 - Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
216 - Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML
219 - A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update
220 - Long-Term Survival Outcomes and Cytogenetic/Molecular Patterns of Relapse in Adults with FLT3-Mutated AML Receiving Frontline Triplet Therapy with a Hypomethylating Agent, Venetoclax and FLT3 Inhibitor
346 - Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant
446 - Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine
642 - Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1-Mutated Myeloid Malignancies
661 - Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials
727 - Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features
728 - Older Age and TP53 Mutations Are Predictors for the Development of Therapy-Related Myeloid Neoplasms in Adults Undergoing Frontline Therapy for Acute Lymphoblastic Leukemia
732 - Dose Optimization of Inotuzumab Ozogamicin in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
734 - A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
837 - Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse
841 - Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3-Tyrosine Kinase Domain (TKD) Mutations
999 - A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib
1007 - Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML
1011 - Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
1427 - Evaluating the Safety of Tyrosine Kinase Inhibitor Discontinuation in Adult Patients with Ph+ ALL Not Undergoing Allogeneic Transplant
1439 - Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
1440 - Single-Agent Subcutaneous Blinatumomab for Advanced B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-up from a Phase 1b Dose Expansion Cohort
1441 - Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update
1442 - Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia
1456 - Age-Related Prognoses of Genetic Subtypes in B-Cell Acute Lymphoblastic Leukemia/Lymphoma (B-ALL): Insights from a Decade of National Data
1461 - Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens
1465 - Clearance of Very Low Levels of Measurable Residual Disease with Blinatumomab Significantly Improves Outcomes in B-Cell Acute Lymphoblastic Leukemia
1472 - Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax
1511 - Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia
1513 - Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up
1572 - Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy
1760 - Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis
1800 - Adolescents and Young Adults (AYA) with Myeloproliferative Neoplasms (MPNs): Analysis of Patient Outcomes and Impact of High-Molecular Risk Mutations
1807 - Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocytopenia and Polycythemia Vera: Final Analysis Focused on the Two Diseases
1816 - Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms
1820 - Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)
1837 - Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies
1842 - Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes
2124 - Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial
2438 - Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds
2811 - Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed/Refractory B-Cell ALL
2821 - Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study
2853 - Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML
2857 - Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT-Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic Mastocytosis
2861 - Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission
2883 - Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials
2896 - Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy
2901 - A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
2912 - Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker
3148 - 5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results
3151 - Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP‑CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses
3156 - A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse
3204 - Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia
3209 - Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML
3246 - Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53-Mutated Chronic Lymphocytic Leukemia
3572 - Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax
3817 - Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods
4194 - Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update
4198 - A Phase I/II Study of Mini-Hyper-CVD, Venetoclax and Navitoclax in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
4219 - Single Cell Profiling of Ph-Positive Acute Lymphoblastic Leukemias Reveals Distinct Cells of Origin
4224 - Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory
4251 - Outcomes of Patients with Treated Secondary AML: A High Risk Subtype of AML Arising from Previously Treated Myeloid Neoplasms That Warrants an Independent Prognostic Designation
4262 - Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
4272 - Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
4277 - Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission
4293 - Patterns of Relapse Following Venetoclax-Based Therapies of Differing Intensity in Acute Myeloid Leukemia
4306 - Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy
4336 - Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1-mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease
4584 - Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis
4593 - Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)
1527.2 - Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation
4265.1 - Phase 2 Multicenter Trial of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
4288.1 - A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Trial in Progress
212 - Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
213 - Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
216 - Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML
219 - A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update
220 - Long-Term Survival Outcomes and Cytogenetic/Molecular Patterns of Relapse in Adults with FLT3-Mutated AML Receiving Frontline Triplet Therapy with a Hypomethylating Agent, Venetoclax and FLT3 Inhibitor
346 - Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant
446 - Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine
642 - Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1-Mutated Myeloid Malignancies
661 - Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials
727 - Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features
728 - Older Age and TP53 Mutations Are Predictors for the Development of Therapy-Related Myeloid Neoplasms in Adults Undergoing Frontline Therapy for Acute Lymphoblastic Leukemia
732 - Dose Optimization of Inotuzumab Ozogamicin in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
734 - A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
837 - Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse
841 - Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3-Tyrosine Kinase Domain (TKD) Mutations
999 - A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib
1007 - Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML
1011 - Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
1427 - Evaluating the Safety of Tyrosine Kinase Inhibitor Discontinuation in Adult Patients with Ph+ ALL Not Undergoing Allogeneic Transplant
1439 - Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
1440 - Single-Agent Subcutaneous Blinatumomab for Advanced B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-up from a Phase 1b Dose Expansion Cohort
1441 - Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update
1442 - Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia
1456 - Age-Related Prognoses of Genetic Subtypes in B-Cell Acute Lymphoblastic Leukemia/Lymphoma (B-ALL): Insights from a Decade of National Data
1461 - Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens
1465 - Clearance of Very Low Levels of Measurable Residual Disease with Blinatumomab Significantly Improves Outcomes in B-Cell Acute Lymphoblastic Leukemia
1472 - Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax
1511 - Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia
1513 - Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up
1572 - Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy
1760 - Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis
1800 - Adolescents and Young Adults (AYA) with Myeloproliferative Neoplasms (MPNs): Analysis of Patient Outcomes and Impact of High-Molecular Risk Mutations
1807 - Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocytopenia and Polycythemia Vera: Final Analysis Focused on the Two Diseases
1816 - Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms
1820 - Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)
1837 - Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies
1842 - Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes
2124 - Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial
2438 - Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds
2811 - Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed/Refractory B-Cell ALL
2821 - Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study
2853 - Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML
2857 - Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT-Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic Mastocytosis
2861 - Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission
2883 - Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials
2896 - Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy
2901 - A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
2912 - Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker
3148 - 5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results
3151 - Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP‑CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses
3156 - A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse
3204 - Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia
3209 - Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML
3246 - Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53-Mutated Chronic Lymphocytic Leukemia
3572 - Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax
3817 - Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods
4194 - Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update
4198 - A Phase I/II Study of Mini-Hyper-CVD, Venetoclax and Navitoclax in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
4219 - Single Cell Profiling of Ph-Positive Acute Lymphoblastic Leukemias Reveals Distinct Cells of Origin
4224 - Genomic Profiling of T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) for Identification of Driver Aberrations Using Combined Next Generation Sequencing and Optical Genome Mapping in Clinical Diagnostic Laboratory
4251 - Outcomes of Patients with Treated Secondary AML: A High Risk Subtype of AML Arising from Previously Treated Myeloid Neoplasms That Warrants an Independent Prognostic Designation
4262 - Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
4272 - Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
4277 - Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission
4293 - Patterns of Relapse Following Venetoclax-Based Therapies of Differing Intensity in Acute Myeloid Leukemia
4306 - Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy
4336 - Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1-mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease
4584 - Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis
4593 - Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)
1527.2 - Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation
4265.1 - Phase 2 Multicenter Trial of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
4288.1 - A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Trial in Progress
Kanter, J.
179 - Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks
180 - Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease Aged 6 to <12 Years: 2-Year Data from the Phase 2 Solace-Kids Study
395 - Identifying Access to Mental Healthcare Services for Pediatric Patients Living with Sickle Cell Disease
511 - An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel
513 - Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises
801 - Evaluating High-Sensitivity Troponin Levels in Patients with Sickle Cell Disease Presenting to the Emergency Department
3576 - Participants with a History of Stroke in Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials
3622 - Establishing a Definition of Transition of Care in Sickle Cell Disease: National Alliance of Sickle Cell Disease Centers Consensus
2100.1 - Motixafortide for Hematopoietic Stem and Progenitor Cell Mobilization and Collection in Sickle Cell Disease
180 - Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease Aged 6 to <12 Years: 2-Year Data from the Phase 2 Solace-Kids Study
395 - Identifying Access to Mental Healthcare Services for Pediatric Patients Living with Sickle Cell Disease
511 - An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel
513 - Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises
801 - Evaluating High-Sensitivity Troponin Levels in Patients with Sickle Cell Disease Presenting to the Emergency Department
3576 - Participants with a History of Stroke in Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials
3622 - Establishing a Definition of Transition of Care in Sickle Cell Disease: National Alliance of Sickle Cell Disease Centers Consensus
2100.1 - Motixafortide for Hematopoietic Stem and Progenitor Cell Mobilization and Collection in Sickle Cell Disease
Kanters, S.
Kanthi, Y.
Kao, G. S. H.
Kao, H. W.
Kao, P. C.
Kao, R.
Kao, W. M.
922 - Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)
2069 - BMS-986393, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1–3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results
2069 - BMS-986393, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1–3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results
Kapadia, A. D.
Kapadia, C.
Kapahnke, K.
Kaparis, S.
Kapetanakis, V.
Kaphan, E.
Kaplan, J.
Kaplan, J.
4187 - Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Study
2828.1 - Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)
2828.1 - Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)
Kaplan, M.
579 - Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL)
740 - A Single Cell Atlas of Follicular Lymphoma across Clinical Stages Defines Tumor B Cell Archetypes, Immune Microenvironment Heterogeneity and Novel Cell States Associated with High-Risk FL
1597 - Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response
1617 - Golcadomide Extends Survival of Lymphoma GEMM Mice in Combination with a CD20xCD3 T-Cell Bispecific through Increased T-Cell Activation and Infiltration
740 - A Single Cell Atlas of Follicular Lymphoma across Clinical Stages Defines Tumor B Cell Archetypes, Immune Microenvironment Heterogeneity and Novel Cell States Associated with High-Risk FL
1597 - Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response
1617 - Golcadomide Extends Survival of Lymphoma GEMM Mice in Combination with a CD20xCD3 T-Cell Bispecific through Increased T-Cell Activation and Infiltration
Kaplan, M.
Kaplan, N.
Kaplanov, K.
Kaplinsky, P.
Kapoor, E.
Kapoor, N.
Kapoor, P.
83 - Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma
931 - Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
1945 - Development of a Three-Gene-Based Proliferation Score (3GPS) to Predict Proliferation Index in Newly Diagnosed Multiple Myeloma
1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
1992 - First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma
2372 - Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy
2400 - Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
3308 - Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients
3368 - Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium
3378 - Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)
4695 - Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma
4716 - Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
5047 - Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)
931 - Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
1945 - Development of a Three-Gene-Based Proliferation Score (3GPS) to Predict Proliferation Index in Newly Diagnosed Multiple Myeloma
1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
1992 - First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma
2372 - Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy
2400 - Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
3308 - Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients
3368 - Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium
3378 - Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)
4695 - Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma
4716 - Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
5047 - Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)
Kapoor, R.
Kapoor, S.
Kapoor, S.
Kaporskaya, T.
Kapp-Schwoerer, S.
Kappes, D.
Kappes, K.
2231 - Novel Liquid Biopsy Approach for Detection and Characterization of Disease Progression of Plasma Cell Disorders
4654 - Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients
4691 - Monovalent XBB1.5 Vaccination Augments Humoral and Cellular Immunity to Novel Sars-Cov-2 Variants in Immunocompromised Patients with Multiple Myeloma
4654 - Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients
4691 - Monovalent XBB1.5 Vaccination Augments Humoral and Cellular Immunity to Novel Sars-Cov-2 Variants in Immunocompromised Patients with Multiple Myeloma
Kapsalis, S. M.
1841 - Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase 1 (mIDH1) Relapsed/Refractory Myelodysplastic Syndromes: Update of the Phase 1 Substudy per the International Working Group 2023 Response Criteria
1845.1 - Phase 3 Study of Either Ivosidenib (IVO) Monotherapy or Azacitidine (AZA) Monotherapy in Patients with IDH1 Mutant Myelodysplastic Syndromes (MDS) Who Are Hypomethylating Agent (HMA) Naive (PyramIDH)
1845.1 - Phase 3 Study of Either Ivosidenib (IVO) Monotherapy or Azacitidine (AZA) Monotherapy in Patients with IDH1 Mutant Myelodysplastic Syndromes (MDS) Who Are Hypomethylating Agent (HMA) Naive (PyramIDH)
Kapsimali, Z.
Kapur, R.
2554 - The ‘Stop TPO-Receptor Agonist in ITP Patients’ (STIP) Study: Clinical and Immune Modulatory Effects of Romiplostim Tapering
2569 - B-Cell Distribution in Immune Thrombocytopenia and Its Relation to Ageing
2643 - Anti-Platelet IgG-Fc Glycosylation As a Novel Regulator in Platelet Transfusion Refractoriness
3950 - Platelet Sequestration Patterns and Clearance Rates in Patients with ITP Compared to Healthy Individuals
3977 - Concizumab As a Possible Treatment for Bleeding Disordersof Unknown Cause
2569 - B-Cell Distribution in Immune Thrombocytopenia and Its Relation to Ageing
2643 - Anti-Platelet IgG-Fc Glycosylation As a Novel Regulator in Platelet Transfusion Refractoriness
3950 - Platelet Sequestration Patterns and Clearance Rates in Patients with ITP Compared to Healthy Individuals
3977 - Concizumab As a Possible Treatment for Bleeding Disordersof Unknown Cause
Kapur, S.
3266 - Mast Cells Support Multiple Myeloma Survival and Engraftment through Secreted Factors
3373 - Belantamab Mafodotin As Pre- and Post-Autologous Stem Cell Transplant (ASCT) Consolidation and Maintenance for Multiple Myeloma (MM) with < Complete Response after Induction: Interim Results of the Ongoing Phase 2 BLAST Study
3779 - Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma
3381.1 - A Multi-Institution Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)
3373 - Belantamab Mafodotin As Pre- and Post-Autologous Stem Cell Transplant (ASCT) Consolidation and Maintenance for Multiple Myeloma (MM) with < Complete Response after Induction: Interim Results of the Ongoing Phase 2 BLAST Study
3779 - Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma
3381.1 - A Multi-Institution Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)
Kapustova, V.
1887 - Composition and Fitness of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment
1962 - Predictive Value of Clonal Plasma Cells in Autografts Assessed By Next Generation Flow Cytometry on Pre-Transplant Bone Marrow MRD in Multiple Myeloma Patients
3270 - Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma
1962 - Predictive Value of Clonal Plasma Cells in Autografts Assessed By Next Generation Flow Cytometry on Pre-Transplant Bone Marrow MRD in Multiple Myeloma Patients
3270 - Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma
Kapustyan, T. A.
Karabayir, I.
Karagiannidis, I.
Karagkouni, D.
123 - Loss of LDH-a Accelerated CD8+ T Memory Cell Differentiation but Impairs Anti-Tumor Responses
2992 - Unveiling the Tumor Microenvironment in Extranodal NK/T-Cell Lymphoma (ENKTCL) Patients with in Situ Spatial Transcriptomics
3258 - Integrated Coding and Non-Coding Transcriptional Single-Cell Atlas of Multiple Myeloma: Unraveling the Effects of Myeloma Genotype on the Bone Marrow Microenvironment
3289 - Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment
4256 - Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1
2992 - Unveiling the Tumor Microenvironment in Extranodal NK/T-Cell Lymphoma (ENKTCL) Patients with in Situ Spatial Transcriptomics
3258 - Integrated Coding and Non-Coding Transcriptional Single-Cell Atlas of Multiple Myeloma: Unraveling the Effects of Myeloma Genotype on the Bone Marrow Microenvironment
3289 - Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment
4256 - Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1
Karahodzic, A.
Karakatsoulis, G.
2358 - Improving Quality of Life Based on Electronic Patient Reported Outcomes in Patients with CLL and MDS: The Mypal Study
3002 - Distinct Signaling Profiles in Primary Splenic Small B-Cell Lymphomas
4619 - Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study
3002 - Distinct Signaling Profiles in Primary Splenic Small B-Cell Lymphomas
4619 - Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study
Karakukcu, M.
Karakyriakou, B.
Karam, M.
Karamanidou, C.
Karamanli, E.
Karami, A.
Karanika, S.
Karanjawala, Z. E.
Karantanos, T.
Karanth, S.
Karaoglu, D. A. A.
Karapatakis, S.
Karapetian, R.
Karasawa, M.
Karasek, M.
319 - Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study
320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry
790 - Independent, International Validation and Refinement of a Machine Learning Algorithm to Classify Acute Leukemia Using Routine Laboratory Features
320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry
790 - Independent, International Validation and Refinement of a Machine Learning Algorithm to Classify Acute Leukemia Using Routine Laboratory Features
Karasuno, T.
Karatepe, K.
Karavalakis, G.
1163 - Long-Term Safety and Efficacy of Autologous Hematopoietic Cell Transplantation for Patients with Progressive Systemic Sclerosis
3408 - Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients
3484 - Long-Term Safety and Efficacy of Treosulfan-Based Conditioning Regimens of Allogeneic Hematopoietic Cell Transplantation
3408 - Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) and Growth Differentiation Factor-15 (GDF-15) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients
3484 - Long-Term Safety and Efficacy of Treosulfan-Based Conditioning Regimens of Allogeneic Hematopoietic Cell Transplantation
Karbassi, B. M.
Kardorff, M.
Kareem, S. S.
1672 - Real World Experience with Sequential Brentuximab Vedotin Plus AVD Chemotherapy As Frontline Therapy for Older Patients with Classical Hodgkin Lymphoma: A Multicenter Retrospective Study
2820 - Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting
3091 - CD20xCD3 Bispecific Antibodies As Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL) – a Multicenter Retrospective Study
2820 - Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting
3091 - CD20xCD3 Bispecific Antibodies As Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL) – a Multicenter Retrospective Study
Karim, B. A.
Karim, C.
Karimi, M.
Karimi, M. M.
Karimi, M. M.
33 - Dynamics of Oligoclonal Hematopoiesis in Severe Aplastic Anemia Patients Undergoing Immunosuppressive Treatment: Longitudinal Somatic Mutation Analysis from the EBMT Race Trial
3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo
3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo
Karimi, Y. H.
111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
1737 - Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial
3105 - Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma
3106 - Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
4477 - Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study
4480 - 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma
4491 - Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy
4497 - Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy
1737 - Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial
3105 - Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma
3106 - Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
4477 - Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study
4480 - 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma
4491 - Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy
4497 - Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy
Karipidou, M.
3000 - Comparative Analysis of T Cell Profiles in Splenic Small B-Cell Malignancies
3002 - Distinct Signaling Profiles in Primary Splenic Small B-Cell Lymphomas
3235 - PD-1 Expression Identifies Proliferating Chronic Lymphocytic Leukemia Cells and Informs Response and Resistance to BTK Inhibitor Therapy
3002 - Distinct Signaling Profiles in Primary Splenic Small B-Cell Lymphomas
3235 - PD-1 Expression Identifies Proliferating Chronic Lymphocytic Leukemia Cells and Informs Response and Resistance to BTK Inhibitor Therapy
Kariri, N.
Karis, E.
Karisani, N.
Karjalainen-Lindsberg, M. L.
Karkoska, K.
Karlin, L.
774 - The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma
1032 - Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
1976 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study
2002 - Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial
3667 - Impact of Health Literacy in Hematology Outpatients Receiving Oral Anticancer Drugs and Followed By the Oncoral Multidisciplinary City-Hospital Educational Follow-up
4734 - Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study
4738 - MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma
4749 - Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial
4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)
1032 - Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
1976 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study
2002 - Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial
3667 - Impact of Health Literacy in Hematology Outpatients Receiving Oral Anticancer Drugs and Followed By the Oncoral Multidisciplinary City-Hospital Educational Follow-up
4734 - Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study
4738 - MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma
4749 - Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial
4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)
Karlon, W. J.
Karlsson, L.
Karlsson, L.
Karlsson-Parra, A.
Karmakar, S.
Karmali, R.
68 - Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
95 - Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)
238 - Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis
398 - Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies
473 - Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma
525 - Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
612 - Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy
1664 - Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy
2344 - Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study
2377 - Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
3053 - Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma
3751 - Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis
4387 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
95 - Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)
238 - Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis
398 - Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies
473 - Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma
525 - Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
612 - Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy
1664 - Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy
2344 - Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study
2377 - Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
3053 - Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma
3751 - Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis
4387 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
Karnati, N.
Karnik, L.
1097 - Donor Trait Status Determines Haematological Outcomes Post-Haemopoietic Stem Cell Transplantation in Transfusion Dependent Thalassaemia Independent of HLA Matching and Chimerism Status
3518 - Abatacept Abrogates the Risk of Acute GvHD in Both Matched and Mismatched Transplantation for Haemoglobinopathies and Bone Marrow Failure
3518 - Abatacept Abrogates the Risk of Acute GvHD in Both Matched and Mismatched Transplantation for Haemoglobinopathies and Bone Marrow Failure
Karol, S. E.
1352 - Oncogenic Potential and Sensitivity to Menin Inhibitors of a Novel Fusion KAT6B::NUTM2B in Congenital Myeloid Sarcoma with Bone Marrow Involvement
4187 - Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Study
4208 - Safety and Feasibility of Blinatumomab As Frontline Therapy for Pediatric Patients with B-Acute Lymphoblastic Leukemia and Lymphoma: St. Jude Total Therapy Study XVII
4187 - Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Study
4208 - Safety and Feasibility of Blinatumomab As Frontline Therapy for Pediatric Patients with B-Acute Lymphoblastic Leukemia and Lymphoma: St. Jude Total Therapy Study XVII
Karow, A.
Karp, R.
Karpen, M. S.
Karpinski, M.
Karrar, O.
Karrar, O.
220 - Long-Term Survival Outcomes and Cytogenetic/Molecular Patterns of Relapse in Adults with FLT3-Mutated AML Receiving Frontline Triplet Therapy with a Hypomethylating Agent, Venetoclax and FLT3 Inhibitor
837 - Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse
3156 - A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse
4198 - A Phase I/II Study of Mini-Hyper-CVD, Venetoclax and Navitoclax in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
4336 - Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1-mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease
837 - Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse
3156 - A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse
4198 - A Phase I/II Study of Mini-Hyper-CVD, Venetoclax and Navitoclax in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
4336 - Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1-mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease
Karsan, A.
Karschen, B.
Karsdal, M.
Karst, J.
Karsten, I. E.
Kartachova, M.
Karthaus, M.
Karulkar, A.
Karulkar, A.
Karumathil, S.
2150 - Lower Mycophenolic Acid Exposure in Patients Undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide/ Cyclosporine a-Based GvHD Prophylaxis – Need for Dose Intensification
4879 - EASIXd0 Predicts Early Transplant-Related Mortality in Patients Undergoing Haploidentical Transplantation with Post-Transplant Cyclophosphamide-Mycophenolate Mofetil-Based GvHD Prophylaxis
4879 - EASIXd0 Predicts Early Transplant-Related Mortality in Patients Undergoing Haploidentical Transplantation with Post-Transplant Cyclophosphamide-Mycophenolate Mofetil-Based GvHD Prophylaxis
Karunakaran, M.
Karunakaran, P.
Karunasiri, M.
Karve, S.
3728 - Duration of Therapy in Patients with Waldenström Macroglobulinemia Undergoing Dose Reductions of First-Line Ibrutinib: A Real-World Analysis
3742 - Association Between Dose Reduction and Duration of Therapy in Patients Receiving Ibrutinib or Acalabrutinib for Chronic Lymphocytic Leukemia: A Medical Chart Review Study
3742 - Association Between Dose Reduction and Duration of Therapy in Patients Receiving Ibrutinib or Acalabrutinib for Chronic Lymphocytic Leukemia: A Medical Chart Review Study
Karvonen, K. A.
Karwoski, J.
Karyampudi, K.
Kasaeian, A.
2102 - Outcomes after Matched Sibling Donor Versus Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
2119 - Outcomes after Bone Marrow Versus Peripheral Blood Matched Sibling Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis
2122 - Sociodemographic and Patient-Related Determinants of Outcomes after Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
2141 - Impact of Conditioning Intensity on Outcomes after Allogeneic Related Donor HCT with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis in Acute Leukemia and Myelodysplastic Syndromes
3503 - Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis
3517 - Factors Associated with Graft-Versus-Host Disease after Related Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3524 - Sociodemographic and Patient-Related Determinants of Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3543 - Outcomes of Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis in Elderly Patients over 70 Years of Age with Acute Leukemia and Myelodysplastic Syndromes
4877 - Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis
2119 - Outcomes after Bone Marrow Versus Peripheral Blood Matched Sibling Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis
2122 - Sociodemographic and Patient-Related Determinants of Outcomes after Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
2141 - Impact of Conditioning Intensity on Outcomes after Allogeneic Related Donor HCT with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis in Acute Leukemia and Myelodysplastic Syndromes
3503 - Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis
3517 - Factors Associated with Graft-Versus-Host Disease after Related Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3524 - Sociodemographic and Patient-Related Determinants of Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3543 - Outcomes of Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis in Elderly Patients over 70 Years of Age with Acute Leukemia and Myelodysplastic Syndromes
4877 - Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis
Kasahara, H.
Kasahara, S.
Kasahara, S.
Kasamatsu, T.
Kasap, C.
Kascak, M.
Käsgen, O.
Kashif, M.
Kashikar-Zuck, S.
Kashinath, S.
Kashyap, M.
Kashyap, R.
Kasinathan, G.
Kasirye, P.
Kaslow-Zieve, E.
Kasonkanji, E.
2357 - Travel Time from Cancer Center Is Associated with Disparities in Non-Hodgkin Lymphoma Diagnosis Among People Living with HIV in Malawi
3005 - High Tumor Mutational Burden Associates with Increased CD8 T-Cell Presence, Decreased Tumor Heterogeneity, and Increased AICDA Expression in an HIV-Inclusive Cohort of Diffuse Large B-Cell Lymphoma
4344 - Immunogenomic Profiles of EBV-Associated Classic Hodgkin Lymphoma in an HIV-Inclusive Cohort
3005 - High Tumor Mutational Burden Associates with Increased CD8 T-Cell Presence, Decreased Tumor Heterogeneity, and Increased AICDA Expression in an HIV-Inclusive Cohort of Diffuse Large B-Cell Lymphoma
4344 - Immunogenomic Profiles of EBV-Associated Classic Hodgkin Lymphoma in an HIV-Inclusive Cohort
Kasow, K. A.
Kasowski, M.
Kasper, M. A.
Kaspers, G. J.
Kaspers, J.
Kaspin, A.
Kassabian, M.
Kassasseya, C.
Kassim, A. A.
3663 - Impact of Patient Distance from Center on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma
4911 - Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis
5172 - Outcomes of Hematopoietic Stem Cell Transplantation in Patients Aged 70 Years and Older
2134.1 - Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207
- Benign Diseases
4911 - Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis
5172 - Outcomes of Hematopoietic Stem Cell Transplantation in Patients Aged 70 Years and Older
2134.1 - Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207
- Benign Diseases
Kassira, A.
Kassner, J.
Kassner, P. D.
Kast, D.
Kasten, J. L.
Kasten, S.
Kasthuri, R. S.
Kasthuri, R.
Kastritis, E.
361 - Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study
490 - A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma
859 - Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First – Line Treatment for Waldenström’s Macroglobulinemia: Results of the Multicenter Phase II trial (ECWM-2) of the European Consortium for Waldenström’s Macroglobulinemia
889 - Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis
891 - Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
1017 - Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants
1020 - Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
1582 - Detection of B Cell Lymphomas By a Simple Epigenetic Blood Test
1600 - Genomic Characterization of Ibrutinib-Resistant Waldenström’s Macroglobulinemia
1603 - The Combined Treatment of Btkis with Venetoclax Exhibits an Enhanced Therapeutic Effect on Waldenström Macroglobulinemia Cells Bearing CXCR4 Mutations
1927 - Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network
1934 - Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)
1948 - Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients
1979 - Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
1991 - Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group
3285 - Circular RNA Profiling Using High-Accuracy Long-Read Nanopore Sequencing of Multiple Myeloma Cell Lines Reveals the Wide Diversity of the Circular Transcriptome
3328 - An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response
3361 - Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
3368 - Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium
3380 - Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma
4352 - Determining the Mutational Landscape of Waldenström’s Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström’s Macroglobulinemia
4397 - Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom’s Macroglobulinemia Treated with Different Regimens in the Real-World Setting
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
4674 - Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis
4675 - Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging
4694 - Measurable Residual Disease and Peripheral Residual Disease to Assess Treatment Response in Real-World Patients with Newly Diagnosed Multiple Myeloma
4696 - Evaluating Minimal Residual Disease Negativity As a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
4715 - Sequential Whole Body Low Dose CTs in Patients with Smoldering Multiple Myeloma Identify Early Progression and May Improve Patient Outcomes
4724 - Early Treatment Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma
5166 - Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee
490 - A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma
859 - Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First – Line Treatment for Waldenström’s Macroglobulinemia: Results of the Multicenter Phase II trial (ECWM-2) of the European Consortium for Waldenström’s Macroglobulinemia
889 - Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis
891 - Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
1017 - Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants
1020 - Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
1582 - Detection of B Cell Lymphomas By a Simple Epigenetic Blood Test
1600 - Genomic Characterization of Ibrutinib-Resistant Waldenström’s Macroglobulinemia
1603 - The Combined Treatment of Btkis with Venetoclax Exhibits an Enhanced Therapeutic Effect on Waldenström Macroglobulinemia Cells Bearing CXCR4 Mutations
1927 - Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network
1934 - Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)
1948 - Ultra Long-Term Myeloma Survivors (>15 years): Characteristics of a Unique Group of Myeloma Patients
1979 - Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
1991 - Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group
3285 - Circular RNA Profiling Using High-Accuracy Long-Read Nanopore Sequencing of Multiple Myeloma Cell Lines Reveals the Wide Diversity of the Circular Transcriptome
3328 - An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response
3361 - Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
3368 - Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium
3380 - Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma
4352 - Determining the Mutational Landscape of Waldenström’s Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström’s Macroglobulinemia
4397 - Clinical Outcomes in Consecutive Newly Diagnosed Patients with Waldenstrom’s Macroglobulinemia Treated with Different Regimens in the Real-World Setting
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
4674 - Outcomes of Venetoclax in Patients with Relapsed or Refractory AL Amyloidosis
4675 - Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging
4694 - Measurable Residual Disease and Peripheral Residual Disease to Assess Treatment Response in Real-World Patients with Newly Diagnosed Multiple Myeloma
4696 - Evaluating Minimal Residual Disease Negativity As a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
4715 - Sequential Whole Body Low Dose CTs in Patients with Smoldering Multiple Myeloma Identify Early Progression and May Improve Patient Outcomes
4724 - Early Treatment Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma
5166 - Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee
Kastrup, C. J.
Kasztan, M.
Kaszuba, C. M.
Katagiri, T.
Katagiri, T.
Katamesh, B.
Kataoka, K.
384 - Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC
1608 - Modeling NK-Cell Lymphoma in Mice Reveals Cell-of-Origin, Microenvironment, and Therapeutic Targets
4116 - Impacts of Monoallelic and Biallelic DDX41 Mutations on Hematopoiesis and the Development of Myeloid Malignancies
4472 - Trends and Outcomes of Hematopoietic Stem Cell Transplantation for Malignant Lymphoma in Japan between 2006 and 2021
1608 - Modeling NK-Cell Lymphoma in Mice Reveals Cell-of-Origin, Microenvironment, and Therapeutic Targets
4116 - Impacts of Monoallelic and Biallelic DDX41 Mutations on Hematopoiesis and the Development of Myeloid Malignancies
4472 - Trends and Outcomes of Hematopoietic Stem Cell Transplantation for Malignant Lymphoma in Japan between 2006 and 2021
Kataoka, S.
Katavolos, P.
Katayama, Y.
1469 - Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia with t(16;21)(p11;q22)
3569 - To What Extent Have Post-Transplant Outcomes Improved Following the Introduction of Tyrosine Kinase Inhibitors in Elderly Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia? a Retrospective Nationwide Survey in Japan
3569 - To What Extent Have Post-Transplant Outcomes Improved Following the Introduction of Tyrosine Kinase Inhibitors in Elderly Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia? a Retrospective Nationwide Survey in Japan
Kater, A. P.
586 - Mutations in BCOR, CCND2, NRAS and XPO1 Predict Clinical Outcomes upon MRD-Guided Venetoclax Plus Ibrutinib in Relapsed and Refractory Chronic Lymphocytic Leukemia
883 - Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1
888 - Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax
1009 - Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial
1013 - Improved Efficacy with Response- and MRD-Guided Ibrutinib–Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial
1846 - In-Depth Immune and Metabolic Profiling of GAIA/CLL13 Patients to Uncover Treatment-Specific Changes to the T-Cell Compartment
1871 - First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis
3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial
4626 - Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study
4803 - Reprogramming CLL T-Cell Mitochondrial Fitness Using PI3K Inhibition for Enhancing CAR T-Cell Therapy
3257.1 - CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naive CLL
- Relapsed/Refractory CLL: The Role of allo-SCT, CAR-T, and T-cell Engagers
883 - Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1
888 - Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax
1009 - Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial
1013 - Improved Efficacy with Response- and MRD-Guided Ibrutinib–Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial
1846 - In-Depth Immune and Metabolic Profiling of GAIA/CLL13 Patients to Uncover Treatment-Specific Changes to the T-Cell Compartment
1871 - First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis
3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial
4626 - Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study
4803 - Reprogramming CLL T-Cell Mitochondrial Fitness Using PI3K Inhibition for Enhancing CAR T-Cell Therapy
3257.1 - CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naive CLL
- Relapsed/Refractory CLL: The Role of allo-SCT, CAR-T, and T-cell Engagers
Katerndahl, C.
Katiyar, S.
Kato, G. J.
Kato, H.
Kato, J.
3541 - Treatment Outcomes of Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed after Allogeneic Stem Cell Transplant in the Era of Novel Immunochemotherapeutic Agents
4925 - The Outcome of Fertility Preservation Strategy in Female Hematopoietic Stem Cell Transplant Recipients of Reproductive Age. Retrospective Study from the Kanto Study Group for Cell Therapy
4925 - The Outcome of Fertility Preservation Strategy in Female Hematopoietic Stem Cell Transplant Recipients of Reproductive Age. Retrospective Study from the Kanto Study Group for Cell Therapy
Kato, K.
67 - Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update
454 - Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas
1636 - Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry
2081 - Pre-CAR-T GTE Scoring of Electroencephalogram Abnormalities As Predictive Biomarkers for Icans
3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
4475 - A Multicenter, Prospective, Observational Study of Pola-R-CHP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (POLASTAR): A Preliminary Analysis
454 - Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas
1636 - Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry
2081 - Pre-CAR-T GTE Scoring of Electroencephalogram Abnormalities As Predictive Biomarkers for Icans
3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
4475 - A Multicenter, Prospective, Observational Study of Pola-R-CHP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (POLASTAR): A Preliminary Analysis
Kato, M.
1426 - Prognostic Factors for T-Cell Acute Lymphoblastic Leukemia in Children and Young Adults: ALL-T11 Study Conducted By Japan Children’s Cancer Group and Japan Adult Leukemia Study Group
2236 - Clinical Utility of Rapid and Comprehensive Genome Profiling Method Using Nanopore Sequencer for Pediatric Leukemia
3907 - Low-Frequency Mosaicism of the BRAF Mutation As the Origin of Langerhans Cell Histiocytosis
2236 - Clinical Utility of Rapid and Comprehensive Genome Profiling Method Using Nanopore Sequencer for Pediatric Leukemia
3907 - Low-Frequency Mosaicism of the BRAF Mutation As the Origin of Langerhans Cell Histiocytosis
Kato, S.
Kato, T.
Kato, Y.
Katoch, O.
432 - Neutrophil-Dependent Interferonopathy Promotes Hemophilic Arthropathy
1100 - Circulating Extracellular Vesicles Enable IFN-I Response in Neutrophils of Sickle Cell Disease Mice
1102 - Platelet RIG-I Promotes Flu-Induced Severe Lung Injury in Sickle Cell Disease
2493 - DNA Sensing By Platelets Promotes Acute Chest Syndrome in Sickle Cell Disease
1100 - Circulating Extracellular Vesicles Enable IFN-I Response in Neutrophils of Sickle Cell Disease Mice
1102 - Platelet RIG-I Promotes Flu-Induced Severe Lung Injury in Sickle Cell Disease
2493 - DNA Sensing By Platelets Promotes Acute Chest Syndrome in Sickle Cell Disease
Katodritou, E.
2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
Katodrytou, E.
1991 - Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group
3361 - Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
3361 - Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
Katopodi, L. X.
Katori, M.
1939 - Gnri (Geriatric Nutritional Risk Index) in Multiple Myeloma
3090 - Short Diagnosis to Treatment Interval Is Associated with Poor Outcomes in Relapse or Refractory Diffuse Large B-Cell Lymphoma
4459 - Low Immunoglobulin G and Low Lymphocyte-Monocyte Ratio at the End of Treatment Predict Early Progression in Diffuse Large B-Cell Lymphoma
3090 - Short Diagnosis to Treatment Interval Is Associated with Poor Outcomes in Relapse or Refractory Diffuse Large B-Cell Lymphoma
4459 - Low Immunoglobulin G and Low Lymphocyte-Monocyte Ratio at the End of Treatment Predict Early Progression in Diffuse Large B-Cell Lymphoma
Katragadda, N.
1363 - Defining the Roles of Base Deaminase and Splicing Deregulation in Pediatric B-Cell Acute Lymphoblastic Leukemia Stem Cell Persistence
4068 - A 3D Niche Nanobioreactor Supports Long-Term Tracking of Hematopoietic Stem and Progenitor Cell Cycle Kinetics, Self-Renewal and Cell Fate Determination
4068 - A 3D Niche Nanobioreactor Supports Long-Term Tracking of Hematopoietic Stem and Progenitor Cell Cycle Kinetics, Self-Renewal and Cell Fate Determination
Katsamakis, Z.
637 - Cross-Talk between Leukemic Blasts and T Cells Drives Targetable T Cell Dysfunction in the AML Tumor Microenvironment
817 - Single-Cell Spatial Transcriptomics Identifies Lymphoid Aggregates with Location-Specific Alterations of Adaptive Immune Cells in Human MDS Bone Marrow
2070 - CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia
817 - Single-Cell Spatial Transcriptomics Identifies Lymphoid Aggregates with Location-Specific Alterations of Adaptive Immune Cells in Human MDS Bone Marrow
2070 - CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia
Katsanou, V.
Katsarou, A.
Katsarou Fasouli, O.
Katsiampoura, P.
Katsimigas, A.
Katsivelos, N.
Katsube, A.
1939 - Gnri (Geriatric Nutritional Risk Index) in Multiple Myeloma
3090 - Short Diagnosis to Treatment Interval Is Associated with Poor Outcomes in Relapse or Refractory Diffuse Large B-Cell Lymphoma
4459 - Low Immunoglobulin G and Low Lymphocyte-Monocyte Ratio at the End of Treatment Predict Early Progression in Diffuse Large B-Cell Lymphoma
3090 - Short Diagnosis to Treatment Interval Is Associated with Poor Outcomes in Relapse or Refractory Diffuse Large B-Cell Lymphoma
4459 - Low Immunoglobulin G and Low Lymphocyte-Monocyte Ratio at the End of Treatment Predict Early Progression in Diffuse Large B-Cell Lymphoma
Katsumura, K. R.
Katsuoka, Y.
Katsuragawa-Taminishi, Y.
Katta, V.
Kattamis, A.
409 - ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia
512 - Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
2703 - Incidence of Myeloid Malignancy in Shwachman-Diamond Syndrome: An International Cohort Study
3860 - Abrupt Increases in Ferritin Levels May Indicate a Malignant Process and Not Changes in Iron Overload in Thalassemic Patients
512 - Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
2703 - Incidence of Myeloid Malignancy in Shwachman-Diamond Syndrome: An International Cohort Study
3860 - Abrupt Increases in Ferritin Levels May Indicate a Malignant Process and Not Changes in Iron Overload in Thalassemic Patients
Kattamuri, L. V.
Kattula, S.
Katz, H.
Katz, J.
677 - Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial
1025 - Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial
3261 - Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide
1025 - Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial
3261 - Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide
Katz, S. G.
Kaueffer, C.
Kaufman, A.
Kaufman, D. S.
Kaufman, D.
1631 - Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study
1718.1 - SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)
1718.1 - SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)
Kaufman, G. P.
Kaufman, G. P.
Kaufman, J. L.
255 - A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma
1983 - Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)
1993 - Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma
3311 - Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies
3381 - The Anti-BCMA Antibody-Drug Conjugate Hdp-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma
3780 - Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)
4663 - Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2
4672 - A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy
4702 - Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes
5142 - Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade
5152 - Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting
1983 - Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)
1993 - Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma
3311 - Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies
3381 - The Anti-BCMA Antibody-Drug Conjugate Hdp-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma
3780 - Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)
4663 - Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2
4672 - A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy
4702 - Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes
5142 - Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade
5152 - Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting
Kaufmann, M.
776 - Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation
2211 - Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
1527.1 - Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial
2211 - Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
1527.1 - Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial
Kaul, H.
566 - Metabolic Tumor Volume after Two Cycles of Chemotherapy in Patients Treated for Advanced-Stage Hodgkin Lymphoma: Analysis of the German Hodgkin Study Group Phase III HD18 and HD21 Trials
568 - PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial
3044 - Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume during Anti-PD1-Based First-Line HL Treatment in the GHSG Phase II Nivahl Trial
3054 - Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial
4355 - Lymphovista HL - a Validated Assay for Genotyping and MRD Assessment in Hodgkin Lymphoma
568 - PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial
3044 - Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume during Anti-PD1-Based First-Line HL Treatment in the GHSG Phase II Nivahl Trial
3054 - Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial
4355 - Lymphovista HL - a Validated Assay for Genotyping and MRD Assessment in Hodgkin Lymphoma
Kauppinen, S.
Kaur, D.
Kaur, G.
897 - Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
1031 - Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
2394 - Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience from 609 Patients
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
3792h - Upfront Use of Anti-CD38 Monoclonal Antibodies Is Associated with Improvement in Renal Failure in Multiple Myeloma: A Flatiron Real World Analysis from 2010 to 2023
2000.1 - MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
1031 - Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
2394 - Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience from 609 Patients
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
3792h - Upfront Use of Anti-CD38 Monoclonal Antibodies Is Associated with Improvement in Renal Failure in Multiple Myeloma: A Flatiron Real World Analysis from 2010 to 2023
2000.1 - MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial
Kaur, I.
Kaur, M.
Kaur, P.
Kaur, S.
Kaushal, N.
2780 - Preclinical Proof-of-Concept of a Novel mRNA-Based Therapeutic Combination of an FcRH5 Targeted NK Cell Engager and an IL-15 Superagonist for the Treatment of Multiple Myeloma
4163 - Preclinical Proof-of-Concept of an mRNA-Based T Cell Engager Targeting BCMA, FcRH5, and GPRC5D for the Treatment of Multiple Myeloma
4163 - Preclinical Proof-of-Concept of an mRNA-Based T Cell Engager Targeting BCMA, FcRH5, and GPRC5D for the Treatment of Multiple Myeloma
Kavaka, V.
Kavakli, K.
718 - Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study
1053 - Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial
3575 - Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec
3577 - Use of Fidanacogene Elaparvovec, a Gene Therapy Vector, to Deliver a Stable, Fully Functional Human Factor IX Transgene for the Treatment of Hemophilia B: A Combined Analysis of Safety
1053 - Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial
3575 - Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec
3577 - Use of Fidanacogene Elaparvovec, a Gene Therapy Vector, to Deliver a Stable, Fully Functional Human Factor IX Transgene for the Treatment of Hemophilia B: A Combined Analysis of Safety
Kavanagh, D.
Kavanagh, M.
Kavanaugh, A. R.
117 - Multi-Site Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Non-Intensive Therapy
5056 - Factors Associated with Early Quality of Life Response to Palliative Care during Hematopoietic Cell Transplantation
5056 - Factors Associated with Early Quality of Life Response to Palliative Care during Hematopoietic Cell Transplantation
Kavaz, T.
Kavcic, M.
Kavelaars, F.
2718 - DNMT3A Mutations Deregulate the DNA Demethylation Pathway in Acute Myeloid Leukemia
2914 - Mutational Landscape and Depth of Response in Patients with Acute Myeloid Leukemia (AML) Treated with Magrolimab in Combination with Venetoclax and Azacitidine Compared to Placebo
4300 - Transcriptional Profiling Directs the Classification of Mixed Phenotype Acute Leukemias into AML, B-ALL or T-ALL
2914 - Mutational Landscape and Depth of Response in Patients with Acute Myeloid Leukemia (AML) Treated with Magrolimab in Combination with Venetoclax and Azacitidine Compared to Placebo
4300 - Transcriptional Profiling Directs the Classification of Mixed Phenotype Acute Leukemias into AML, B-ALL or T-ALL
Kavuri, S.
Kavuri, S.
Kawada, H.
Kawaji-Kanayama, Y.
Kawakita, T.
Kawale, A. S.
Kawamura, K.
1469 - Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia with t(16;21)(p11;q22)
2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
3569 - To What Extent Have Post-Transplant Outcomes Improved Following the Introduction of Tyrosine Kinase Inhibitors in Elderly Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia? a Retrospective Nationwide Survey in Japan
4472 - Trends and Outcomes of Hematopoietic Stem Cell Transplantation for Malignant Lymphoma in Japan between 2006 and 2021
4548 - Optimal Procedures of Allogeneic Transplantation for BCR::ABL1-Negative Atypical Chronic Myeloid Leukemia
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study
2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
3569 - To What Extent Have Post-Transplant Outcomes Improved Following the Introduction of Tyrosine Kinase Inhibitors in Elderly Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia? a Retrospective Nationwide Survey in Japan
4472 - Trends and Outcomes of Hematopoietic Stem Cell Transplantation for Malignant Lymphoma in Japan between 2006 and 2021
4548 - Optimal Procedures of Allogeneic Transplantation for BCR::ABL1-Negative Atypical Chronic Myeloid Leukemia
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study
Kawamura, S.
Kawanaka, Y.
Kawano, M.
Kawano, N.
Kawari, M.
Kawasaki, N.
Kawasaki, T.
Kawashima, M.
1939 - Gnri (Geriatric Nutritional Risk Index) in Multiple Myeloma
3090 - Short Diagnosis to Treatment Interval Is Associated with Poor Outcomes in Relapse or Refractory Diffuse Large B-Cell Lymphoma
4459 - Low Immunoglobulin G and Low Lymphocyte-Monocyte Ratio at the End of Treatment Predict Early Progression in Diffuse Large B-Cell Lymphoma
3090 - Short Diagnosis to Treatment Interval Is Associated with Poor Outcomes in Relapse or Refractory Diffuse Large B-Cell Lymphoma
4459 - Low Immunoglobulin G and Low Lymphocyte-Monocyte Ratio at the End of Treatment Predict Early Progression in Diffuse Large B-Cell Lymphoma
Kawashima, N.
1688 - Low-Count T-/NK-Large Granular Lymphocytic Leukemia: A Nosologically Distinct Disease Subtype at the Crossroads between Lymphoproliferation, Autoimmunity and Immunodeficiency
2920 - Distinct Phenotypes of Myeloid Neoplasia Associated with Truncating C-CBL Mutations
4104 - Telomere Content Diversity in Myeloid Neoplasia Could Inform on Differential Sensitivity to Telomerase Inhibitors
2920 - Distinct Phenotypes of Myeloid Neoplasia Associated with Truncating C-CBL Mutations
4104 - Telomere Content Diversity in Myeloid Neoplasia Could Inform on Differential Sensitivity to Telomerase Inhibitors
Kawtharany, H.
1257 - Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
Kawwass, J. F.
Kay, N. E.
397 - Prevalence, Genetic Predispositions and Clinical Consequences of Non-CLL-Type MBL: Screening in 10,330 Individuals
1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
3233 - The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia
4606 - Rewiring Cancer Drivers to Induce Apoptosis By Transcriptional Chemical Inducers of Proximity in Chronic Lymphocytic Leukemia
4615 - Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up
4616 - Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)
1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
3233 - The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia
4606 - Rewiring Cancer Drivers to Induce Apoptosis By Transcriptional Chemical Inducers of Proximity in Chronic Lymphocytic Leukemia
4615 - Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up
4616 - Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)
Kaya, D.
Kayal, S.
Kays, S. K.
Kayser, S.
Kayukawa, S.
Kazadi, C.
521 - Baseline Neurological Morbidity Assessment in Adult Patients with Sickle Cell Disease : The Montreal Brain-SCD Cohort
804 - Lifetime Prevalence of Stroke within an Adult Population with Sickle Cell Disease: A Cross-Sectional Study
3883 - Systematic Transcranial Doppler Examination in Adults with Sickle Cell Disease : A Cross-Sectional Single Center Study
5068 - Validitation of the Rowland Universal Dementia Assessment Scale (RUDAS) for the Detection of Cognitive Impairment Among Adults with Sickle Cell Disease
804 - Lifetime Prevalence of Stroke within an Adult Population with Sickle Cell Disease: A Cross-Sectional Study
3883 - Systematic Transcranial Doppler Examination in Adults with Sickle Cell Disease : A Cross-Sectional Single Center Study
5068 - Validitation of the Rowland Universal Dementia Assessment Scale (RUDAS) for the Detection of Cognitive Impairment Among Adults with Sickle Cell Disease
Kazandjian, D.
496 - ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study
932 - Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab
1907 - Novel T-Cell Receptor Signature Linked to Plasma Cell Dyscrasias
2389 - Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma
2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results
3364 - Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma
4669 - Increased Risk of Monoclonal Gammopathy of Undetermined Significance in US Military Service Members: A Case-Control Study of 1,589 Service Members Deployed to Either Iraq, Germany, or Not-Deployed Ex-US with or without Reported Burn Pit and Toxic Smoke Exposure
932 - Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab
1907 - Novel T-Cell Receptor Signature Linked to Plasma Cell Dyscrasias
2389 - Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma
2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results
3364 - Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma
4669 - Increased Risk of Monoclonal Gammopathy of Undetermined Significance in US Military Service Members: A Case-Control Study of 1,589 Service Members Deployed to Either Iraq, Germany, or Not-Deployed Ex-US with or without Reported Burn Pit and Toxic Smoke Exposure
Kazanowska, B. J.
Kazantsev, D.
974 - A Murine Phase 2 Proof-of-Concept Study of Polatuzumab Vedotin in Combination with Venetoclax in Experimental Therapy of BCL2-Positive Aggressive Lymphomas
2973 - Comprehensive Genomic Analysis of Non-Relapsed and Late-Relapsed Mantle Cell Lymphoma Patients Compared to Refractory and Early-Relapsed Patients Treated By Standard Immunochemotherapy
2973 - Comprehensive Genomic Analysis of Non-Relapsed and Late-Relapsed Mantle Cell Lymphoma Patients Compared to Refractory and Early-Relapsed Patients Treated By Standard Immunochemotherapy
Kazantzaki, E.
Kazantzidis, G.
990 - Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072
4180 - Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients
4180 - Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients
Kazerani, M.
Kazeroun, M.
1909 - A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data
3333 - Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
3333 - Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
Kazianka, L.
Kazmi, S.
Kaźmierczak, M.
1000 - Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis
4590 - Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents
4590 - Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents
Kazolia, E.
Kazoom, R.
Kazura, J.
Kazybay, B.
Ke, B.
2755 - Targeting Co-Regulatory Feedback Loop of MYC and GSPT1 By MYC/GSPT1 Dual Degradation Is Synthetic Lethal in Combination with Ven/Aza in TP53 Mutant Acute Myeloid Leukemia Stem and Progenitor Cells
4155 - Reactivation of p53 in TP53-Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations
4155 - Reactivation of p53 in TP53-Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations
Ke, X.
1745 - The Clinical Value of Prognostic Nutritional Index in CAR-T Therapy for Patients with Malignant Lymphoma
3079 - Treatment Outcomes in Patients with R/R CNSL in the Era of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
3387 - Efficacy and Safety of BCMA-CAR-T Cell Therapy in Relapsed/Refractory Extramedullary Plasmacytoma: Exploring the Role of Consolidation Therapy
3079 - Treatment Outcomes in Patients with R/R CNSL in the Era of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
3387 - Efficacy and Safety of BCMA-CAR-T Cell Therapy in Relapsed/Refractory Extramedullary Plasmacytoma: Exploring the Role of Consolidation Therapy
Ke, Y.
Kean, L.
1041 - Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation
1042 - Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis
3516 - Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2’)
1042 - Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis
3516 - Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2’)
Keane, C.
1721 - Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma
3006 - Multiomics Analysis of Paired Diagnosis and Relapse DLBCL Biopsies Shows a Reduction in T Cell Infiltration and Function at Relapse
4376 - T Cell CD62L Expression Following Nivolumab Therapy Is Associated with Long Term Response to Rituximab-Nivolumab in Treatment Naïve Follicular Lymphoma: Results from the 1st FLOR Study
4502.2 - Australasian Leukaemia & Lymphoma Group NHL32 Block PCNSL: An Open Label Phase II Study of Pembrolizumab Following Chemoimmunotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma - Trial in Progress
3006 - Multiomics Analysis of Paired Diagnosis and Relapse DLBCL Biopsies Shows a Reduction in T Cell Infiltration and Function at Relapse
4376 - T Cell CD62L Expression Following Nivolumab Therapy Is Associated with Long Term Response to Rituximab-Nivolumab in Treatment Naïve Follicular Lymphoma: Results from the 1st FLOR Study
4502.2 - Australasian Leukaemia & Lymphoma Group NHL32 Block PCNSL: An Open Label Phase II Study of Pembrolizumab Following Chemoimmunotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma - Trial in Progress
Keane, E. P.
Kearl, T.
Kearney, S.
Keating, A. K.
Keating, A.
Keating, J.
Keating, J.
Keating, M. J.
1011 - Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
1014 - Atezolizumab Combined with Venetoclax and Obinutuzumab for Frontline CLL
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
1014 - Atezolizumab Combined with Venetoclax and Obinutuzumab for Frontline CLL
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
Keats, J.
Keats, J. J.
251 - DNA Methylation Analysis of Commpass Reveals Distinct Epigenetic Programs of High-Risk Disease
1359 - Ectopic NSD2 Remodels H3K36me2 and DNA Methylation to Promote Oncogenic Gene Expression in Multiple Myeloma
3274 - Comprehensive Assessment of Immunoglobulin Translocation Detection in Multiple Myeloma By Whole Genome Sequencing
4651 - BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma
1359 - Ectopic NSD2 Remodels H3K36me2 and DNA Methylation to Promote Oncogenic Gene Expression in Multiple Myeloma
3274 - Comprehensive Assessment of Immunoglobulin Translocation Detection in Multiple Myeloma By Whole Genome Sequencing
4651 - BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma
Keay, W. D.
Kebriaei, P.
506 - Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial
727 - Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
1497 - Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML
2124 - Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial
2191 - Primary Induction Failure Acute Myeloid Leukemia: Immediate Use of Allogeneic Stem Cell Transplantation Vs. Further Induction Chemotherapy
2810 - Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
2950 - Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia
3001 - Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma
3344 - Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant
3428 - Imaging Activated Innate Immune Myeloid Cells in Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-Cell Therapy
3514 - Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis
4182 - CNS Involvement in Adult Patients with B-Cell Acute Lymphoblastic Leukemia
4207 - Combination Therapy with Nelarabine, Peg-Asparaginase and Venetoclax for Adults Patients with Relapsed/Refractory T-Cell ALL
4506 - Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma
4841 - Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies
5092 - Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry
5154 - Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma
- Transplant in ALL: Who, When, and How?
727 - Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
1497 - Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML
2124 - Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial
2191 - Primary Induction Failure Acute Myeloid Leukemia: Immediate Use of Allogeneic Stem Cell Transplantation Vs. Further Induction Chemotherapy
2810 - Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
2950 - Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia
3001 - Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma
3344 - Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant
3428 - Imaging Activated Innate Immune Myeloid Cells in Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-Cell Therapy
3514 - Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis
4182 - CNS Involvement in Adult Patients with B-Cell Acute Lymphoblastic Leukemia
4207 - Combination Therapy with Nelarabine, Peg-Asparaginase and Venetoclax for Adults Patients with Relapsed/Refractory T-Cell ALL
4506 - Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma
4841 - Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies
5092 - Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry
5154 - Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma
- Transplant in ALL: Who, When, and How?
Kebudi, R.
Keck, J. G.
Kedmi, M.
Kedmi, M.
Keegan, S.
Keegan, T. H.
Keel, S.
198 - CD74 Signaling Regulates Inflammatory Stress to Drive Defective Hematopoiesis and Fitness Advantage of Progenitors in RUNX1-Familial Platelet Disorder
1089 - Results from the Aurora Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin in Erythropoietic Protoporphyria
1293 - iPSC Reprogramming Identifies the Role of Cryptic Drivers in Preleukemic Clonal Evolution
1089 - Results from the Aurora Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin in Erythropoietic Protoporphyria
1293 - iPSC Reprogramming Identifies the Role of Cryptic Drivers in Preleukemic Clonal Evolution
Keelara, A.
990 - Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072
3123 - BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL
3123 - BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL
Keele, G. R.
Keen, M. A.
3791 - CAR-T Therapy Showdown: Comparative Efficacy and Safety of of Ide-Cel (Idecabtagene vicleucel) and Cilta-Cel (Ciltacabtagene Autoleucel) in Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Study
5160 - Risk of Infection: Real-World Analysis of (Ide-cel) Idecabtagene Vicleucel and (Cilta-cel) Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
5197 - FLT3 Inhibitors As Maintenance Therapy Post Allogenic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients with FLT3 Mutations; A Systematic Review and Meta-Analysis
5160 - Risk of Infection: Real-World Analysis of (Ide-cel) Idecabtagene Vicleucel and (Cilta-cel) Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
5197 - FLT3 Inhibitors As Maintenance Therapy Post Allogenic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients with FLT3 Mutations; A Systematic Review and Meta-Analysis
Keer, H. N.
661 - Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials
662 - Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN)
662 - Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN)
Keesari, P. R.
Keeton, A. B.
Kehret, A. R.
2750 - Preclinical Characterization of the Anti-Leukemia Activity of the CD123 Antibody-Drug Conjugate, Pivekimab Sunirine (IMGN632)
3436 - Targeting the Membrane-Proximal Domain of CD33 to Maximize the Efficacy of Natural Killer Cell-Based Immunotherapies
4779 - Humanization of Clinically Used Murine CD45 Antibody for Optimized CD45-Targeted Radioimmunotherapy
3436 - Targeting the Membrane-Proximal Domain of CD33 to Maximize the Efficacy of Natural Killer Cell-Based Immunotherapies
4779 - Humanization of Clinically Used Murine CD45 Antibody for Optimized CD45-Targeted Radioimmunotherapy
Keidar-Haran, T.
Keiffer, G.
213 - Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
3215 - Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies
3215 - Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies
Keijzer, K.
Keil, F.
568 - PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial
3793 - Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven – Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group
3793 - Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven – Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group
Keiser, M.
Kekre, N. K.
Kelkar, A. H.
1045 - Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT
3538 - Impact of Consolidative Cellular Therapy with DLI or Second Transplant in Patients with AML Who Achieve Complete Remission Following Post-Transplant Relapse
3657 - Using Circulating Tumor DNA to Spare Patients with DLBCL Unnecessary Treatment and Cost: A Model-Based Analysis
4833 - Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant
4938 - Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes
4951 - Ulcerative Colitis and Adverse Outcomes in Hematopoietic Stem Cell Transplantation: A Nationwide Analysis
5205 - Moral Distress and Burnout Among Hematologists in Mexico: Results of a National Survey
3538 - Impact of Consolidative Cellular Therapy with DLI or Second Transplant in Patients with AML Who Achieve Complete Remission Following Post-Transplant Relapse
3657 - Using Circulating Tumor DNA to Spare Patients with DLBCL Unnecessary Treatment and Cost: A Model-Based Analysis
4833 - Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant
4938 - Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes
4951 - Ulcerative Colitis and Adverse Outcomes in Hematopoietic Stem Cell Transplantation: A Nationwide Analysis
5205 - Moral Distress and Burnout Among Hematologists in Mexico: Results of a National Survey
Kelleher, N.
Kellems, R. E.
Keller, A. L.
Keller, C. A.
Keller, F. G.
462 - Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study
3055 - Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study
3055 - Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study
Keller, G.
Keller, U.
44 - Tracing Clonal Hematopoiesis and Tumor-Specific Mutations in Hematopoietic Progenitors of B Cell Non-Hodgkin Lymphoma (NHL) Patients
230 - Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma
1351 - Parallel Sequencing of Transposons and Transcriptomes in Single Cells for Genome-Wide Cancer Gene Discovery
1460 - Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia
3818 - Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis
230 - Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma
1351 - Parallel Sequencing of Transposons and Transcriptomes in Single Cells for Genome-Wide Cancer Gene Discovery
1460 - Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia
3818 - Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis
Kellet, V.
Kellett, J.
Kellner, C.
914 - A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies
2023 - CD47 Upregulation Inhibits Phagocytic Clearance of Alloreactive Donor T Cells after Allo-HCT
4173 - Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia
2023 - CD47 Upregulation Inhibits Phagocytic Clearance of Alloreactive Donor T Cells after Allo-HCT
4173 - Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia
Kelly, A.
1666 - Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma
1667 - Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma
3051 - High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD
1667 - Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma
3051 - High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD
Kelly, A.
Kelly, B.
Kelly, C.
Kelly, C. A.
402 - Pediatric RISE: Development of a Poverty-Targeted Cash Support Intervention for Pediatric Cancer
3649 - Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001
3750 - Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies
5130 - Food Insecurity and Cardiovascular Risk Among Survivors of Pediatric Hematologic Malignancies
3649 - Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001
3750 - Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies
5130 - Food Insecurity and Cardiovascular Risk Among Survivors of Pediatric Hematologic Malignancies
Kelly, C.
Kelly, D.
Kelly, I.
Kelly, J. W.
Kelly, K. M.
Kelly, K. M.
307 - Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001
311 - Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001
462 - Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study
3055 - Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study
3750 - Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies
311 - Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001
462 - Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study
3055 - Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study
3750 - Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies
Kelly, R. J.
2687 - Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition
4072 - Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study
5012 - Incremental Effectiveness of Iptacopan Compared with C5 Inhibitors in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from a Modelling Analysis
4072 - Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study
5012 - Incremental Effectiveness of Iptacopan Compared with C5 Inhibitors in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from a Modelling Analysis
Kelly, S.
Kelsey, P.
1802 - Efficacy and Tolerability of Trametinib in Adults with Histiocytic Neoplasms
2823 - A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access
3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications
2823 - A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access
3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications
Kelton, J. G.
Kemp, F.
Kempe, S.
Kemper, R.
Kempf, V. A.
Kempton, C. L.
Kendall, E.
Kenderian, S. S.
887 - Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study
907 - Caspase-1 Inhibition Ameliorates CAR T-Cell Apoptosis and Tumor Cell Pyroptosis to Enhance the Efficacy and Safety of CAR T-Cell Therapy
908 - Intrinsic Immunosuppressive Features of Monocytes Suppress CART19 through IL-1 Pathway Modulation in Mantle Cell Lymphoma
1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
2274 - Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy
2372 - Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy
4616 - Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)
4633 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004
4808 - Identification of T Cell Senescence As a Cell Fate Limiting the Antitumor Activity of 41BB-Costimulated CART Cells
907 - Caspase-1 Inhibition Ameliorates CAR T-Cell Apoptosis and Tumor Cell Pyroptosis to Enhance the Efficacy and Safety of CAR T-Cell Therapy
908 - Intrinsic Immunosuppressive Features of Monocytes Suppress CART19 through IL-1 Pathway Modulation in Mantle Cell Lymphoma
1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
2274 - Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy
2372 - Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy
4616 - Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)
4633 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004
4808 - Identification of T Cell Senescence As a Cell Fate Limiting the Antitumor Activity of 41BB-Costimulated CART Cells
Kendrick, N.
Kenealy, M.
Kenet, G.
Kenet, G.
Keng, M.
791 - Quality Improvement Initiative of Patients with Acute Myeloid Leukemia Receiving Non-Intensive Therapy in Academic-Community Medicine Partnerships in Rural Appalachia
2878 - A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
2878 - A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Kenichi, M.
Kenkre, V. P.
473 - Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma
525 - Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
570 - Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma
612 - Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
4415 - A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study
525 - Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
570 - Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma
612 - Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
4415 - A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study
Kennah, M.
Kennaway, C.
Kennedy, A.
Kennedy, C. T.
Kennedy, C. C.
Kennedy, II, D.
Kennedy, N.
Kennedy, V. E.
69 - CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up
96 - Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
679 - Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL
723 - CDK8 Inhibition Represses Monocyte-like Gene Expression in Acute Myeloid Leukemia Cells and Antagonizes In Vivo Resistance to FLT3 Inhibition
1379 - AML Derived Induced Pluripotent Stem Cells Reveal a Genotype-Independent Effect of Monocytic Differentiation in Mediating Venetoclax Resistance
2006 - Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma
2064 - CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma
2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
4846 - Indolent CD8+ CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
96 - Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
679 - Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL
723 - CDK8 Inhibition Represses Monocyte-like Gene Expression in Acute Myeloid Leukemia Cells and Antagonizes In Vivo Resistance to FLT3 Inhibition
1379 - AML Derived Induced Pluripotent Stem Cells Reveal a Genotype-Independent Effect of Monocytic Differentiation in Mediating Venetoclax Resistance
2006 - Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma
2064 - CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma
2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
4846 - Indolent CD8+ CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
Kennel, S. J.
Kenney, L. B.
Kent, A.
969 - Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy
1828 - Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts
3803 - Access to Novel Therapies Impacts Overall Survival (OS) in Low Socioeconomic (SES) Acute Myeloid Leukemia (AML) Patients (Pts)
4259 - Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia
4266 - Efficacy and Molecular Predictors of Response and Survival for Venetoclax/Azacitidine Therapy in Relapsed or Refractory Acute Myeloid Leukemia
1828 - Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts
3803 - Access to Novel Therapies Impacts Overall Survival (OS) in Low Socioeconomic (SES) Acute Myeloid Leukemia (AML) Patients (Pts)
4259 - Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia
4266 - Efficacy and Molecular Predictors of Response and Survival for Venetoclax/Azacitidine Therapy in Relapsed or Refractory Acute Myeloid Leukemia
Kent, D.
Kent, G.
Kent, J.
Kent, T.
Kentos, A.
Kentsis, A.
825 - The Histone Acetyltransferase MOZ (KAT6A) Is a Molecular Dependency and Therapeutic Target in NUP98-Rearranged Acute Myeloid Leukemia
4137 - Targeting PERK Arm of Unfolded Protein Response Helps to Eliminate Therapy-Induced Residual Senescent-like Acute Myeloid Leukemia Cells
4149 - Proteolytic Control and Therapeutic Targeting of Oncogenic Gene Expression in Acute Myeloid Leukemia
4265.2 - A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)
4137 - Targeting PERK Arm of Unfolded Protein Response Helps to Eliminate Therapy-Induced Residual Senescent-like Acute Myeloid Leukemia Cells
4149 - Proteolytic Control and Therapeutic Targeting of Oncogenic Gene Expression in Acute Myeloid Leukemia
4265.2 - A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)
Kenyon, R.
991 - Strong Association between Cancer Gene Variants at Diagnosis, Especially ASXL1, and Emergence of Kinase Domain Mutation-Driven Resistance in CML Patients Despite Frontline Treatment with More Potent BCR::ABL1 Inhibitors
996 - Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure
996 - Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure
Keogh, L.
Keppeler, H.
Keren, L.
Keresteci, E.
Kerkhoff, A.
114 - Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
568 - PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial
859 - Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First – Line Treatment for Waldenström’s Macroglobulinemia: Results of the Multicenter Phase II trial (ECWM-2) of the European Consortium for Waldenström’s Macroglobulinemia
4242 - “As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022
568 - PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial
859 - Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First – Line Treatment for Waldenström’s Macroglobulinemia: Results of the Multicenter Phase II trial (ECWM-2) of the European Consortium for Waldenström’s Macroglobulinemia
4242 - “As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022
Kerlin, B. A.
297 - Development and Validation of a Risk Assessment Model for Venous Thromboembolism in the Pediatric Intensive Care Unit
1257 - Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
3963 - Hypoalbuminemia Increases Clot Fibrin Network Density and Reduces Fibrinolytic Susceptibility through a Paraoxonase 1 Dependent Mechanism
1257 - Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
3963 - Hypoalbuminemia Increases Clot Fibrin Network Density and Reduces Fibrinolytic Susceptibility through a Paraoxonase 1 Dependent Mechanism
Kermani, P.
Kern, M. A.
2018 - Local Myeloid Network Resilience Determines Organ-Specific Acute GvHD Outcomes
2023 - CD47 Upregulation Inhibits Phagocytic Clearance of Alloreactive Donor T Cells after Allo-HCT
3402 - Allogeneic Hematopoietic Cell Transplantation Promotes Atherosclerosis in Mice Driven By Donor CD8+ T Cells
2023 - CD47 Upregulation Inhibits Phagocytic Clearance of Alloreactive Donor T Cells after Allo-HCT
3402 - Allogeneic Hematopoietic Cell Transplantation Promotes Atherosclerosis in Mice Driven By Donor CD8+ T Cells
Kern, W.
899 - Secondary Cytogenetic and Molecular Genetic Abnormalities in Newly Diagnosed Multiple Myeloma Patients
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
1819 - Similarities and Differences of DNMT3A, TET2 and ASXL1 Mutations across Ccus, MDS and AML
1836 - Two Ways to Complex Karyotype in MDS - the Role of Del(5q) and TP53
4104 - Telomere Content Diversity in Myeloid Neoplasia Could Inform on Differential Sensitivity to Telomerase Inhibitors
4318 - Clonal Hematopoiesis Can Precede AML with Defining Cytogenetic Abnormalities - the Frequencies Vary Considerably
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
1819 - Similarities and Differences of DNMT3A, TET2 and ASXL1 Mutations across Ccus, MDS and AML
1836 - Two Ways to Complex Karyotype in MDS - the Role of Del(5q) and TP53
4104 - Telomere Content Diversity in Myeloid Neoplasia Could Inform on Differential Sensitivity to Telomerase Inhibitors
4318 - Clonal Hematopoiesis Can Precede AML with Defining Cytogenetic Abnormalities - the Frequencies Vary Considerably
Kerper, R.
Kerr, II, D. A.
Kerridge, I. H.
Kersilova, A.
Kersten, M. J.
93 - Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
748 - Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)
4388 - Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
748 - Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)
4388 - Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
Kersten, M. J.
1654 - Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical
1747 - Population-Based External Validation of the CAR-Hematotox Score to Predict CAR T Cell Related Toxicity and Outcome in R/R LBCL Patients
2042 - CTLA-4-Based Activation Inducible Costimulatory Receptors Endow CAR-T Cells with Safe, Tumor-Restricted, Multi-Targeting and Increased Persistence
3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
1747 - Population-Based External Validation of the CAR-Hematotox Score to Predict CAR T Cell Related Toxicity and Outcome in R/R LBCL Patients
2042 - CTLA-4-Based Activation Inducible Costimulatory Receptors Endow CAR-T Cells with Safe, Tumor-Restricted, Multi-Targeting and Increased Persistence
3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
Kersting, S.
586 - Mutations in BCOR, CCND2, NRAS and XPO1 Predict Clinical Outcomes upon MRD-Guided Venetoclax Plus Ibrutinib in Relapsed and Refractory Chronic Lymphocytic Leukemia
888 - Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax
1013 - Improved Efficacy with Response- and MRD-Guided Ibrutinib–Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial
888 - Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax
1013 - Improved Efficacy with Response- and MRD-Guided Ibrutinib–Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial
Kertész, L.
Keruakous, A. R.
2132 - Efficacy of Recombinant Human Erythropoietin in Enhancing Erythroid Hematopoietic Recovery after Allogeneic Hematopoietic Stem Cell Transplantation: A Meta-Analysis
2443 - Unveiling Regional Disparities in Cancer Care - Analysis of the Geographical Journey and Relocation Patterns of Hematology/Oncology Fellowship Graduates
3160 - Clinical Assessment of Cumulative Stress Via Allostatic Load in Chronic Myeloid Leukemia Patients: Implications for Treatment Outcomes
2443 - Unveiling Regional Disparities in Cancer Care - Analysis of the Geographical Journey and Relocation Patterns of Hematology/Oncology Fellowship Graduates
3160 - Clinical Assessment of Cumulative Stress Via Allostatic Load in Chronic Myeloid Leukemia Patients: Implications for Treatment Outcomes
Kesavan, M.
Keschner, Y.
Keshamoni, S.
Keshari, R. S.
Keshishian, H.
Keshvari, S.
Kesler, M.
Kesper, S.
Kesse-Adu, R.
Kessel, J.
Kesselheim, A. S.
2077 - Secondary Hematologic Malignancies in Patients Following Chimeric Antigen Receptor T-Cell Therapy: Aggregated Clinical Trial Data from 1542 Patients
3659 - Global Access to Chimeric Antigen Receptor (CAR) T-Cell Therapies: Health Technology Assessment (HTA) of CAR T in G7 Countries and Australia
3659 - Global Access to Chimeric Antigen Receptor (CAR) T-Cell Therapies: Health Technology Assessment (HTA) of CAR T in G7 Countries and Australia
Kessler, C.
2592 - Indirect Comparison of the Efficacy and Therapy-Related Costs of a Pharmacokinetic and Individualized Prophylaxis Regimen with Simoctocog Alfa Versus Other Extended-Half Life Factor VIII Concentrates
3972 - Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors
3972 - Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors
Kessler, D. A.
23 - Iron Repletion of Iron-Deficient Blood Donors Affects Brain Iron, Myelin, and Neural Network Activation Patterns
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
Kessler, L.
Kester, L. A.
1459 - Challenging Conventional Diagnostic Methods By Comprehensive Molecular Diagnostics: Results of a Nationwide Prospective Comparison in Children with Acute Lymphoblastic Leukemia
2830 - A Non-Canonical Lymphoblast in Refractory Childhood T-Cell Acute Lymphoblastic Leukemia
2985 - High Clinical Benefit of Diagnostic RNA Sequencing in Pediatric T-Cell Lymphoblastic Lymphoma for the Identification of Potentially Targetable Risk Groups
2830 - A Non-Canonical Lymphoblast in Refractory Childhood T-Cell Acute Lymphoblastic Leukemia
2985 - High Clinical Benefit of Diagnostic RNA Sequencing in Pediatric T-Cell Lymphoblastic Lymphoma for the Identification of Potentially Targetable Risk Groups
Kester, M. G.
Ketela, T.
Ketharnathan, S.
Ketineni, S.
Kettlun, C.
Keuker, C. P.
Kevane, B.
Kevličius, L.
Kewan, T.
664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
736 - Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)
788 - Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia
850 - Clinical and Molecular Insights into the Classification Dilemma: Are MDS/AML Cases Distinct from Secondary AML?
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
3199 - Could Somatic Gene Rescue Explain Frequency of Compound Heterozygous and Concurrent Receptor Tyrosine Kinase Mutations in Hematological Diseases?
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
3644 - Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States
4436 - Clinically Driven Algorithms Identify Patients with Large Granular Lymphocytic Leukemia at Risk of Significant Cytopenia Requiring Treatment
4440 - Gene Copy Number Alterations Identify Subsets of Mycosis Fungoides/Sézary Syndrome Patients with Worse Survival Outcomes
4582 - ETV6 Mutations in Myeloid Neoplasia: Unraveling Clinical Features and Molecular Signatures
4585 - Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab
736 - Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)
788 - Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia
850 - Clinical and Molecular Insights into the Classification Dilemma: Are MDS/AML Cases Distinct from Secondary AML?
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
3199 - Could Somatic Gene Rescue Explain Frequency of Compound Heterozygous and Concurrent Receptor Tyrosine Kinase Mutations in Hematological Diseases?
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
3644 - Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States
4436 - Clinically Driven Algorithms Identify Patients with Large Granular Lymphocytic Leukemia at Risk of Significant Cytopenia Requiring Treatment
4440 - Gene Copy Number Alterations Identify Subsets of Mycosis Fungoides/Sézary Syndrome Patients with Worse Survival Outcomes
4582 - ETV6 Mutations in Myeloid Neoplasia: Unraveling Clinical Features and Molecular Signatures
4585 - Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab
Key, N. S.
Keyvanfar, K.
Kfir-Erenfeld, S.
Kfoury, A.
Khabusheva, E.
Khaddour, K.
Khadka, S.
Khaire, N. S.
1427 - Evaluating the Safety of Tyrosine Kinase Inhibitor Discontinuation in Adult Patients with Ph+ ALL Not Undergoing Allogeneic Transplant
4207 - Combination Therapy with Nelarabine, Peg-Asparaginase and Venetoclax for Adults Patients with Relapsed/Refractory T-Cell ALL
4306 - Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy
4207 - Combination Therapy with Nelarabine, Peg-Asparaginase and Venetoclax for Adults Patients with Relapsed/Refractory T-Cell ALL
4306 - Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy
Khalaf, D.
2764 - The Transcription Factor IRF8 Regulates the Sensitivity of AML Cells to LSD1 Inhibition and All-Trans Retinoic Acid
4583 - Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment
4598 - Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents
4583 - Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment
4598 - Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents
Khalaf, D.
Khalaf, M. H.
Khaled, A.
Khalid, A.
Khalid, M. F.
2622 - Uncovering the Risks: Bleeding and Thrombotic Complications of JAK Inhibitors in Hematological Conditions: A Comprehensive Systematic Review and Meta-Analysis
3503 - Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis
3524 - Sociodemographic and Patient-Related Determinants of Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3543 - Outcomes of Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis in Elderly Patients over 70 Years of Age with Acute Leukemia and Myelodysplastic Syndromes
4877 - Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis
3503 - Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis
3524 - Sociodemographic and Patient-Related Determinants of Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3543 - Outcomes of Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis in Elderly Patients over 70 Years of Age with Acute Leukemia and Myelodysplastic Syndromes
4877 - Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis
Khalife, R.
554 - Clinical and Economic Outcome Analysis of First-Line Immunosuppression in Acquired Hemophilia a
3632 - “I Didn’t Know I Had a Choice” – Patient Values and Preferences Regarding Resumption of Oral Anticoagulants after Gastrointestinal Bleeding
3634 - From Theory to Therapy: Evaluating Canadian Hemophilia Treatment Centres' Readiness for Gene Therapy Implementation
3821 - Development of a National Needs Driven Intrinsic Roles Curriculum for Canadian Hematology Residency Training Programs
3632 - “I Didn’t Know I Had a Choice” – Patient Values and Preferences Regarding Resumption of Oral Anticoagulants after Gastrointestinal Bleeding
3634 - From Theory to Therapy: Evaluating Canadian Hemophilia Treatment Centres' Readiness for Gene Therapy Implementation
3821 - Development of a National Needs Driven Intrinsic Roles Curriculum for Canadian Hematology Residency Training Programs
Khalil, M.
Khalili, L.
Khalilian, K. E.
Khaliq, F.
Kham, S. K. Y.
Khamari, M.
Khamis, A.
Khamis, Z.
2641 - Cancer-Associated Venous Thromboembolism Among Solid and Hematological Malignancies: A Comprehensive National Study
3903 - From Harmless to Harmful: Meta-Analysis and Systematic Review of Adverse Clinical Outcomes in Sickle Cell Trait
3936 - Maternal Bleeding Complications in Pregnant Women with Immune Thrombocytopenic Purpura: A Retrospective National Study
3903 - From Harmless to Harmful: Meta-Analysis and Systematic Review of Adverse Clinical Outcomes in Sickle Cell Trait
3936 - Maternal Bleeding Complications in Pregnant Women with Immune Thrombocytopenic Purpura: A Retrospective National Study
Khamissi, F.
Khammanivong, A.
Khamwong, M.
Khan, A. N.
Khan, A.
Khan, A.
Khan, A. M.
285 - Lovesick: Examining Couples Health during Myeloma Transplant
2009 - A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment
2404 - Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities—a Multicenter Study
2411b - Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial
2411g - Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma
4717 - Cytomegalovirus Reactivation in Patients with Multiple Myeloma Treated with Teclistamab: Risk Factors and Clinical Impact
5040 - Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns
5170d - Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients
2000.1 - MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial
- Adult BMT/Cellular Therapy
2009 - A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment
2404 - Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities—a Multicenter Study
2411b - Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial
2411g - Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma
4717 - Cytomegalovirus Reactivation in Patients with Multiple Myeloma Treated with Teclistamab: Risk Factors and Clinical Impact
5040 - Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns
5170d - Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients
2000.1 - MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial
- Adult BMT/Cellular Therapy
Khan, A. O.
Khan, A. M.
933 - Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings
3792h - Upfront Use of Anti-CD38 Monoclonal Antibodies Is Associated with Improvement in Renal Failure in Multiple Myeloma: A Flatiron Real World Analysis from 2010 to 2023
3792h - Upfront Use of Anti-CD38 Monoclonal Antibodies Is Associated with Improvement in Renal Failure in Multiple Myeloma: A Flatiron Real World Analysis from 2010 to 2023
Khan, A.
Khan, A.
Khan, A.
485 - Dynamics of Calr variant Allele Frequency with Therapy in Myeloproliferative Neoplasms
1804 - Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
4557 - Mympnvoice – a Novel Smartphone App for Monitoring Patient Reported Outcomes and Biometric Data in Patients with Myeloproliferative Neoplasms
1804 - Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
4557 - Mympnvoice – a Novel Smartphone App for Monitoring Patient Reported Outcomes and Biometric Data in Patients with Myeloproliferative Neoplasms
Khan, A.
Khan, A. N.
1119 - Beyond the Binary: Analysis of Sickle Cell Disease Crisis Hospitalizations in the Transgender Population in United States: National Inpatient Data Base Study from 2012-2020
1128 - Beyond the Binary: Analysis of Sickle Cell Disease Crisis Hospitalizations in the Transgender Population in United States
1128 - Beyond the Binary: Analysis of Sickle Cell Disease Crisis Hospitalizations in the Transgender Population in United States
Khan, D.
Khan, F. A.
Khan, F.
Khan, F.
Khan, H.
2303 - Comprehensive Assessment of Adequate Nutrition in Children and Adults with Sickle Cell Disease As Determined By Dietary Guidelines for Americans
2309 - Pain-Specific Patient-Reported Outcomes Are Worse in Adults Compared to Children with Sickle Cell Disease
3893 - Individuals with Sickle Cell Disease Have Decreased Intestinal Microbial Diversity Compared to Healthy Related and Unrelated Black Individuals without Sickle Cell Disease
2309 - Pain-Specific Patient-Reported Outcomes Are Worse in Adults Compared to Children with Sickle Cell Disease
3893 - Individuals with Sickle Cell Disease Have Decreased Intestinal Microbial Diversity Compared to Healthy Related and Unrelated Black Individuals without Sickle Cell Disease
Khan, H. N.
Khan, H.
Khan, I.
2423 - Association of Neighborhood Crime with AML Molecular Subtypes and Survival
2887 - Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
3794 - Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis
2887 - Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
3794 - Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis
Khan, M. A.
3791 - CAR-T Therapy Showdown: Comparative Efficacy and Safety of of Ide-Cel (Idecabtagene vicleucel) and Cilta-Cel (Ciltacabtagene Autoleucel) in Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Study
5160 - Risk of Infection: Real-World Analysis of (Ide-cel) Idecabtagene Vicleucel and (Cilta-cel) Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
5160 - Risk of Infection: Real-World Analysis of (Ide-cel) Idecabtagene Vicleucel and (Cilta-cel) Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Khan, M. A.
Khan, M.
Khan, N.
Khan, N.
Khan, N.
Khan, N.
Khan, R.
Khan, S.
Khan, S.
Khan, S. J.
Khan, T.
3791 - CAR-T Therapy Showdown: Comparative Efficacy and Safety of of Ide-Cel (Idecabtagene vicleucel) and Cilta-Cel (Ciltacabtagene Autoleucel) in Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Study
5160 - Risk of Infection: Real-World Analysis of (Ide-cel) Idecabtagene Vicleucel and (Cilta-cel) Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
5160 - Risk of Infection: Real-World Analysis of (Ide-cel) Idecabtagene Vicleucel and (Cilta-cel) Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Khanal, M.
Khanal, R.
864 - 5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
2091 - Comparative Analysis of Dexamethasone-Enhanced Pre-Medication in Motixafortide-Induced Hematopoietic Stem Cell Mobilization for Multiple Myeloma: A Retrospective Study
2165 - Effects of Post-Transplant Cyclophosphamide on Outcomes of Allogeneic Stem Cell Transplant Are Different between Older and Younger Adult Patients: A Single Institutional Experience
3052 - Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study
2091 - Comparative Analysis of Dexamethasone-Enhanced Pre-Medication in Motixafortide-Induced Hematopoietic Stem Cell Mobilization for Multiple Myeloma: A Retrospective Study
2165 - Effects of Post-Transplant Cyclophosphamide on Outcomes of Allogeneic Stem Cell Transplant Are Different between Older and Younger Adult Patients: A Single Institutional Experience
3052 - Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study
Khanam, R.
Khanapara, D.
Khandaker, I.
Khandanpour, C.
2003 - Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma
3383 - Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study
4759 - Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis
3383 - Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study
4759 - Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis
Khandelwal, N.
Khandelwal, S.
174 - Molecular Mechanism Underlying Excessive Phosphatidylserine Exposure in Sickle Red Blood Cells and Potential Therapeutics
2605 - Complement Activation As a Biomarker for Platelet Activating Antibodies in Heparin-Induced Thrombocytopenia (HIT)
2609 - Inflammasome Cytokine Secretion in Heparin-Induced Thrombocytopenia Is Supported By Platelet-Derived Mediators and Complement
2605 - Complement Activation As a Biomarker for Platelet Activating Antibodies in Heparin-Induced Thrombocytopenia (HIT)
2609 - Inflammasome Cytokine Secretion in Heparin-Induced Thrombocytopenia Is Supported By Platelet-Derived Mediators and Complement
Khandros, E.
Khanhlinh, D.
Khanlari, M.
Khanna, A.
2347 - Acuity of Illness at Initial Presentation Mediates Early Mortality in Adolescent and Young Adult Leukemia
4204 - A Retrospective Study of Inotuzumab Ozogamicin in Individuals with Down Syndrome and B-Cell Acute Lymphoblastic Leukemia
5110 - Association of Race, Ethnicity, and Social Deprivation on the Incidence and Severity of Adverse Events in Induction in Children with Acute Lymphoblastic Leukemia
4204 - A Retrospective Study of Inotuzumab Ozogamicin in Individuals with Down Syndrome and B-Cell Acute Lymphoblastic Leukemia
5110 - Association of Race, Ethnicity, and Social Deprivation on the Incidence and Severity of Adverse Events in Induction in Children with Acute Lymphoblastic Leukemia
Khanna, P.
Khanna, S.
Khanna, S.
1267 - Higher Rate of Red Blood Cell (RBC) Alloimmunization in RBC-Transfused Myelodysplastic Syndrome Compared to Acute Myeloid Leukemia
3208 - Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS
4237 - High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies
3208 - Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS
4237 - High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies
Khanna, V.
Kharabsheh, H.
Kharas, M. G.
627 - Rbmx Regulates YTHDC1 Nuclear Condensates to Promote Nascent Transcription in Acute Myeloid Leukemia
2207 - Selective Inhibition of the m6a RNA Reader, YTHDC1, As a Novel Therapeutic Strategy for MYC-Driven Acute Myeloid Leukemia
4106 - Uncovering the HOXA9 Translational Regulatory Complex That Promotes AML Leukemic Stem Cells
2207 - Selective Inhibition of the m6a RNA Reader, YTHDC1, As a Novel Therapeutic Strategy for MYC-Driven Acute Myeloid Leukemia
4106 - Uncovering the HOXA9 Translational Regulatory Complex That Promotes AML Leukemic Stem Cells
Kharat, S. V.
Kharboutli, S.
684 - Update on Monocentric CD19-CAR T-Cell Therapy in 30 Patients with Autoimmune Disease
2003 - Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma
4835 - Distinct Safety and Toxicity Profile of CD19-Directed CAR T-Cell Therapy in Systemic Lupus Erythematosus Versus B-Cell Lymphoma – a Single-Center Experience
2003 - Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma
4835 - Distinct Safety and Toxicity Profile of CD19-Directed CAR T-Cell Therapy in Systemic Lupus Erythematosus Versus B-Cell Lymphoma – a Single-Center Experience
Khare, S.
Kharel, H.
Kharfan-Dabaja, M. A.
507 - Impact of Total Body Irradiation-Based Conditioning Regimens on Outcomes in Patients with Aggressive Mature T-Cell Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplant
887 - Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study
1651 - Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma
1823 - Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series
2372 - Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy
3218 - PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations
5129 - Impact of Extranodal Involvement on Outcomes with Chimeric Antigen Receptor T-Cell Therapy in B-Cell Non-Hodgkin Lymphoma
887 - Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study
1651 - Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma
1823 - Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series
2372 - Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy
3218 - PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations
5129 - Impact of Extranodal Involvement on Outcomes with Chimeric Antigen Receptor T-Cell Therapy in B-Cell Non-Hodgkin Lymphoma
Kharya, G.
176 - Allogeneic Transplantation for Sickle Cell Disease Offers High Rates of Cure with Low Incidence of Severe Chronic GVHD in Both Children and Adults: Real World Data from 2010-2021. An Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
4927 - Patient-Parent Reported Quality of Life Assessment Post Hematopoietic Stem Cell Transplant for Sickle Cell Disease: Validation and Clinical Application of Sickle Cell Disease Burden Index
4927 - Patient-Parent Reported Quality of Life Assessment Post Hematopoietic Stem Cell Transplant for Sickle Cell Disease: Validation and Clinical Application of Sickle Cell Disease Burden Index
Khasabov, S. G.
Khasabova, I. A.
Khasawneh, A.
Khater, E. E.
Khatib, H.
1748 - Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma
3482 - The Ability of Currently Used Scoring Systems to Predict 30 and 100-Days Non-Relapse Mortality Among Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
4269 - For Patients with Adverse-Risk Acute Myeloid Leukemia, Frontline FLAG Ida with Venetoclax Is Safe and Efficacious
4393 - Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma
3482 - The Ability of Currently Used Scoring Systems to Predict 30 and 100-Days Non-Relapse Mortality Among Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
4269 - For Patients with Adverse-Risk Acute Myeloid Leukemia, Frontline FLAG Ida with Venetoclax Is Safe and Efficacious
4393 - Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma
Khatib, H.
Khattry, N.
852 - Machine Learning Identifies Gene Mutations and Variant Allele Fractions That Refine the 2022 European Leukemianet Risk Stratification for Acute Myeloid Leukemia
1550 - Prognostic Significance of Wilms’ Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes
2931 - Double Trouble: Composite Mutations in Driver Genes in Acute Myeloid Leukemia (AML)
2953 - Leukemic Stem Cell Measurable Residual Disease (LSC MRD) Status Is a Better Predictor of Relapse Than Multiparametric Flowcytometric Analysis in Acute Myeloid Leukemia Patients
3161 - Making Treatment Free Remission “Feasible” in Low- and Middle- Income Countries - Outcomes, Patterns of Failure and Compliance of Treatment Free Remission (TFR) in Chronic Myeloid Leukemia (CML) from a Tertiary Care Cancer Centre in India
3755 - Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile
4290 - Mutational Landscape and Factors Affecting Prognosis in Acute Myeloid Leukaemia (AML) with RUNX1::RUNX1T1
4310 - Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia (AML)
4901 - Diagnostic Value, Predictive Significance and Kinetics of Fecal Calprotectin in Suspected Acute Gut Gvhd / Gvhd Flare Post Allogeneic Stem Cell Transplant
1550 - Prognostic Significance of Wilms’ Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes
2931 - Double Trouble: Composite Mutations in Driver Genes in Acute Myeloid Leukemia (AML)
2953 - Leukemic Stem Cell Measurable Residual Disease (LSC MRD) Status Is a Better Predictor of Relapse Than Multiparametric Flowcytometric Analysis in Acute Myeloid Leukemia Patients
3161 - Making Treatment Free Remission “Feasible” in Low- and Middle- Income Countries - Outcomes, Patterns of Failure and Compliance of Treatment Free Remission (TFR) in Chronic Myeloid Leukemia (CML) from a Tertiary Care Cancer Centre in India
3755 - Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile
4290 - Mutational Landscape and Factors Affecting Prognosis in Acute Myeloid Leukaemia (AML) with RUNX1::RUNX1T1
4310 - Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia (AML)
4901 - Diagnostic Value, Predictive Significance and Kinetics of Fecal Calprotectin in Suspected Acute Gut Gvhd / Gvhd Flare Post Allogeneic Stem Cell Transplant
Khavandgar, N.
2102 - Outcomes after Matched Sibling Donor Versus Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
2119 - Outcomes after Bone Marrow Versus Peripheral Blood Matched Sibling Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis
2122 - Sociodemographic and Patient-Related Determinants of Outcomes after Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
2141 - Impact of Conditioning Intensity on Outcomes after Allogeneic Related Donor HCT with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis in Acute Leukemia and Myelodysplastic Syndromes
3503 - Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis
3517 - Factors Associated with Graft-Versus-Host Disease after Related Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3524 - Sociodemographic and Patient-Related Determinants of Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3543 - Outcomes of Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis in Elderly Patients over 70 Years of Age with Acute Leukemia and Myelodysplastic Syndromes
4877 - Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis
2119 - Outcomes after Bone Marrow Versus Peripheral Blood Matched Sibling Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis
2122 - Sociodemographic and Patient-Related Determinants of Outcomes after Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
2141 - Impact of Conditioning Intensity on Outcomes after Allogeneic Related Donor HCT with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis in Acute Leukemia and Myelodysplastic Syndromes
3503 - Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis
3517 - Factors Associated with Graft-Versus-Host Disease after Related Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3524 - Sociodemographic and Patient-Related Determinants of Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3543 - Outcomes of Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis in Elderly Patients over 70 Years of Age with Acute Leukemia and Myelodysplastic Syndromes
4877 - Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis
Khaw, S. L.
Khawaja, F.
Khawaja, R.
Khazaee, T.
Khazaei, S.
726 - Mitigating Therapy-Related Myeloid Neoplasia in p53-Mutant Clones through Targeted DNA Repair Pathway Inhibition with PARP Inhibitors
882 - Novel p53 Mutant Mouse Model Recapitulates the Biology of Human Therapy-Related Myeloid Neoplasms
2755 - Targeting Co-Regulatory Feedback Loop of MYC and GSPT1 By MYC/GSPT1 Dual Degradation Is Synthetic Lethal in Combination with Ven/Aza in TP53 Mutant Acute Myeloid Leukemia Stem and Progenitor Cells
882 - Novel p53 Mutant Mouse Model Recapitulates the Biology of Human Therapy-Related Myeloid Neoplasms
2755 - Targeting Co-Regulatory Feedback Loop of MYC and GSPT1 By MYC/GSPT1 Dual Degradation Is Synthetic Lethal in Combination with Ven/Aza in TP53 Mutant Acute Myeloid Leukemia Stem and Progenitor Cells
Khazal, S.
Khemani, K.
Khera, N.
507 - Impact of Total Body Irradiation-Based Conditioning Regimens on Outcomes in Patients with Aggressive Mature T-Cell Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplant
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
Khiabanian, H.
Khimani, F.
1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2103 - Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy
2130 - Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide
4826 - Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation
4871 - Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis
4881 - Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2103 - Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy
2130 - Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide
4826 - Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation
4871 - Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis
4881 - Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia
Khismatullin, R. R.
Khodadoust, M. S.
454 - Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas
466 - Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial
980 - Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization
1609 - Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial
1677 - Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma
2955 - Circulating Tumor DNA (ctDNA) Enables Superior and Universal Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) Highly Predictive of Relapse Free and Overall Survival
4846 - Indolent CD8+ CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma
466 - Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial
980 - Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization
1609 - Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial
1677 - Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma
2955 - Circulating Tumor DNA (ctDNA) Enables Superior and Universal Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) Highly Predictive of Relapse Free and Overall Survival
4846 - Indolent CD8+ CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma
Khodaparast, N.
Khoel, B.
Khogeer, H. A.
Kholodenko, B.
Khonkhammy, D.
Khoo, A. S.
Khopanlert, W.
Khorana, A. A.
2259 - Utilization and Clinical Outcomes of an Electronic Best Practice Alert to Prevent Venous Thromboembolism in High-Risk Cancer Patients
5086 - Clinical Outcomes of Cancer-Associated Venous Thromboembolism in Patients with Gastrointestinal or Genitourinary Cancers Treated with Direct Oral Anticoagulant Vs. Low Molecular Weight Heparin
5086 - Clinical Outcomes of Cancer-Associated Venous Thromboembolism in Patients with Gastrointestinal or Genitourinary Cancers Treated with Direct Oral Anticoagulant Vs. Low Molecular Weight Heparin
Khorashad, J.
Khoriaty, R.
Khoruts, A.
Khoshdeli, M.
Khosla, M.
Khouja, M.
2959 - Circulating Tumor DNA Kinetics at Day 14 after CAR T-Cell Therapy Identifies Patients with B-Cell Lymphoma at Risk for Early Treatment Failure
4352 - Determining the Mutational Landscape of Waldenström’s Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström’s Macroglobulinemia
4352 - Determining the Mutational Landscape of Waldenström’s Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström’s Macroglobulinemia
Khouri, A.
Khouri, I. F.
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
2124 - Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial
2810 - Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
3514 - Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis
2124 - Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial
2810 - Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
3514 - Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis
Khouri, J.
897 - Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
1022 - Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light‑Chain (AL) Amyloidosis
1911 - Assessing the Efficacy and Safety of Reduced Dexamethasone Duration in Newly Diagnosed AL Amyloidosis Versus Standard Therapy
1918 - Current Management of Non-Amyloidosis Monoclonal Gammopathy of Renal Significance: Clinical Features, Treatment Selection, Response, and Renal Outcomes in a Recently Treated Patients
1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1969 - Epidemiological Trends in Incidence, Death and Associated Risk Factors of Multiple Myeloma 1990-2021 and Projection to 2040
2382 - Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4708 - An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
4858 - An Open-Label, Multi-Center Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) and Propranolol with G-CSF for the Mobilization of Stem Cells in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant
5170h - Improving Specialty Access for Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Plasma Cell Disorders (PCDs): 10 Years of Experience and a Successful Model of Care
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
1022 - Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light‑Chain (AL) Amyloidosis
1911 - Assessing the Efficacy and Safety of Reduced Dexamethasone Duration in Newly Diagnosed AL Amyloidosis Versus Standard Therapy
1918 - Current Management of Non-Amyloidosis Monoclonal Gammopathy of Renal Significance: Clinical Features, Treatment Selection, Response, and Renal Outcomes in a Recently Treated Patients
1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1969 - Epidemiological Trends in Incidence, Death and Associated Risk Factors of Multiple Myeloma 1990-2021 and Projection to 2040
2382 - Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4708 - An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
4858 - An Open-Label, Multi-Center Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) and Propranolol with G-CSF for the Mobilization of Stem Cells in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant
5170h - Improving Specialty Access for Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Plasma Cell Disorders (PCDs): 10 Years of Experience and a Successful Model of Care
Khouri, M. R.
Khoury, H.
Khoury, J. D.
Khraise, T.
1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
Khurana, A.
580 - A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma
784 - Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience
1651 - Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma
2274 - Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy
2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes
2372 - Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy
3019 - Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients
3093 - Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study
784 - Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience
1651 - Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma
2274 - Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy
2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes
2372 - Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy
3019 - Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients
3093 - Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study
Khurana, R. K.
Khush, K.
Khvat, A.
Khvedelidze, I.
399 - Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
464 - Autologous and Allogeneic Stem Cell Transplantation for Major T-Cell Lymphoma Entities: An Analysis of the EBMT Lymphoma Working Party
749 - Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
3010 - Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenström’s Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)
3027 - Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
4950 - Outcome of Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma (ATL) after Allogeneic SCT: Results of the EBMT LWP
464 - Autologous and Allogeneic Stem Cell Transplantation for Major T-Cell Lymphoma Entities: An Analysis of the EBMT Lymphoma Working Party
749 - Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
3010 - Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Waldenström’s Macroglobulinemia. Report from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (LWP EBMT)
3027 - Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
4950 - Outcome of Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma (ATL) after Allogeneic SCT: Results of the EBMT LWP
Khvedelidze, I.
1663 - Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group
3656 - Real-World Practice Patterns of Patient Management in the Peri-CAR T-Cell Therapy Setting for Patients with Mantle Cell Lymphoma: An International Survey on Behalf of the EBMT Lymphoma Working Party
3656 - Real-World Practice Patterns of Patient Management in the Peri-CAR T-Cell Therapy Setting for Patients with Mantle Cell Lymphoma: An International Survey on Behalf of the EBMT Lymphoma Working Party
Khwaja, J.
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
890 - Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System
3023 - Focal Symptomatic Bone Involvement with Waldenström’s Macroglobulinaemia and Non-IgM Lymphoplasmacytic Lymphoma
3039 - Bing-Neel Syndrome – a Case Series of 46 Patients from the United Kingdom
4684 - Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis
890 - Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System
3023 - Focal Symptomatic Bone Involvement with Waldenström’s Macroglobulinaemia and Non-IgM Lymphoplasmacytic Lymphoma
3039 - Bing-Neel Syndrome – a Case Series of 46 Patients from the United Kingdom
4684 - Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis
Kiani, A.
1766 - Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) – an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial
4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial
Kida, J.
Kidane, A.
290 - Oxygen Gradient Ektacytometry Is Associated with Markers of Hemolysis and Inflammation in a Large Sickle Cell Disease Cohort within the GenoMed4ALL Project
1112 - Iron Deficiency in HbSC Disease Is Associated with Less Sickle Cell Disease-Related Complications – a Rationale for Repetitive Phlebotomy As Disease Modifying Therapy
3901 - Mapping Total Cortical Volume of Children and Adolescents with Sickle Cell Disease Against Normative Growth Trajectories: First Baseline Results of the Brick Study
1112 - Iron Deficiency in HbSC Disease Is Associated with Less Sickle Cell Disease-Related Complications – a Rationale for Repetitive Phlebotomy As Disease Modifying Therapy
3901 - Mapping Total Cortical Volume of Children and Adolescents with Sickle Cell Disease Against Normative Growth Trajectories: First Baseline Results of the Brick Study
Kidd, M.
Kidson-Gerber, G.
Kidwell, A.
652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
1870 - Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton’s Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study
2374 - Split-Dose R-CHOP for Older Patients with Treatment Naïve DLBCL
1870 - Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton’s Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study
2374 - Split-Dose R-CHOP for Older Patients with Treatment Naïve DLBCL
Kiecolt-Glaser, J.
Kiefer, S.
Kiehl, M. G.
Kiełbasa, S. M.
Kiem, H. P.
502 - Vivovec™ Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human Primates
2014 - CD45-Directed Radioimmunotherapy with the Alpha-Emitter Astatine-211 As Conditioning for Autologous Hematopoietic Stem/Progenitor Cell Gene Therapy: Results from a Nonhuman Primate Model
3422 - TNFα Apoptotic Signaling By Antigen-Engaged CAR T-Cells Mediates Clearance of Target Antigen-Negative Acute Myeloid Leukemia
2014 - CD45-Directed Radioimmunotherapy with the Alpha-Emitter Astatine-211 As Conditioning for Autologous Hematopoietic Stem/Progenitor Cell Gene Therapy: Results from a Nonhuman Primate Model
3422 - TNFα Apoptotic Signaling By Antigen-Engaged CAR T-Cells Mediates Clearance of Target Antigen-Negative Acute Myeloid Leukemia
Kienzle, D.
Kiialainen, A.
2486 - Inhibition of the Complement Alternative Pathway Attenuates Hemolysis and Preserves Renal Function in a Mouse Model of Sickle Cell Disease
3870 - Complement Activation and Its Implication in the Pathophysiology of Hemolytic Anemia and Aging in Mouse Models of Sickle Cell Disease and Beta-Thalassemia
3870 - Complement Activation and Its Implication in the Pathophysiology of Hemolytic Anemia and Aging in Mouse Models of Sickle Cell Disease and Beta-Thalassemia
Kikani, B.
Kikuchi, T.
Kikuchi, T.
Kikushige, Y.
Kiladjian, J. J.
245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
655 - Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
1755 - SH2B3 Loss of Function Variants Are Potential Drivers of Severe Thrombocytosis
3133 - Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)
3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis
4513 - JAK Inhibition Results in Aggressive Cutaneous Squamous Cell Carcinoma through MAPK Pathway Activation and Shapes the Tumor Immune Microenvironment to Create Novel Therapeutic Opportunities
4516 - Spatial Transcriptomic Profiling of Bone Marrow Vascular Niches Unveils an Endothelial Stress Signature in Myeloproliferative Neoplasms
1808.1 - Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial
4569.3 - A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy
- Pegylated Interferon: The Who, Why, and How
655 - Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
1755 - SH2B3 Loss of Function Variants Are Potential Drivers of Severe Thrombocytosis
3133 - Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)
3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis
4513 - JAK Inhibition Results in Aggressive Cutaneous Squamous Cell Carcinoma through MAPK Pathway Activation and Shapes the Tumor Immune Microenvironment to Create Novel Therapeutic Opportunities
4516 - Spatial Transcriptomic Profiling of Bone Marrow Vascular Niches Unveils an Endothelial Stress Signature in Myeloproliferative Neoplasms
1808.1 - Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial
4569.3 - A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy
- Pegylated Interferon: The Who, Why, and How
Kiladjian, J. J.
482 - Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial
483 - Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis
1000 - Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis
3179 - Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
483 - Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis
1000 - Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis
3179 - Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
Kilian, M.
Kilic, A.
Kilic, D. K.
Killander Möller, I.
Kim, A.
Kim, A. I.
1669 - Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade
1865 - Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
1874 - A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
4408 - Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)
4409 - Long-Term Follow-up of Bendamustine/Rituximab – Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)
4617 - Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL
4628 - A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)
1865 - Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
1874 - A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
4408 - Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)
4409 - Long-Term Follow-up of Bendamustine/Rituximab – Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)
4617 - Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL
4628 - A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)
Kim, B.
805 - ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis
3978 - Disparities in Real-World Treatment Patterns Among Patients with Von Willebrand Disease in a Large US Population-Based Dataset
3980 - Diagnosis and Disease Burden of Von Willebrand Disease in a Large US Population Based-Dataset
3981 - A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding
3982 - Factor VIII Coagulant Activity (FVIII:C) As an Independent Predictor of Bleeding across Different Subtypes of Von Willebrand Disease (VWD)
3978 - Disparities in Real-World Treatment Patterns Among Patients with Von Willebrand Disease in a Large US Population-Based Dataset
3980 - Diagnosis and Disease Burden of Von Willebrand Disease in a Large US Population Based-Dataset
3981 - A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding
3982 - Factor VIII Coagulant Activity (FVIII:C) As an Independent Predictor of Bleeding across Different Subtypes of Von Willebrand Disease (VWD)
Kim, C. H.
Kim, C. Y.
Kim, D. K.
Kim, D. D.
475 - Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study
687 - Survival and Engraftment Post Allogeneic Hematopoietic Stem Cell Transplantation: ABO Mismatch Matters in RIC
778 - Multicenter, Real-World Experience Study of FLT3-Inhibitor Post-Transplant Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia with FLT3-ITD
1570 - Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in the Patients with CCAAT Enhancer-Binding Protein a Gene (CEBPA) Mutated Acute Myeloid Leukemia
1768 - Prognostic Implication of Framingham Risk Score As a Comorbidity Measure on Treatment Outcomes Following First-Line Tyrosine Kinase Inhibitor in Newly Diagnosed CML Patients
2151 - The Effect of Smoking and Pre-Transplant Pulmonary Comorbidity on the Incidence of Lung Graft Versus Host Disease and Post Transplant Outcomes
2183 - Expanding the Donor Pool, the Number of Antigen Mismatches Has No Impact in the Outcomes of Haploidentical Stem Cell Transplantation with Peripheral Blood Stem Cells and Dual T Cell Depletion
3149 - Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia
3151 - Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP‑CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses
3810 - Retrospective Evaluation of BCR::ABL Kinase Domain Mutation Profiles and Treatment Outcomes in Patients with Chronic Myeloid Leukemia to Confirm Clinical Relevance of in Vitro Sensitivity-Based Treatment Switch: Real-World Experience
4526 - Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study
4863 - Strength to Endure: Superiority of MAC over RIC in Patients <65 Years Undergoing Stem Cell Transplantation Using ATG-Ptcy-CSA for Gvhd Prophylaxis
4865 - Haploidentical and Mismatched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Cohort Study
4883 - Tolerability and Efficacy of Post-Transplant Cyclophosphamide in Older Adults Undergoing Matched Sibling Donor Allogeneic Transplantation: A Retrospective Analysis
4896 - Monocytes Matter: Impact of Monocyte Recovery on Allogeneic Hematopoietic Stem Cell Transplant Outcomes with Post-Transplantation Cyclophosphamide As Graft Versus Host Disease Prophylaxis
4899 - Identification of High-Risk Patients and Establishment of a Clinical Prediction Model for Frontline Steroid Failure in Chronic Graft-Versus-Host-Disease
4930 - Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse
687 - Survival and Engraftment Post Allogeneic Hematopoietic Stem Cell Transplantation: ABO Mismatch Matters in RIC
778 - Multicenter, Real-World Experience Study of FLT3-Inhibitor Post-Transplant Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia with FLT3-ITD
1570 - Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in the Patients with CCAAT Enhancer-Binding Protein a Gene (CEBPA) Mutated Acute Myeloid Leukemia
1768 - Prognostic Implication of Framingham Risk Score As a Comorbidity Measure on Treatment Outcomes Following First-Line Tyrosine Kinase Inhibitor in Newly Diagnosed CML Patients
2151 - The Effect of Smoking and Pre-Transplant Pulmonary Comorbidity on the Incidence of Lung Graft Versus Host Disease and Post Transplant Outcomes
2183 - Expanding the Donor Pool, the Number of Antigen Mismatches Has No Impact in the Outcomes of Haploidentical Stem Cell Transplantation with Peripheral Blood Stem Cells and Dual T Cell Depletion
3149 - Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia
3151 - Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP‑CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses
3810 - Retrospective Evaluation of BCR::ABL Kinase Domain Mutation Profiles and Treatment Outcomes in Patients with Chronic Myeloid Leukemia to Confirm Clinical Relevance of in Vitro Sensitivity-Based Treatment Switch: Real-World Experience
4526 - Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study
4863 - Strength to Endure: Superiority of MAC over RIC in Patients <65 Years Undergoing Stem Cell Transplantation Using ATG-Ptcy-CSA for Gvhd Prophylaxis
4865 - Haploidentical and Mismatched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Cohort Study
4883 - Tolerability and Efficacy of Post-Transplant Cyclophosphamide in Older Adults Undergoing Matched Sibling Donor Allogeneic Transplantation: A Retrospective Analysis
4896 - Monocytes Matter: Impact of Monocyte Recovery on Allogeneic Hematopoietic Stem Cell Transplant Outcomes with Post-Transplantation Cyclophosphamide As Graft Versus Host Disease Prophylaxis
4899 - Identification of High-Risk Patients and Establishment of a Clinical Prediction Model for Frontline Steroid Failure in Chronic Graft-Versus-Host-Disease
4930 - Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse
Kim, D. W.
475 - Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study
1765 - Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial
1779 - A More Rapid Initial Decline of BCR::ABL1 Transcripts and Longer Treatment Duration with Improvement of Treatment-Free Remission Rate after Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
1765 - Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial
1779 - A More Rapid Initial Decline of BCR::ABL1 Transcripts and Longer Treatment Duration with Improvement of Treatment-Free Remission Rate after Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Kim, D.
Kim, D.
Kim, E.
1868 - A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
4631 - Time-Limited Therapy with Zanubrutinib Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase II Trial
4631 - Time-Limited Therapy with Zanubrutinib Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase II Trial
Kim, E.
Kim, G.
Kim, H.
2104 - Comparison of Tacrolimus/Methotrexate and Post-Transplant Cyclophosphamide Graft-Versus Host Disease Prophylaxis for Haploidentical and Matched Allogeneic Stem Cell Transplantation Demonstrates Improved Overall Survival and Reduced Mortality, Shorter Length of Stay, Less Peritransplant Toxicity with Post-Transplant Cyclophosphamide
4202 - Concurrent Blinatumomab and Human Leukocyte Antigen-Mismatched Cellular Therapy in Patients with High-Risk B-Cell Acute Lymphoblastic Leukemia, a Phase I Prospective Cohort Study
4202 - Concurrent Blinatumomab and Human Leukocyte Antigen-Mismatched Cellular Therapy in Patients with High-Risk B-Cell Acute Lymphoblastic Leukemia, a Phase I Prospective Cohort Study
Kim, H. T.
102 - Acute GvHD of the Gut Is Associated with Minor Histocompatibility Antigens Cross-Reactive Against Gut-Tropic Viral Epitopes
379 - Heterogeneity of PD-1+regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease
926 - Leukemia Evolution and Resistance to Graft-Versus-Leukemia Responses Revealed By Mitochondrial DNA Mutations
1041 - Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation
1045 - Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT
3500 - BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study
3538 - Impact of Consolidative Cellular Therapy with DLI or Second Transplant in Patients with AML Who Achieve Complete Remission Following Post-Transplant Relapse
4833 - Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant
4938 - Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes
379 - Heterogeneity of PD-1+regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease
926 - Leukemia Evolution and Resistance to Graft-Versus-Leukemia Responses Revealed By Mitochondrial DNA Mutations
1041 - Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation
1045 - Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT
3500 - BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study
3538 - Impact of Consolidative Cellular Therapy with DLI or Second Transplant in Patients with AML Who Achieve Complete Remission Following Post-Transplant Relapse
4833 - Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant
4938 - Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes
Kim, H.
Kim, H. J.
778 - Multicenter, Real-World Experience Study of FLT3-Inhibitor Post-Transplant Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia with FLT3-ITD
848 - Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3-ITD–Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial
1495 - PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML
2889 - Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
4220 - Impact of Concurrent IKZF1 and CDKN2 Deletions on Prognostic Outcomes in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation
4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia
4892 - Feasibility of TBI-Augmented Reduced Toxicity Conditioning Regimen with ATG/Ptcy Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia
4977 - Transcriptional Profiling of Plasma Cells in AL Amyloidosis and Multiple Myeloma: A Single-Cell RNA Sequencing Approach
848 - Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3-ITD–Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial
1495 - PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML
2889 - Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
4220 - Impact of Concurrent IKZF1 and CDKN2 Deletions on Prognostic Outcomes in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation
4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia
4892 - Feasibility of TBI-Augmented Reduced Toxicity Conditioning Regimen with ATG/Ptcy Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia
4977 - Transcriptional Profiling of Plasma Cells in AL Amyloidosis and Multiple Myeloma: A Single-Cell RNA Sequencing Approach
Kim, H. S.
Kim, H. J.
Kim, H. J.
778 - Multicenter, Real-World Experience Study of FLT3-Inhibitor Post-Transplant Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia with FLT3-ITD
4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia
4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia
Kim, H.
Kim, H. J.
Kim, I.
475 - Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study
4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia
4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia
Kim, J. S.
Kim, J. J.
1768 - Prognostic Implication of Framingham Risk Score As a Comorbidity Measure on Treatment Outcomes Following First-Line Tyrosine Kinase Inhibitor in Newly Diagnosed CML Patients
3810 - Retrospective Evaluation of BCR::ABL Kinase Domain Mutation Profiles and Treatment Outcomes in Patients with Chronic Myeloid Leukemia to Confirm Clinical Relevance of in Vitro Sensitivity-Based Treatment Switch: Real-World Experience
3810 - Retrospective Evaluation of BCR::ABL Kinase Domain Mutation Profiles and Treatment Outcomes in Patients with Chronic Myeloid Leukemia to Confirm Clinical Relevance of in Vitro Sensitivity-Based Treatment Switch: Real-World Experience
Kim, J.
Kim, J. J.
527 - Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report
609 - Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
609 - Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Kim, J. H.
Kim, J. A.
510 - Low Dose Fludarabine Is an Effective Conditioning Treatment to Suppress Relapse Rate in PT-CY-Based Haploidentical Peripheral Blood Stem Cell Transplantation
3101 - Durability of Complete Responses in Patients from the ECHELON-3 Study
4483 - Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
4489 - Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
3101 - Durability of Complete Responses in Patients from the ECHELON-3 Study
4483 - Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
4489 - Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
Kim, J. A.
Kim, J. A.
Kim, J. S.
465 - Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium
668 - CD4 Cytotoxic T Cells Promote Antitumor Immunity in Multiple Myeloma
3101 - Durability of Complete Responses in Patients from the ECHELON-3 Study
4078 - Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Ravulizumab
668 - CD4 Cytotoxic T Cells Promote Antitumor Immunity in Multiple Myeloma
3101 - Durability of Complete Responses in Patients from the ECHELON-3 Study
4078 - Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Ravulizumab
Kim, J.
Kim, J.
Kim, J.
532 - A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes
1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
1906 - De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression
1995 - Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2103 - Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy
2130 - Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide
4270 - Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
4826 - Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation
4871 - Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis
4881 - Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia
1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
1906 - De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression
1995 - Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2103 - Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy
2130 - Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide
4270 - Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
4826 - Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation
4871 - Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis
4881 - Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia
Kim, J.
Kim, J. G.
Kim, J. H.
756 - HMGA1 Chromatin Regulators Disrupt 3D Genome Architecture and Chromatin Looping to Repress MHC II Genes and Drive Immune Evasion during MPN Progression
1277 - High Mobility Group A1 (HMGA1) Chromatin Regulators Maintain Quiescent, Regenerative HSC By Repressing IGF1 Networks That Promote Stem Cell Aging
1361 - Targeting HMGA1 Epigenetic Regulators and Downstream ETV5 Pathways with Histone Deacetylase Inhibitors in Combination Therapy for Relapsed, Pediatric B-ALL
1277 - High Mobility Group A1 (HMGA1) Chromatin Regulators Maintain Quiescent, Regenerative HSC By Repressing IGF1 Networks That Promote Stem Cell Aging
1361 - Targeting HMGA1 Epigenetic Regulators and Downstream ETV5 Pathways with Histone Deacetylase Inhibitors in Combination Therapy for Relapsed, Pediatric B-ALL
Kim, K. Y.
Kim, K.
494 - Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
668 - CD4 Cytotoxic T Cells Promote Antitumor Immunity in Multiple Myeloma
772 - Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
891 - Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
4731 - Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide
668 - CD4 Cytotoxic T Cells Promote Antitumor Immunity in Multiple Myeloma
772 - Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
891 - Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
4731 - Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide
Kim, K.
1679 - Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases
5121 - Identifying the Barriers of Clinical Trial Access after CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma
4511.1 - Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma
5121 - Identifying the Barriers of Clinical Trial Access after CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma
4511.1 - Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma
Kim, K. H.
Kim, K. T.
Kim, K. T.
Kim, L. E.
Kim, M. K.
Kim, M.
Kim, M.
Kim, N. Y.
Kim, N.
933 - Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings
3783 - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab
3792g - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval
3783 - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab
3792g - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval
Kim, N.
1829 - Response Rate, Event-Free Survival (EFS), and Overall Survival in Higher-Risk Myelodysplastic Syndromes (MDS): U.S. Food and Drug Administration (FDA) Trial-Level and Patient-Level Analyses
2416 - FDA Analysis of Enrollment of Pediatric and AYA Patients in Clinical Trials By Race and Ethnicity
3806 - FDA Analysis of Race and Ethnic Enrollment of Clinical Trials for Drug Registration in Adult Patients for Leukemia and Myelodysplastic Syndrome
2416 - FDA Analysis of Enrollment of Pediatric and AYA Patients in Clinical Trials By Race and Ethnicity
3806 - FDA Analysis of Race and Ethnic Enrollment of Clinical Trials for Drug Registration in Adult Patients for Leukemia and Myelodysplastic Syndrome
Kim, O. V.
Kim, P.
Kim, R.
13 - Association of Clonal Hematopoiesis of Indeterminate Potential (CHIP) with Incidence of Venous Thromboembolism Varies By Age: The Atherosclerosis Risk in Communities Study
812 - External Validation of EHR-CAT Risk Assessment Model for Cancer Associated Thrombosis in 150 Healthcare Organizations
3727 - Clinical Outcomes and Patterns of Care Among Patients with Newly Diagnosed Hodgkin Lymphoma in a Safety-Net Health System
4013 - Circulating Tumor DNA Predicts Venous Thromboembolism in Minority Patients with Cancers
812 - External Validation of EHR-CAT Risk Assessment Model for Cancer Associated Thrombosis in 150 Healthcare Organizations
3727 - Clinical Outcomes and Patterns of Care Among Patients with Newly Diagnosed Hodgkin Lymphoma in a Safety-Net Health System
4013 - Circulating Tumor DNA Predicts Venous Thromboembolism in Minority Patients with Cancers
Kim, S.
Kim, S. J.
651 - Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL
1032 - Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
1595 - Gut Microbiome Composition As a Prognostic Marker in CD19-Targeting CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
1683 - Multicenter, Open-Label, Phase I Study of Azacitidine-CHOP for Patients with Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype
3107 - Real-World Outcomes of Polatuzumab Vedotin with Bendamustine and Rituximab As Salvage and Bridge Therapy to CAR T-Cell Treatment in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
1032 - Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
1595 - Gut Microbiome Composition As a Prognostic Marker in CD19-Targeting CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
1683 - Multicenter, Open-Label, Phase I Study of Azacitidine-CHOP for Patients with Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype
3107 - Real-World Outcomes of Polatuzumab Vedotin with Bendamustine and Rituximab As Salvage and Bridge Therapy to CAR T-Cell Treatment in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Kim, S. H.
Kim, S. J.
Kim, S.
1742.4 - A Phase II Investigator-Initiated Trial of Epcoritamab with Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-Cell Lymphoma
1927.2 - A Decentralized Phase II Open-Label Trial Assessing the Safety and Efficacy of Dapagliflozin in Renal AL Amyloidosis (FLORAL)
3123.4 - An Investigator Initiated Study of RCHOP in Combination with Selinexor (KPT-330) in Diffuse Large B Cell Lymphoma and Richter Transformation
1927.2 - A Decentralized Phase II Open-Label Trial Assessing the Safety and Efficacy of Dapagliflozin in Renal AL Amyloidosis (FLORAL)
3123.4 - An Investigator Initiated Study of RCHOP in Combination with Selinexor (KPT-330) in Diffuse Large B Cell Lymphoma and Richter Transformation
Kim, S.
Kim, S. J.
Kim, S. J.
Kim, S.
71 - Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)
470 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
472 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
5092 - Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry
470 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
472 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
5092 - Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR® Registry
Kim, S. H.
1779 - A More Rapid Initial Decline of BCR::ABL1 Transcripts and Longer Treatment Duration with Improvement of Treatment-Free Remission Rate after Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
2057 - Tumor-Primed CD3+CD56+ natural Killer T-like Cells As an Efficient Novel Cell Therapy for Relapsed/Refractory Multiple Myeloma
2897 - Intensity-Adjusted Salvage Chemotherapy Plus FLT3-Inhibitor Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia with Mutated FLT3-ITD/TKD (SAPPHIRE-G)
4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia
2057 - Tumor-Primed CD3+CD56+ natural Killer T-like Cells As an Efficient Novel Cell Therapy for Relapsed/Refractory Multiple Myeloma
2897 - Intensity-Adjusted Salvage Chemotherapy Plus FLT3-Inhibitor Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia with Mutated FLT3-ITD/TKD (SAPPHIRE-G)
4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia
Kim, S. K.
Kim, S.
3279 - Early Serum Protein Clonal Dynamics Preceding Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Years before Diagnosis
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages
4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages
4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy
Kim, T. K.
Kim, T. M.
341 - Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma
578 - Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma
862 - Efficacy and Safety of Odronextamab in Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL): Data from the R/R MZL Cohort in the ELM-2 Study
867 - Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
868 - Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T–Naive and CAR-T–Exposed Patients
1650 - Evaluation of Baseline CAR-Hematotox Scores to Predict Increased Severe Infection Risk in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Odronextamab
1737 - Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial
3076 - Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20×CD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
3102 - Spectrum: Phase II Study of Tislelizumab Plus Pemetrexed in Patients with Relapsed or Refractory (R/R) Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS): The Korean Cancer Study Group LY22-07
3115 - Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)
3118 - Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies
4502 - Efficacy and Safety of Odronextamab in Rare Subtypes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL): Data from a Dedicated Cohort of Other B-NHLs in the ELM-2 Study
1674.2 - PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies
1718.1 - SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)
578 - Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma
862 - Efficacy and Safety of Odronextamab in Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL): Data from the R/R MZL Cohort in the ELM-2 Study
867 - Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
868 - Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T–Naive and CAR-T–Exposed Patients
1650 - Evaluation of Baseline CAR-Hematotox Scores to Predict Increased Severe Infection Risk in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Odronextamab
1737 - Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial
3076 - Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20×CD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
3102 - Spectrum: Phase II Study of Tislelizumab Plus Pemetrexed in Patients with Relapsed or Refractory (R/R) Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS): The Korean Cancer Study Group LY22-07
3115 - Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)
3118 - Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies
4502 - Efficacy and Safety of Odronextamab in Rare Subtypes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL): Data from a Dedicated Cohort of Other B-NHLs in the ELM-2 Study
1674.2 - PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies
1718.1 - SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)
Kim, T. O.
Kim, T.
966 - CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study
3127 - Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease
3127 - Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease
Kim, W. J.
Kim, W. S.
399 - Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
465 - Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium
1595 - Gut Microbiome Composition As a Prognostic Marker in CD19-Targeting CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
1636 - Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry
1683 - Multicenter, Open-Label, Phase I Study of Azacitidine-CHOP for Patients with Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype
1992 - First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma
2990 - Evaluation of Anti-Tumor Activity and Impact on T Cell Activation of Glofitamab in Combination with Gemcitabine and Oxaliplatin (Glofit-GemOx)
3018 - Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study
3107 - Real-World Outcomes of Polatuzumab Vedotin with Bendamustine and Rituximab As Salvage and Bridge Therapy to CAR T-Cell Treatment in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
465 - Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium
1595 - Gut Microbiome Composition As a Prognostic Marker in CD19-Targeting CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
1636 - Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry
1683 - Multicenter, Open-Label, Phase I Study of Azacitidine-CHOP for Patients with Nodal T-Cell Lymphoma with T-Follicular Helper Phenotype
1992 - First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma
2990 - Evaluation of Anti-Tumor Activity and Impact on T Cell Activation of Glofitamab in Combination with Gemcitabine and Oxaliplatin (Glofit-GemOx)
3018 - Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study
3107 - Real-World Outcomes of Polatuzumab Vedotin with Bendamustine and Rituximab As Salvage and Bridge Therapy to CAR T-Cell Treatment in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Kim, W. S.
867 - Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
4480 - 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma
4480 - 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma
Kim, W. S.
651 - Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL
747 - Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial
3070 - Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
3110 - Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial
3118 - Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies
4405 - Zilovertamab Vedotin Monotherapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort a of the Multicenter, Open-Label, Phase 2 Waveline-006 Study
4501 - Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
4502.1 - Phase 3, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared with Rituximab Plus Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
747 - Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial
3070 - Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
3110 - Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial
3118 - Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies
4405 - Zilovertamab Vedotin Monotherapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort a of the Multicenter, Open-Label, Phase 2 Waveline-006 Study
4501 - Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
4502.1 - Phase 3, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared with Rituximab Plus Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Kim, Y. M.
Kim, Y. J.
4220 - Impact of Concurrent IKZF1 and CDKN2 Deletions on Prognostic Outcomes in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation
4892 - Feasibility of TBI-Augmented Reduced Toxicity Conditioning Regimen with ATG/Ptcy Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia
4892 - Feasibility of TBI-Augmented Reduced Toxicity Conditioning Regimen with ATG/Ptcy Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia
Kim, Y. H.
466 - Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial
980 - Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization
1609 - Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial
1677 - Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma
3056 - Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule
980 - Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization
1609 - Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial
1677 - Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma
3056 - Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule
Kim, Y. H.
Kim, Y. R.
Kim-Hoehammer, Y. I.
Kimball, B. C.
Kimball, B. L.
907 - Caspase-1 Inhibition Ameliorates CAR T-Cell Apoptosis and Tumor Cell Pyroptosis to Enhance the Efficacy and Safety of CAR T-Cell Therapy
908 - Intrinsic Immunosuppressive Features of Monocytes Suppress CART19 through IL-1 Pathway Modulation in Mantle Cell Lymphoma
4808 - Identification of T Cell Senescence As a Cell Fate Limiting the Antitumor Activity of 41BB-Costimulated CART Cells
908 - Intrinsic Immunosuppressive Features of Monocytes Suppress CART19 through IL-1 Pathway Modulation in Mantle Cell Lymphoma
4808 - Identification of T Cell Senescence As a Cell Fate Limiting the Antitumor Activity of 41BB-Costimulated CART Cells
Kimball, V. M.
Kimberger, K.
Kimberlin, C.
Kimberly, R.
Kimble, A.
Kimble, E. L.
2028 - Prediction of Therapeutic Potential of CD19 CAR-T Cells for LBCL By Histone Mark Analyses of Core Epigenetic Programming
3422 - TNFα Apoptotic Signaling By Antigen-Engaged CAR T-Cells Mediates Clearance of Target Antigen-Negative Acute Myeloid Leukemia
3772 - Trends in Pre-CAR-T Attrition in Relapsed/Refractory Multiple Myeloma: Prevalence, Risk Factors, and Outcomes at a Tertiary Academic Medical Center
3422 - TNFα Apoptotic Signaling By Antigen-Engaged CAR T-Cells Mediates Clearance of Target Antigen-Negative Acute Myeloid Leukemia
3772 - Trends in Pre-CAR-T Attrition in Relapsed/Refractory Multiple Myeloma: Prevalence, Risk Factors, and Outcomes at a Tertiary Academic Medical Center
Kimes, P.
Kimmerlin, Q.
Kimpton, M.
Kimura, F.
Kimura, S.
Kimura, S. I.
4870 - Appropriate Threshold of Quantitative Cytomegalovirus DNA Polymerase Chain Reaction for Preemptive Treatment in Stem Cell Transplant Recipients
4925 - The Outcome of Fertility Preservation Strategy in Female Hematopoietic Stem Cell Transplant Recipients of Reproductive Age. Retrospective Study from the Kanto Study Group for Cell Therapy
4925 - The Outcome of Fertility Preservation Strategy in Female Hematopoietic Stem Cell Transplant Recipients of Reproductive Age. Retrospective Study from the Kanto Study Group for Cell Therapy
Kimura, Y.
Kin, A.
3379 - Phase 2 Study Using Minimal Residual Disease-Driven Adaptive Strategy in Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy – First Report from the Maestro Trial
4681 - Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis
4828 - A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort
1927.2 - A Decentralized Phase II Open-Label Trial Assessing the Safety and Efficacy of Dapagliflozin in Renal AL Amyloidosis (FLORAL)
4681 - Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis
4828 - A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort
1927.2 - A Decentralized Phase II Open-Label Trial Assessing the Safety and Efficacy of Dapagliflozin in Renal AL Amyloidosis (FLORAL)
Kincaid, Z.
Kindler, T.
Kineavy, B.
Kiner-Strachan, B.
King, A. A.
145 - Motixafortide (CXCR4 Inhibition) Alone and in Combination with Natalizumab (VLA-4 Inhibition) As a Novel Regimen to Mobilize Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease: A First-in-Human, Proof-of-Principle Safety and Feasibility Study
396 - Identifying Determinants of Sickle Cell Disease Knowledge, Awareness, and Management in St. Louis Area School Districts
2245 - Understanding the Experiences of Caregivers for Children Five Years and Above Living with Sickle Cell Diseases in Kaduna, Nigeria
2313 - High Concordance between Investigator-Verified Diagnosis and Manual Data Abstraction for Sickle Cell Diagnosis Type: An ASH Research Collaborative Data Hub Validation Study
4998 - Assessing Primary Stroke Prevention Barriers and Facilitators in Children with Sickle Cell Anemia in Puerto Rico: A Mixed Methods Study Design
5202 - "It Was Bootstrap All the Way": Exploring the Barriers and Facilitators to the Development of Non-Hematology Sickle Cell Disease Experts in the United States
- Building, Nurturing, and Sustaining a Research Program
- Negotiating Your First Leadership Position
396 - Identifying Determinants of Sickle Cell Disease Knowledge, Awareness, and Management in St. Louis Area School Districts
2245 - Understanding the Experiences of Caregivers for Children Five Years and Above Living with Sickle Cell Diseases in Kaduna, Nigeria
2313 - High Concordance between Investigator-Verified Diagnosis and Manual Data Abstraction for Sickle Cell Diagnosis Type: An ASH Research Collaborative Data Hub Validation Study
4998 - Assessing Primary Stroke Prevention Barriers and Facilitators in Children with Sickle Cell Anemia in Puerto Rico: A Mixed Methods Study Design
5202 - "It Was Bootstrap All the Way": Exploring the Barriers and Facilitators to the Development of Non-Hematology Sickle Cell Disease Experts in the United States
- Building, Nurturing, and Sustaining a Research Program
- Negotiating Your First Leadership Position
King, D.
King, D. J.
King, E.
King, E. R.
985 - Phase I Results of Acalabrutinib in Combination with Durvalumab in Primary Central Nervous System Lymphoma: Safety, Efficacy, and Central Nervous System Penetration
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
4414 - Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
4414 - Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma
King, K. Y.
King, R. L.
King, R. L.
King Sainos, P.
King, S. J.
King, S.
59 - A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial
3805 - Patient-Reported Outcomes in Older Acute Myeloid Leukemia Patients Fit for Intensive Treatment, Who Received Intensified Treatment (DA +/- cladribine) Following No Evidence of Response to Course 1: Results from the NCRI AML18 Trial
3805 - Patient-Reported Outcomes in Older Acute Myeloid Leukemia Patients Fit for Intensive Treatment, Who Received Intensified Treatment (DA +/- cladribine) Following No Evidence of Response to Course 1: Results from the NCRI AML18 Trial
Kingdom, J.
Kingsley, E. C.
Kingsley, E.
Kinlay, S.
Kinney, M. A.
Kinoshita, S.
Kinoshita, S.
2411f - Prognostic Impact of Clinical Factors and Cell Composition of Apheresis Samples on BCMA CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
3075 - The Impact of MYD88 and/or CD79B Gene Mutations on Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma
3342 - Stratifying 'frail' Patients Defined By the Simplified Frailty Scale in Multiple Myeloma: Correlation with Clinical Outcomes
4638 - Targeting Overexpressed IDO on Stromal Cells As a Potential Therapeutic Strategy in Multiple Myeloma
3075 - The Impact of MYD88 and/or CD79B Gene Mutations on Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma
3342 - Stratifying 'frail' Patients Defined By the Simplified Frailty Scale in Multiple Myeloma: Correlation with Clinical Outcomes
4638 - Targeting Overexpressed IDO on Stromal Cells As a Potential Therapeutic Strategy in Multiple Myeloma
Kinsella, F.
Kinsella, S.
Kinz, N.
Kipps, T. J.
744 - Expression of ROR1 and ROR2 in Hairy Cell Leukemia Cells Enhances Constitutive Activation of ERK1/2 and Cancer Stemness
887 - Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study
1852 - ROR1-Signaling Increases Levels of Mutant TP53 Protein and Cyclin A1 Via Activation of NRF2, Potentially Potentiating Genomic Instability in Chronic Lymphocytic Leukemia Cells with Del(17p)
1869 - Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study
3233 - The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia
887 - Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study
1852 - ROR1-Signaling Increases Levels of Mutant TP53 Protein and Cyclin A1 Via Activation of NRF2, Potentially Potentiating Genomic Instability in Chronic Lymphocytic Leukemia Cells with Del(17p)
1869 - Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study
3233 - The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia
Kirby, S.
2001 - Characterizing and Risk Stratifying Musculoskeletal Toxicities after BCMA CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
5044 - Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina
5044 - Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina
Kirchberg, J.
Kirchmeier, D.
Kirchner, M.
Kirillova, E.
Kirita, S.
Kirito, K.
3678 - Modified Delphi Process to Develop Best Practice Recommendations for Myelofibrosis Management in Routine Clinical Practice in the Asia-Pacific Region (The APAC-MF Alliance)
4569.3 - A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy
4569.3 - A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy
Kiriza, N.
178 - A Phase 1b/2 Study of the Efficacy and Safety of Combination Hydroxyurea and Dose-Escalated Erythropoietin for Treatment of Anemia in Sickle Cell Disease (ACHiEvE-SCD)
294 - Higher Hemoglobin Level Correlates with Increased Tissue Oxygenation in a Comprehensive Profile of Hemorheology in Sickle Cell Disease
294 - Higher Hemoglobin Level Correlates with Increased Tissue Oxygenation in a Comprehensive Profile of Hemorheology in Sickle Cell Disease
Kirk, K.
Kirk, S. E.
Kirkey, D.
Kirkey, D. C.
638 - Dysregulation of Developmental Transcription Factors in Acute Myeloid Leukemia Predicts Poor Outcome and Impacts Adaptive Immune Pathway Genes
849 - Comprehensive Characterization of Rare Recurrent Mutations in Pediatric AML
1555 - Contrasting Clinical Implications of NRAS Vs. KRAS Mutations in AML – Only KRAS Mutations Are Associated with Adverse Outcome
1562 - Haplo-Insufficiency of RAS Genes Is the Determinant of Outcome in AML
2050 - Potent Target-Specific Efficacy of CAR T Cells Directed Toward the AML and KMT2A-Rearranged Specific Antigen CLEC2A
2925 - The AML HOX-Ome: The Landscape of Developmental Transcription Factors across Pediatric Acute Myeloid Leukemia
3417 - Effective Dual Targeting of PRAME and WT1 with CD33-Gated ARTEMIS® Antibody-TCR Platform in Acute Myeloid Leukemia
4793 - Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia
849 - Comprehensive Characterization of Rare Recurrent Mutations in Pediatric AML
1555 - Contrasting Clinical Implications of NRAS Vs. KRAS Mutations in AML – Only KRAS Mutations Are Associated with Adverse Outcome
1562 - Haplo-Insufficiency of RAS Genes Is the Determinant of Outcome in AML
2050 - Potent Target-Specific Efficacy of CAR T Cells Directed Toward the AML and KMT2A-Rearranged Specific Antigen CLEC2A
2925 - The AML HOX-Ome: The Landscape of Developmental Transcription Factors across Pediatric Acute Myeloid Leukemia
3417 - Effective Dual Targeting of PRAME and WT1 with CD33-Gated ARTEMIS® Antibody-TCR Platform in Acute Myeloid Leukemia
4793 - Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia
Kirkwood, A. A.
567 - Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium
890 - Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System
1454 - The Role of the Bone Marrow Immune Niche in Preventing Relapse in Adult B-ALL Following Reduced Intensity Conditioning Allogeneic HSCT
2342 - Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK
890 - Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System
1454 - The Role of the Bone Marrow Immune Niche in Preventing Relapse in Adult B-ALL Following Reduced Intensity Conditioning Allogeneic HSCT
2342 - Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK
Kirmaier, M. E.
Kirner, J. A.
Kirpalani, A.
Kirsch, I. R.
1 - Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731
2838 - Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages
2838 - Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages
Kirshner, J.
Kirtsios, E.
Kiryakoza, M.
Kirylczuk, J.
Kiseleva, M.
Kishibe, T.
Kishida, M.
Kishore, B.
385 - Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma – an Economic Evaluation of the Fitness Trial
673 - IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial
673 - IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial
Kishtagari, A.
221 - Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML
353 - Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study
927 - Predictive Modeling of Hematopoietic Stem Cell Transplant Outcomes: Discovering the Role of Immunogenetic Features through Machine Learning Models
1474 - Impact of Co-Mutations, Monocytic Differentiation, and Choice of Hypomethylating Agent Combined with Venetoclax on the Predictive Value of Molecular Prognostic Risk Signature in Newly Diagnosed AML Patients
2322 - Chive-Impact: Establishing the Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE) Registry and Biorepository in Underserved Areas
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis
3607 - Combined Natural Language Processing and Gpt-4 Pathology Report Interpretation Efficiently Identify a Myelodysplastic Syndrome Cohort for Large Scale Clinical Research Applications
4561 - Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes
4577 - Bone Marrow Spatial Multi-Omics Identifies Reduced Interactions between Hematopoietic Stem Cells and Myeloid Cells in Myelodysplastic Syndrome
353 - Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study
927 - Predictive Modeling of Hematopoietic Stem Cell Transplant Outcomes: Discovering the Role of Immunogenetic Features through Machine Learning Models
1474 - Impact of Co-Mutations, Monocytic Differentiation, and Choice of Hypomethylating Agent Combined with Venetoclax on the Predictive Value of Molecular Prognostic Risk Signature in Newly Diagnosed AML Patients
2322 - Chive-Impact: Establishing the Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE) Registry and Biorepository in Underserved Areas
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis
3607 - Combined Natural Language Processing and Gpt-4 Pathology Report Interpretation Efficiently Identify a Myelodysplastic Syndrome Cohort for Large Scale Clinical Research Applications
4561 - Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes
4577 - Bone Marrow Spatial Multi-Omics Identifies Reduced Interactions between Hematopoietic Stem Cells and Myeloid Cells in Myelodysplastic Syndrome
Kisiel, M.
Kislinger, T.
Kiss, T. L.
Kissel, S.
Kitadate, A.
Kitagawa, D.
Kitamura, T.
272 - Machine Learning-Based Predictive Modeling Maximizes the Efficacy of mTOR/TP53 Co-Targeting Therapy Against Acute Myeloid Leukemia
949 - CRISPR/Cas9 Library Screens Identified Atp2a2 As an In Vivo Specific Tumor Suppressor in Myeloid Neoplasms
2913 - PCYT1A Is a Metabolic Vulnerability in Monocytic Acute Myeloid Leukemia
949 - CRISPR/Cas9 Library Screens Identified Atp2a2 As an In Vivo Specific Tumor Suppressor in Myeloid Neoplasms
2913 - PCYT1A Is a Metabolic Vulnerability in Monocytic Acute Myeloid Leukemia
Kitamura, W.
Kitko, C. L.
Kittai, A. S.
524 - Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma
1864 - Real-World Comparison of BCL2 Inhibitor and BTK Inhibitor Therapy in the Front-Line Treatment of CLL Including Patients with Del(17p)/TP53 Mutation
2078 - Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
4484 - Final Update of Safety, Efficacy and T-Cell Predictive Biomarkers from a Phase I Trial of Copanlisib+Nivolumab in Patients with Richter’s Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)
4629 - Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects
5031 - Cost-Offset Analysis Performed Utilizing Covalent Bruton's Tyrosine Kinase Inhibitors Safety Profiles Among Medicare Patients with Chronic Lymphocytic Leukemia
5099 - Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy
4634.1 - Prospective Randomized Phase 2 Study of Acalabrutinib + Obinutuzumab or Venetoclax in Previously Untreated CLL
1864 - Real-World Comparison of BCL2 Inhibitor and BTK Inhibitor Therapy in the Front-Line Treatment of CLL Including Patients with Del(17p)/TP53 Mutation
2078 - Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
4484 - Final Update of Safety, Efficacy and T-Cell Predictive Biomarkers from a Phase I Trial of Copanlisib+Nivolumab in Patients with Richter’s Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)
4629 - Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects
5031 - Cost-Offset Analysis Performed Utilizing Covalent Bruton's Tyrosine Kinase Inhibitors Safety Profiles Among Medicare Patients with Chronic Lymphocytic Leukemia
5099 - Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy
4634.1 - Prospective Randomized Phase 2 Study of Acalabrutinib + Obinutuzumab or Venetoclax in Previously Untreated CLL
Kittai, A. S.
Kittisares, K.
Kivelä, H.
Kiven, S. B.
Kives, M.
Kiwan, A.
850 - Clinical and Molecular Insights into the Classification Dilemma: Are MDS/AML Cases Distinct from Secondary AML?
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
4436 - Clinically Driven Algorithms Identify Patients with Large Granular Lymphocytic Leukemia at Risk of Significant Cytopenia Requiring Treatment
4440 - Gene Copy Number Alterations Identify Subsets of Mycosis Fungoides/Sézary Syndrome Patients with Worse Survival Outcomes
4582 - ETV6 Mutations in Myeloid Neoplasia: Unraveling Clinical Features and Molecular Signatures
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
4436 - Clinically Driven Algorithms Identify Patients with Large Granular Lymphocytic Leukemia at Risk of Significant Cytopenia Requiring Treatment
4440 - Gene Copy Number Alterations Identify Subsets of Mycosis Fungoides/Sézary Syndrome Patients with Worse Survival Outcomes
4582 - ETV6 Mutations in Myeloid Neoplasia: Unraveling Clinical Features and Molecular Signatures
Kiyaga, C.
Kiyoi, H.
1426 - Prognostic Factors for T-Cell Acute Lymphoblastic Leukemia in Children and Young Adults: ALL-T11 Study Conducted By Japan Children’s Cancer Group and Japan Adult Leukemia Study Group
2819 - JALSG Ph (-) B-ALL213 Study: Pediatric-Type Chemotherapy Improves Prognosis in Adult Ph-Negative Acute Lymphoblastic Leukemia Patients, Including Older Adults
2819 - JALSG Ph (-) B-ALL213 Study: Pediatric-Type Chemotherapy Improves Prognosis in Adult Ph-Negative Acute Lymphoblastic Leukemia Patients, Including Older Adults
Kiziltug, M. T.
Kjær, L.
1806 - Identification of Calr Mutations in Individuals of the Background Population Reveals Undiagnosed Myeloproliferative Neoplasms and Surprisingly Stable Low Levels of Calr Mutant Allele Burden in Individuals Not Developing Myeloproliferative Neoplasm during 10-14 Year Follow-up
3184 - Statins Enhance the Efficacy of Pegylated Interferon-alpha2 in Patients with Ph-Negative Chronic Myeloproliferative Neoplasms. Results from a Danish Single-Institution Cohort Study
4545 - Circulating Extracellular Matrix Fragments As Biomarkers in Myeloproliferative Neoplasms – Baseline Data from the Daliah Trial
3184 - Statins Enhance the Efficacy of Pegylated Interferon-alpha2 in Patients with Ph-Negative Chronic Myeloproliferative Neoplasms. Results from a Danish Single-Institution Cohort Study
4545 - Circulating Extracellular Matrix Fragments As Biomarkers in Myeloproliferative Neoplasms – Baseline Data from the Daliah Trial
Kjeldsen, E.
Kjellander, C.
Klaassen, R. J.
Klacking, E. E.
1363 - Defining the Roles of Base Deaminase and Splicing Deregulation in Pediatric B-Cell Acute Lymphoblastic Leukemia Stem Cell Persistence
4068 - A 3D Niche Nanobioreactor Supports Long-Term Tracking of Hematopoietic Stem and Progenitor Cell Cycle Kinetics, Self-Renewal and Cell Fate Determination
4068 - A 3D Niche Nanobioreactor Supports Long-Term Tracking of Hematopoietic Stem and Progenitor Cell Cycle Kinetics, Self-Renewal and Cell Fate Determination
Kladis, G.
Klahr, M.
Klaiber-Hakimi, M.
364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Klamroth, R.
555 - Sustained Improvement of Survival in Patients Receiving Emicizumab Prophylaxis Instead of Immunosuppression during Early Management of Acquired Hemophilia a (AHA)
717 - Clinical Outcomes over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study
3578 - Stable Factor IX Expression and Sustained Reductions in Factor IX Use 8 Years after Gene Therapy with CSL220 (Formerly AMT-060) in Adults with Hemophilia B
717 - Clinical Outcomes over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study
3578 - Stable Factor IX Expression and Sustained Reductions in Factor IX Use 8 Years after Gene Therapy with CSL220 (Formerly AMT-060) in Adults with Hemophilia B
Klanova, M.
Klapper, W.
230 - Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma
237 - Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project
240 - Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
2959 - Circulating Tumor DNA Kinetics at Day 14 after CAR T-Cell Therapy Identifies Patients with B-Cell Lymphoma at Risk for Early Treatment Failure
4796 - Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma
237 - Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project
240 - Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
2959 - Circulating Tumor DNA Kinetics at Day 14 after CAR T-Cell Therapy Identifies Patients with B-Cell Lymphoma at Risk for Early Treatment Failure
4796 - Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma
Klär, A.
Klasa, Ł.
Klaskin, D.
Klaus, T.
Klausz, K.
Klco, J. M.
103 - Rapid Long-Read Epigenomic Diagnosis and Prognosis of Acute Myeloid Leukemia
325 - Genetic and Functional Characterization of NUP98-Rearranged Leukemia
825 - The Histone Acetyltransferase MOZ (KAT6A) Is a Molecular Dependency and Therapeutic Target in NUP98-Rearranged Acute Myeloid Leukemia
1352 - Oncogenic Potential and Sensitivity to Menin Inhibitors of a Novel Fusion KAT6B::NUTM2B in Congenital Myeloid Sarcoma with Bone Marrow Involvement
2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia
4149 - Proteolytic Control and Therapeutic Targeting of Oncogenic Gene Expression in Acute Myeloid Leukemia
325 - Genetic and Functional Characterization of NUP98-Rearranged Leukemia
825 - The Histone Acetyltransferase MOZ (KAT6A) Is a Molecular Dependency and Therapeutic Target in NUP98-Rearranged Acute Myeloid Leukemia
1352 - Oncogenic Potential and Sensitivity to Menin Inhibitors of a Novel Fusion KAT6B::NUTM2B in Congenital Myeloid Sarcoma with Bone Marrow Involvement
2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia
4149 - Proteolytic Control and Therapeutic Targeting of Oncogenic Gene Expression in Acute Myeloid Leukemia
Klebaner, D.
Klebanoff, C. A.
Klei, T. T.
Kleigrewe, K.
780 - Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined By Microbial Metabolite Profiles and Linked to Long-Term Outcomes
4904 - Loss of Microbiota-Derived Metabolites Is Associated with Mucosal-Barrier-Injury Bloodstream Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
4904 - Loss of Microbiota-Derived Metabolites Is Associated with Mucosal-Barrier-Injury Bloodstream Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Klein, A. M.
Klein, C.
Klein, C.
Klein, D.
Klein, E.
Klein, F.
Klein, N. Y.
Klein, S. K.
Klein, S.
776 - Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation
2179 - Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies – a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group
3554 - Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group
4143 - The Bispecific Innate Cell Engager AFM28 Can Leverage AML Patient’s NK Cells in Addition to Allogeneic NK Cells, Enabling Elimination of CD123+ Leukemic Stem and Progenitor Cells in AML and MDS
1527.1 - Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial
2179 - Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies – a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group
3554 - Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group
4143 - The Bispecific Innate Cell Engager AFM28 Can Leverage AML Patient’s NK Cells in Addition to Allogeneic NK Cells, Enabling Elimination of CD123+ Leukemic Stem and Progenitor Cells in AML and MDS
1527.1 - Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial
Klein, S. A.
Klein, V.
Klein-Gonzalez, N.
Kleinert, E.
Kleinman, M.
Kleinman, S.
Kleinschmidt, K.
2182 - Analysis of Outcomes after Second Allogeneic Stem Cell Transplant in Relapsed Acute Myeloid Leukaemia in Children: A Study from the EBMT Pediatric Diseases Working Party
3540 - Total Body Irradiation Versus Chemotherapy Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia Patients Aged 2 to 4 Years: A Retrospective Study of the EBMT Pediatric Diseases Working Party
3540 - Total Body Irradiation Versus Chemotherapy Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia Patients Aged 2 to 4 Years: A Retrospective Study of the EBMT Pediatric Diseases Working Party
Kleinsorge-Block, S.
Kleinstern, G.
Kleisman, M. M.
Klema, J.
Klemm, N.
41 - The Pathogenesis of Therapy-Related Myeloid Neoplasms from TP53-Mutant Clonal Hematopoiesis
193 - Somatic TP53 Mutations Rescue the Hematopoietic Stem and Progenitor Cell Defect at the Expense of Increased Risk for Myeloid Malignancies in ERCC6L2-Associated Inherited Bone Marrow Failure Syndrome
193 - Somatic TP53 Mutations Rescue the Hematopoietic Stem and Progenitor Cell Defect at the Expense of Increased Risk for Myeloid Malignancies in ERCC6L2-Associated Inherited Bone Marrow Failure Syndrome
Klener, P.
230 - Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma
974 - A Murine Phase 2 Proof-of-Concept Study of Polatuzumab Vedotin in Combination with Venetoclax in Experimental Therapy of BCL2-Positive Aggressive Lymphomas
2973 - Comprehensive Genomic Analysis of Non-Relapsed and Late-Relapsed Mantle Cell Lymphoma Patients Compared to Refractory and Early-Relapsed Patients Treated By Standard Immunochemotherapy
3012 - Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?
974 - A Murine Phase 2 Proof-of-Concept Study of Polatuzumab Vedotin in Combination with Venetoclax in Experimental Therapy of BCL2-Positive Aggressive Lymphomas
2973 - Comprehensive Genomic Analysis of Non-Relapsed and Late-Relapsed Mantle Cell Lymphoma Patients Compared to Refractory and Early-Relapsed Patients Treated By Standard Immunochemotherapy
3012 - Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?
Klener, P.
Kleppe, M.
Klerk, C.
Klesse, L. J.
Klievink, J.
329 - Genomic Subtypes of AML Define Sensitivity to NK Cell Cytotoxicity
913 - Comprehensive Drug Profiling and CRISPR Screening Reveal Essential Pathways for NK Cell Cytotoxicity
3596 - Predicting Antigen-Specific T Cell Immunity Against Wilms Tumor 1 in Hematologic Cancer
4814 - Bone Marrow Stromal Cells Hamper Leukemia Cell Induced NK Cell Activation and Cytotoxicity
913 - Comprehensive Drug Profiling and CRISPR Screening Reveal Essential Pathways for NK Cell Cytotoxicity
3596 - Predicting Antigen-Specific T Cell Immunity Against Wilms Tumor 1 in Hematologic Cancer
4814 - Bone Marrow Stromal Cells Hamper Leukemia Cell Induced NK Cell Activation and Cytotoxicity
Kliman, D.
3519 - A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) with ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)
1661.1 - BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia
1661.1 - BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia
Klimiankou, M.
417 - Autosomal Recessive COPZ1 Mutations Cause Isolated Severe Neutropenia or Complex Syndrome with Severe Neutropenia
419 - Flavopiridol Restores Granulopoiesis in an Experimental Model of Severe Congenital Neutropenia
2530 - Genotype-Phenotype Correlations in Patients with Severe Chronic Neutropenia Harboring ELANE Mutations: A Long-Term Study of the Severe Chronic Neutropenia International Registry
4967 - Modulating G-CSFR Signaling Using De Novo Designed Cytokines
419 - Flavopiridol Restores Granulopoiesis in an Experimental Model of Severe Congenital Neutropenia
2530 - Genotype-Phenotype Correlations in Patients with Severe Chronic Neutropenia Harboring ELANE Mutations: A Long-Term Study of the Severe Chronic Neutropenia International Registry
4967 - Modulating G-CSFR Signaling Using De Novo Designed Cytokines
Klimovsky, J.
Kline, J.
Kline, J.
111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
1669 - Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade
2026 - Inhibition of PI3Kγ/δ Signaling Promotes an Early Memory State in CAR T Cells and Enhances Their In Vivo Persistence and Efficacy
3751 - Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis
4497 - Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy
- Integrative Genomic Analysis Identifies Unique Immune Environments Associated with Immunotherapy Response in Diffuse Large B-Cell Lymphoma
1669 - Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade
2026 - Inhibition of PI3Kγ/δ Signaling Promotes an Early Memory State in CAR T Cells and Enhances Their In Vivo Persistence and Efficacy
3751 - Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis
4497 - Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy
- Integrative Genomic Analysis Identifies Unique Immune Environments Associated with Immunotherapy Response in Diffuse Large B-Cell Lymphoma
Klingborg, S.
Klingebiel, T.
Klinger, B.
Klingler, C.
Klings, E. S.
2241 - Validation of ICD-10 Codes for Identifying Acute Chest Syndrome in Patients with Sickle Cell Disease
3617 - SNAP: Supportive Non-Invasive Ventilation for Acute Chest Syndrome Prevention in Hospitalized Children with Sickle Cell Disease: Facilitators, Barriers, and Contextual Factors Related to Implementation
3617 - SNAP: Supportive Non-Invasive Ventilation for Acute Chest Syndrome Prevention in Hospitalized Children with Sickle Cell Disease: Facilitators, Barriers, and Contextual Factors Related to Implementation
Klink, T.
Klinkova, O.
2103 - Delayed Immune Reconstitution and Increased Infections in Allogeneic Transplant Recipients with B Cell Malignancies Treated Previously with CAR T-Cell Therapy
2130 - Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide
2130 - Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide
Klisovic, R. B.
218 - 10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years
2115 - A Retrospective Study of C5b-9 and MASP2 Deposition in Skin Microvasculature As a Prognostic and Diagnostic Tool for Transplant-Associated Thrombotic Microangiopathy
2131 - A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation
2115 - A Retrospective Study of C5b-9 and MASP2 Deposition in Skin Microvasculature As a Prognostic and Diagnostic Tool for Transplant-Associated Thrombotic Microangiopathy
2131 - A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation
Kloet, S. L.
Klok, F. A.
Klomjit, N.
Kloos, A.
Kloos, I.
748 - Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)
4388 - Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
4388 - Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
Klostergaard, A.
Kluetz, P. G.
Kluiver, J. L.
Klusmann, J. H.
Klyuchnikov, E.
3547 - Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation
3571 - Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission
3571 - Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission
Knapp, J.
Knapp, S.
Knapper, S.
120 - Prospective Cohort Study of Non-COVID Infection in Patients with AML/MDS Undergoing Treatment: Implications for Practice
407 - Profiling Baseline Health-Related Quality of Life of Patients with Newly Diagnosed Myeloid Malignancies: A Pooled Analysis of 3349 Patients with AML, APL and MDS from the International Proactive Project
1023 - Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
2907 - Gemtuzumab Based Induction Chemotherapy Combined with Midostaurin for FLT3 Mutated Patients. Results from the Patient- Reported Outcome Measures from the NCRI AML19V2 ‘Midotarg Pilot’
3146 - RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study
4191.1 - Optimising Therapy in FLT3-Mutated Acute Myeloid Leukaemia
407 - Profiling Baseline Health-Related Quality of Life of Patients with Newly Diagnosed Myeloid Malignancies: A Pooled Analysis of 3349 Patients with AML, APL and MDS from the International Proactive Project
1023 - Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
2907 - Gemtuzumab Based Induction Chemotherapy Combined with Midostaurin for FLT3 Mutated Patients. Results from the Patient- Reported Outcome Measures from the NCRI AML19V2 ‘Midotarg Pilot’
3146 - RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study
4191.1 - Optimising Therapy in FLT3-Mutated Acute Myeloid Leukaemia
Knapper, S.
59 - A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial
3300 - A Novel Approach to Lower Risk Monoclonal Gammopathy of Undetermined Significance (MGUS) Follow-up Based on Isotype-Specific Annualised Progression Risk: A Retrospective Real World Evidence Single Centre UK Study
3805 - Patient-Reported Outcomes in Older Acute Myeloid Leukemia Patients Fit for Intensive Treatment, Who Received Intensified Treatment (DA +/- cladribine) Following No Evidence of Response to Course 1: Results from the NCRI AML18 Trial
3300 - A Novel Approach to Lower Risk Monoclonal Gammopathy of Undetermined Significance (MGUS) Follow-up Based on Isotype-Specific Annualised Progression Risk: A Retrospective Real World Evidence Single Centre UK Study
3805 - Patient-Reported Outcomes in Older Acute Myeloid Leukemia Patients Fit for Intensive Treatment, Who Received Intensified Treatment (DA +/- cladribine) Following No Evidence of Response to Course 1: Results from the NCRI AML18 Trial
Knauf, W.
364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Knauf, W. U.
Kneisel, N.
Knepper, T. C.
Knight Asorey, T.
Knight, J.
Knight, K. A.
Knight, T. G.
685 - The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704
5194 - Outcomes with Real-World Use of Azacitidine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Are Comparable to Long-Term Viale-a Results
- Cancer and Poverty - Mitigating the Impact of Financial Toxicity in Patients with Hematologic Malignancies
5194 - Outcomes with Real-World Use of Azacitidine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Are Comparable to Long-Term Viale-a Results
- Cancer and Poverty - Mitigating the Impact of Financial Toxicity in Patients with Hematologic Malignancies
Knight-Scott, J.
Knightly, K. A.
1176 - Medical Problems of Mothers of Children with Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT): Autoimmunity and Psychological Symptoms
1178 - Analysis of Screening for Autism Spectrum Disorders in Children Affected By Fnait with and without Intra-Cranial Hemorrhage
1179 - Fetal and Neonatal Alloimmune Thrombocytopenia: Risk of ICH in Second Pregnancy and Treatments to Maintain an Adequate Platelet Count
1178 - Analysis of Screening for Autism Spectrum Disorders in Children Affected By Fnait with and without Intra-Cranial Hemorrhage
1179 - Fetal and Neonatal Alloimmune Thrombocytopenia: Risk of ICH in Second Pregnancy and Treatments to Maintain an Adequate Platelet Count
Knisbacher, B.
Knittel, G.
Knittel, G.
Knobe, K.
Knöbl, P. N.
Knoechel, B.
Knöll, M.
Knop, S.
Knorr, K.
Knowles, T.
Knuckles, P.
Knudsen, T. A.
1806 - Identification of Calr Mutations in Individuals of the Background Population Reveals Undiagnosed Myeloproliferative Neoplasms and Surprisingly Stable Low Levels of Calr Mutant Allele Burden in Individuals Not Developing Myeloproliferative Neoplasm during 10-14 Year Follow-up
3184 - Statins Enhance the Efficacy of Pegylated Interferon-alpha2 in Patients with Ph-Negative Chronic Myeloproliferative Neoplasms. Results from a Danish Single-Institution Cohort Study
4545 - Circulating Extracellular Matrix Fragments As Biomarkers in Myeloproliferative Neoplasms – Baseline Data from the Daliah Trial
3184 - Statins Enhance the Efficacy of Pegylated Interferon-alpha2 in Patients with Ph-Negative Chronic Myeloproliferative Neoplasms. Results from a Danish Single-Institution Cohort Study
4545 - Circulating Extracellular Matrix Fragments As Biomarkers in Myeloproliferative Neoplasms – Baseline Data from the Daliah Trial
Knurowski, T.
Knutson, T. P.
Knysh, H.
Ko, B. S.
2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study
Ko, T. K.
Ko, Y. D.
Kobayashi, A.
Kobayashi, H.
Kobayashi, H.
Kobayashi, M.
Kobayashi, N.
Kobayashi, N.
Kobayashi, S.
Kobayashi, T.
Kobayashi, T.
Kobbe, G.
1479 - Day 30 Mortality in Patients with AML: A Single Center Analysis Based on 1036 Patients
3560 - Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
3560 - Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
Kobbe, R.
Kobe, C.
566 - Metabolic Tumor Volume after Two Cycles of Chemotherapy in Patients Treated for Advanced-Stage Hodgkin Lymphoma: Analysis of the German Hodgkin Study Group Phase III HD18 and HD21 Trials
3044 - Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume during Anti-PD1-Based First-Line HL Treatment in the GHSG Phase II Nivahl Trial
4428 - Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial
3044 - Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume during Anti-PD1-Based First-Line HL Treatment in the GHSG Phase II Nivahl Trial
4428 - Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial
Kobold, S.
367 - Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma
918 - CSF1R Targeting T Cell Engaging Bispecific Antibodies Enable Safe and Efficient Immunotherapies in Acute Myeloid Leukemia
4796 - Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma
918 - CSF1R Targeting T Cell Engaging Bispecific Antibodies Enable Safe and Efficient Immunotherapies in Acute Myeloid Leukemia
4796 - Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma
Kobos, R.
494 - Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
495 - Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm‑2 Studies
495 - Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm‑2 Studies
Kobrosly, M.
Kobulsky, D. R.
Koc, Y.
600 - Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Study on Behalf of the Chronic Malignancies Working Party of the EBMT
2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
4939 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
4939 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
Koca, E.
Koch, C.
Koch, F. C.
Koch, H.
Koch, K.
Koch, R.
Koch, T.
Koch, V.
Koch, V. B.
307 - Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001
311 - Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001
3750 - Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies
311 - Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001
3750 - Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies
Koch-Nolte, F.
Koche, R.
671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
756 - HMGA1 Chromatin Regulators Disrupt 3D Genome Architecture and Chromatin Looping to Repress MHC II Genes and Drive Immune Evasion during MPN Progression
756 - HMGA1 Chromatin Regulators Disrupt 3D Genome Architecture and Chromatin Looping to Repress MHC II Genes and Drive Immune Evasion during MPN Progression
Kochenderfer, J. N.
Kocher, F.
Köcher, T.
Kochhar, M.
709 - Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
795 - Pediatric Autoimmune Hemolytic Anemia Is Associated with a High Incidence of an Underlying Immune Disorder and High Mortality Rate
3689 - Prioritizing Mental Health in Sickle Cell Disease: Implementing Routine Psychological and Neurocognitive Assessments in a Comprehensive Sickle Cell Clinic
795 - Pediatric Autoimmune Hemolytic Anemia Is Associated with a High Incidence of an Underlying Immune Disorder and High Mortality Rate
3689 - Prioritizing Mental Health in Sickle Cell Disease: Implementing Routine Psychological and Neurocognitive Assessments in a Comprehensive Sickle Cell Clinic
Kockerols, C.
Kocoglu, M. H.
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4828 - A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4828 - A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort
Koçoğlu, M. H.
922 - Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)
1031 - Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
1031 - Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
Kodas, E.
770 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study
1976 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study
1976 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study
Kodera, Y.
2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study
Kodgule, R.
Koduri, V.
- RTAF
Koehl, B.
Koehler, A.
1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
Koehler, N.
264 - Immunomodulatory Microbial Metabolites Protect Against Graft-Vs-Host Disease and Enhance Anti-Leukemia Responses in Mice and Patients Receiving Stem Cell Transplantation
3392 - FLT3-ITD Driven CMTM6 Expression Contributes to Immune Escape of Acute Myeloid Leukemia
4119 - STAT5-Activating Oncogenes Drive Oncostatin M Production Causing T Cell Exhaustion and Suppressive Myeloid Cell Recruitment
3392 - FLT3-ITD Driven CMTM6 Expression Contributes to Immune Escape of Acute Myeloid Leukemia
4119 - STAT5-Activating Oncogenes Drive Oncostatin M Production Causing T Cell Exhaustion and Suppressive Myeloid Cell Recruitment
Koehne, G.
1499 - A Phase I Dose Escalation and Expansion Trial of Lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) Alone and in Combination with Venetoclax/HMA in Relapsed/Refractory AML/MDS
2873 - A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
2873 - A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
Koene, H. R.
Koenen, R. R.
2603 - Citrullination in the C-Terminus of Tissue Factor Pathway Inhibitor-Alpha Impairs the Inhibition of Factor V Activation, and the Synergy with Protein S in Factor Xa Inactivation
3994 - Citrullination of TFPI By PAD4 Impairs Its Natural Anticoagulant Activity Towards Factors Xa, VIIa and Tissue Factor, and Reduces Binding to Its Cofactor Protein S
- Inactivation of Tissue Factor Pathway Inhibitor
3994 - Citrullination of TFPI By PAD4 Impairs Its Natural Anticoagulant Activity Towards Factors Xa, VIIa and Tissue Factor, and Reduces Binding to Its Cofactor Protein S
- Inactivation of Tissue Factor Pathway Inhibitor
Koenig, J.
Koenig, K. L.
1564 - Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
2432 - Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia
4286 - A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
4324 - Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
2883.4 - A Phase 1, Open-Label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Lomonitinib (ZE46-0134) in Adults with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia
2907.2 - A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years
2432 - Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia
4286 - A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
4324 - Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
2883.4 - A Phase 1, Open-Label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Lomonitinib (ZE46-0134) in Adults with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia
2907.2 - A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years
Koenig, R.
Koeppen, K. U.
Koetsier, J. J.
Koff, J. L.
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
1652 - Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma
1717 - Clinical Features and Outcomes of Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Single-Center Analysis
2289 - Demystifying the Delivery and Adverse Event Management of Bispecific Antibodies in the Community Setting
3093 - Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study
3235 - PD-1 Expression Identifies Proliferating Chronic Lymphocytic Leukemia Cells and Informs Response and Resistance to BTK Inhibitor Therapy
4348 - Genomic and Spatial Proteomic Characterization of the Microenvironment of Diffuse Large B-Cell Lymphoma in African American Patients
1652 - Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma
1717 - Clinical Features and Outcomes of Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Single-Center Analysis
2289 - Demystifying the Delivery and Adverse Event Management of Bispecific Antibodies in the Community Setting
3093 - Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study
3235 - PD-1 Expression Identifies Proliferating Chronic Lymphocytic Leukemia Cells and Informs Response and Resistance to BTK Inhibitor Therapy
4348 - Genomic and Spatial Proteomic Characterization of the Microenvironment of Diffuse Large B-Cell Lymphoma in African American Patients
Kofides, A.
743 - Single-Cell RNA Analysis of Bone Marrow Mononuclear Cells Reveals Abnormal Activation of T Cells and Monocytes, and Identifies CD35 As a Novel Biomarker and Therapeutic Target in Waldenstrom Macroglobulinemia
834 - Development and Characterization of Novel Dual HCK/BTK Bifunctional Protacs That Potently Inhibit Kinase Function and Demonstrate Robust in Vitro and In Vivo Degradation of Targets for the Treatment of MYD88-Mutated B-Cell Malignancies
1647 - Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
2968 - Multi-Omic Analysis Identifies Deletions in Chr17p and High ROR1 Expression, but Not TP53 Mutations As Predictors of Overall Survival in Patients with Untreated Waldenstrom’s Macroglobulinemia (WM)
2972 - Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström’s Macroglobulinemia and Represent Novel Therapeutic Targets.
2986 - Analysis of Alternative Splicing in Waldenstrom’s Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates
3011 - A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
4338 - Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom’s Macroglobulinemia Undergoing Ibrutinib Monotherapy
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors
834 - Development and Characterization of Novel Dual HCK/BTK Bifunctional Protacs That Potently Inhibit Kinase Function and Demonstrate Robust in Vitro and In Vivo Degradation of Targets for the Treatment of MYD88-Mutated B-Cell Malignancies
1647 - Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
2968 - Multi-Omic Analysis Identifies Deletions in Chr17p and High ROR1 Expression, but Not TP53 Mutations As Predictors of Overall Survival in Patients with Untreated Waldenstrom’s Macroglobulinemia (WM)
2972 - Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström’s Macroglobulinemia and Represent Novel Therapeutic Targets.
2986 - Analysis of Alternative Splicing in Waldenstrom’s Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates
3011 - A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
4338 - Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom’s Macroglobulinemia Undergoing Ibrutinib Monotherapy
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors
Kofron, M.
Kogan Zajdman, A.
Kogila, S.
Koglin, A. S.
Kogure, Y.
Koh, A. Y.
Koh, J.
Koh, J. S.
Koh, J. Y.
Koh, M. B.
2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study
Koh, W. K.
Koh, Y.
497 - Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis
1375 - ATR Inhibitor Elimusertib Suppresses Drug Persister Clones in TP53-Mutated Acute Myeloid Leukemia Via CGAS-Sting-Mediated Cell Death
1636 - Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry
4707 - Efficacy and Safety of T-Cell Engagers Compared to Standard of Care for Relapsed/Refractory Multiple Myeloma Treatment: A Real-World RCT Mimicking Analyses
1375 - ATR Inhibitor Elimusertib Suppresses Drug Persister Clones in TP53-Mutated Acute Myeloid Leukemia Via CGAS-Sting-Mediated Cell Death
1636 - Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry
4707 - Efficacy and Safety of T-Cell Engagers Compared to Standard of Care for Relapsed/Refractory Multiple Myeloma Treatment: A Real-World RCT Mimicking Analyses
Köhl, U.
Kohler, A.
Kohler, J. J.
Kohler, M. E.
369 - Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro, In Vivo, and Ex Vivo Anti-Leukemia Activity
1446 - Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-Cell Acute Lymphoblastic Leukemia
2219 - Validation of a Digital Polymerase Chain Reaction Assay to Quantify Chimeric Antigen Receptor-Positive T-Cells Relative to Total T-Cells
3416 - CD64 CAR-T Therapy Targets Venetoclax-Resistant Monocytic Acute Myeloid Leukemia
4129 - Developing a Pediatric-Relevant Murine MLL-r B-ALL Model to Study Factors Involved in Lineage Switching
4510 - Preliminary Safety and Tolerability of CD19x22 CAR-T Cell Therapy in Adolescent and Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
1446 - Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-Cell Acute Lymphoblastic Leukemia
2219 - Validation of a Digital Polymerase Chain Reaction Assay to Quantify Chimeric Antigen Receptor-Positive T-Cells Relative to Total T-Cells
3416 - CD64 CAR-T Therapy Targets Venetoclax-Resistant Monocytic Acute Myeloid Leukemia
4129 - Developing a Pediatric-Relevant Murine MLL-r B-ALL Model to Study Factors Involved in Lineage Switching
4510 - Preliminary Safety and Tolerability of CD19x22 CAR-T Cell Therapy in Adolescent and Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Kohlhagen, M.
Kohli, M.
3783 - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab
3792g - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval
3792g - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval
Kohli, P.
Kohlscheen, S.
Koide, S.
Koifman, M.
Koike, T.
Koirala, S.
Koizumi, R.
Kojima, K.
260 - Gvhd-Induced Inflammatory Memory in Intestinal Stem Cells Enhances IFN-y-Induced Antigen Presentation and Apoptosis of Intestinal Epithelial Cells
902 - Ropeginterferon Alfa-2b Induces Apoptosis and Differentiation of Leukemia Stem Cells and Separates GVL Effects from Gvhd after Allogeneic Hematopoietic Cell Transplantation
903 - Early Initiation of Calcineurin Inhibitor Induces CD8+ Transitory Exhausted-like and CD4+ Cytotoxic T Cells, Maintaining Responsiveness to PD-1 Blockade and Contributing to the Development of Chronic Gvhd after Post-Transplant Cyclophosphamide
902 - Ropeginterferon Alfa-2b Induces Apoptosis and Differentiation of Leukemia Stem Cells and Separates GVL Effects from Gvhd after Allogeneic Hematopoietic Cell Transplantation
903 - Early Initiation of Calcineurin Inhibitor Induces CD8+ Transitory Exhausted-like and CD4+ Cytotoxic T Cells, Maintaining Responsiveness to PD-1 Blockade and Contributing to the Development of Chronic Gvhd after Post-Transplant Cyclophosphamide
Kojima, K.
Kojima, Y.
Kok, C. H.
991 - Strong Association between Cancer Gene Variants at Diagnosis, Especially ASXL1, and Emergence of Kinase Domain Mutation-Driven Resistance in CML Patients Despite Frontline Treatment with More Potent BCR::ABL1 Inhibitors
993 - Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia
996 - Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
993 - Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia
996 - Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
Kok, C. H.
1267 - Higher Rate of Red Blood Cell (RBC) Alloimmunization in RBC-Transfused Myelodysplastic Syndrome Compared to Acute Myeloid Leukemia
2715 - Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity
3208 - Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS
4237 - High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies
4596 - Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure
2715 - Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity
3208 - Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS
4237 - High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies
4596 - Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure
Kok, J. S.
Kokalovski, J.
Kokavec, J.
Koko, T.
1500 - EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Final Results of Dose Escalation and Optimization Cohorts from a Phase I/IIa Study in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) or Myelodysplastic Syndrome (MDS)
1535 - Bone Marrow Failure in AML: Residual Neutrophils and Erythroblasts Are Derived By Differentiation from the AML
1535 - Bone Marrow Failure in AML: Residual Neutrophils and Erythroblasts Are Derived By Differentiation from the AML
Köksal, Y.
Koksoy, A. A.
Kolarich, D.
Kolb, A.
103 - Rapid Long-Read Epigenomic Diagnosis and Prognosis of Acute Myeloid Leukemia
209 - Identification of DLK1 As a Novel Therapeutic Target in Down Syndrome Myeloid Leukemia
967 - A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group
2949 - Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children’s Oncology Group
209 - Identification of DLK1 As a Novel Therapeutic Target in Down Syndrome Myeloid Leukemia
967 - A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group
2949 - Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children’s Oncology Group
Koldej, R.
217 - A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial
223 - Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A-rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial
4376 - T Cell CD62L Expression Following Nivolumab Therapy Is Associated with Long Term Response to Rituximab-Nivolumab in Treatment Naïve Follicular Lymphoma: Results from the 1st FLOR Study
4384 - Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment
223 - Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A-rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial
4376 - T Cell CD62L Expression Following Nivolumab Therapy Is Associated with Long Term Response to Rituximab-Nivolumab in Treatment Naïve Follicular Lymphoma: Results from the 1st FLOR Study
4384 - Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment
Koldobskiy, M.
Koleci, N.
Koletsa, T.
Kolhatkar, S. M.
Kolitz, J. E.
221 - Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML
641 - Transcriptomically Defined Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) Phenotype Governs Mutation-Based Disease Group Assignment
1849 - Delivery of Foreign Antigen Selectively to Membrane IgD on CLL and Normal B Cells Leads to Superior T-Cell Activation: A Possible Approach to Restore/Enhance T-Cell Immunity and T-Cell Help
2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
641 - Transcriptomically Defined Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) Phenotype Governs Mutation-Based Disease Group Assignment
1849 - Delivery of Foreign Antigen Selectively to Membrane IgD on CLL and Normal B Cells Leads to Superior T-Cell Activation: A Possible Approach to Restore/Enhance T-Cell Immunity and T-Cell Help
2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
Koll, T. T.
Koller, P. B.
479 - Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)
729 - TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
1043 - Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)
2278 - Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible
2876 - ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction
3151 - Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP‑CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses
4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)
729 - TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
1043 - Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)
2278 - Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible
2876 - ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction
3151 - Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP‑CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses
4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)
Kollias, I.
Kolloch, L.
2177 - Post-Transplant Relapse in Patients Transplanted with Active Acute Myeloid Leukemia (AML) – Treatment Options and Outcomes at a Large AML Referral Center
4242 - “As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022
4242 - “As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022
Kolodny, S.
1191 - Analysis of Durability of Response to Avatrombopag (AVA) from a Phase 3b Multicenter, Randomized, Double-Blind, Placebo (PBO)-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of AVA for the Treatment of Pediatric Patients with Immune Thrombocytopenia
2559 - Enhanced Patient Satisfaction and Stability of Platelet Counts Following a Switch from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA) in Adult Idiopathic Thrombocytopenic Purpura (ITP): Post-Hoc Analyses from a Prospective Phase 4 Study
2560 - Results of a Prospective, Open-Label, Phase 4 Study Evaluating the Safety, Efficacy, and Treatment Satisfaction in Adult Immune Thrombocytopenia (ITP) Subjects after Switching to Avatrombopag from Eltrombopag or Romiplostim
3700 - Real-World Treatment Patterns and Outcomes in Patients with Primary Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Interim Analysis Results
2559 - Enhanced Patient Satisfaction and Stability of Platelet Counts Following a Switch from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA) in Adult Idiopathic Thrombocytopenic Purpura (ITP): Post-Hoc Analyses from a Prospective Phase 4 Study
2560 - Results of a Prospective, Open-Label, Phase 4 Study Evaluating the Safety, Efficacy, and Treatment Satisfaction in Adult Immune Thrombocytopenia (ITP) Subjects after Switching to Avatrombopag from Eltrombopag or Romiplostim
3700 - Real-World Treatment Patterns and Outcomes in Patients with Primary Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Interim Analysis Results
Kolodziej, M.
Kolodziej, M. A.
3756 - Symptoms Detection Among Patients with Lymphoid Malignancies (LM) Using Electronic Patient-Reported Outcomes (ePROs) in Community Hematology-Oncology Clinics
5046 - Electronic Patient-Reported Outcome (ePRO) Symptom Monitoring for Relapsed/Refractory Multiple Myeloma in Community Settings, Focusing on Bispecific Antibody Therapy
5046 - Electronic Patient-Reported Outcome (ePRO) Symptom Monitoring for Relapsed/Refractory Multiple Myeloma in Community Settings, Focusing on Bispecific Antibody Therapy
Kolovos, P.
Kolstad, A.
Komanduri, K. V.
Komar, C.
Komaroff, A.
Komatsu, H.
2411f - Prognostic Impact of Clinical Factors and Cell Composition of Apheresis Samples on BCMA CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
3075 - The Impact of MYD88 and/or CD79B Gene Mutations on Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma
3342 - Stratifying 'frail' Patients Defined By the Simplified Frailty Scale in Multiple Myeloma: Correlation with Clinical Outcomes
4638 - Targeting Overexpressed IDO on Stromal Cells As a Potential Therapeutic Strategy in Multiple Myeloma
3075 - The Impact of MYD88 and/or CD79B Gene Mutations on Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma
3342 - Stratifying 'frail' Patients Defined By the Simplified Frailty Scale in Multiple Myeloma: Correlation with Clinical Outcomes
4638 - Targeting Overexpressed IDO on Stromal Cells As a Potential Therapeutic Strategy in Multiple Myeloma
Komatsu, N.
Komrokji, R. S.
105 - Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)
350 - Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent–Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial
352 - Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes
354 - High-Risk Ccus Is Clinically Indistinguishable from Low-Risk Myelodysplastic Syndromes/Neoplasms
481 - A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia
532 - A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes
664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium
666 - Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1004 - CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
1046 - Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes
1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
1520 - A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
1818 - Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial
1821 - A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results
1831 - Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)
1832 - Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial
1843 - High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax – Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes
1845 - Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1del5q): Outcomes and Response to Treatment
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
2415 - Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience
2820 - Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting
2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results
3210 - Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial
3214 - The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms
3216 - Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study
3217 - Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
3227 - Clinical Relevance of Subgrouping in TP53 mutated Myelodysplastic Neoplasms: Insights from ICC and Who Classifications
3228 - IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)
3597 - The “David Vs Goliath” Study: Application of Large Language Models (LLM) for Automatic Medical Information Retrieval from Multiple Data Sources to Accelerate Clinical and Translational Research in Hematology
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
3679 - Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey
4270 - Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
4332 - Prospective Evaluation of the Impact of Measurable Residual Disease (MRD) By Error Corrected Next-Generation Sequencing (NGS) with CPX-351 in Acute Myeloid Leukemia (AML)
4561 - Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes
4578 - Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin
4584 - Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis
4589 - The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS
4590 - Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents
4597 - Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes
4938 - Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
4991 - A Deep-Learning Pipeline for Diagnosis of Myelodysplastic Syndromes/Neoplasms Using Bone Marrow Smears
5190 - Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas
1808.1 - Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial
3228.1 - Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)
4569.2 - A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm
350 - Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent–Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial
352 - Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes
354 - High-Risk Ccus Is Clinically Indistinguishable from Low-Risk Myelodysplastic Syndromes/Neoplasms
481 - A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia
532 - A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes
664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium
666 - Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1004 - CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
1046 - Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes
1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
1520 - A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
1818 - Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial
1821 - A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results
1831 - Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)
1832 - Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial
1843 - High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax – Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes
1845 - Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1del5q): Outcomes and Response to Treatment
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
2415 - Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience
2820 - Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting
2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results
3210 - Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial
3214 - The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms
3216 - Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study
3217 - Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
3227 - Clinical Relevance of Subgrouping in TP53 mutated Myelodysplastic Neoplasms: Insights from ICC and Who Classifications
3228 - IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)
3597 - The “David Vs Goliath” Study: Application of Large Language Models (LLM) for Automatic Medical Information Retrieval from Multiple Data Sources to Accelerate Clinical and Translational Research in Hematology
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
3679 - Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey
4270 - Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
4332 - Prospective Evaluation of the Impact of Measurable Residual Disease (MRD) By Error Corrected Next-Generation Sequencing (NGS) with CPX-351 in Acute Myeloid Leukemia (AML)
4561 - Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes
4578 - Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin
4584 - Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis
4589 - The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS
4590 - Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents
4597 - Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes
4938 - Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
4991 - A Deep-Learning Pipeline for Diagnosis of Myelodysplastic Syndromes/Neoplasms Using Bone Marrow Smears
5190 - Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas
1808.1 - Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial
3228.1 - Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)
4569.2 - A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm
Komrokji, Z.
354 - High-Risk Ccus Is Clinically Indistinguishable from Low-Risk Myelodysplastic Syndromes/Neoplasms
1004 - CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?
1461 - Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens
2811 - Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed/Refractory B-Cell ALL
3217 - Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes
3228 - IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)
4194 - Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update
1004 - CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?
1461 - Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens
2811 - Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed/Refractory B-Cell ALL
3217 - Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes
3228 - IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)
4194 - Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update
Kon, A.
Kondo, A.
Kondo, T.
2930 - Combination of Low White Blood Cell Count and Impaired Renal Function Is a Risk Factor for Higher Concentrations of Venetoclax and Prolonged Neutropenia in AML Patients with Venetoclax Combined Regimen: Real World Experience in the Japanese Cohort
4548 - Optimal Procedures of Allogeneic Transplantation for BCR::ABL1-Negative Atypical Chronic Myeloid Leukemia
4548 - Optimal Procedures of Allogeneic Transplantation for BCR::ABL1-Negative Atypical Chronic Myeloid Leukemia
Kondyli, M.
Kone-Paut, I.
Kong, F.
3465 - Safety and Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy Plus Camrelizumab in Patients with Relapsed/Refractory CD30+ Lymphoma
4280 - Azacitidine, Homoharringtonine and Cytarabine Combined with Granulocyte Colony-Stimulating Factor As Frontline Treatment for Older Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase III Study in China
4280 - Azacitidine, Homoharringtonine and Cytarabine Combined with Granulocyte Colony-Stimulating Factor As Frontline Treatment for Older Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase III Study in China
Kong, K. L.
Kong, K. A.
Kong, P.
Kong, R.
833 - ST6GALNAC4 Promotes Diffuse Large B-Cell Lymphoma Progression Via Mediating Sialylation of Bmpr-1B at Thr24
956 - A Highly Selective and Orally Bioavailable CK1α Molecular Glue Degrader Targets B-Cell Lymphoma Cells
2779 - PRPS2 Facilitates the Tumorigenesis of Diffuse Large B-Cell Lymphoma By Promoting Fatty Acid β-Oxidation
956 - A Highly Selective and Orally Bioavailable CK1α Molecular Glue Degrader Targets B-Cell Lymphoma Cells
2779 - PRPS2 Facilitates the Tumorigenesis of Diffuse Large B-Cell Lymphoma By Promoting Fatty Acid β-Oxidation
Kong, T.
Kong, X.
Kong, Y.
Kong, Y.
2684 - Inhibition of TGF-β in Bone Marrow Endothelial Progenitor Cells Promotes Hematopoietic Recovery in Acute Myeloid Leukemia after Chemotherapy
4074 - TGF-β Pathway Inhibition Improves Hematopoietic Deficiency and Immune Imbalance By Repairing Endothelial Progenitor Cell Function in Aplastic Anemia
4074 - TGF-β Pathway Inhibition Improves Hematopoietic Deficiency and Immune Imbalance By Repairing Endothelial Progenitor Cell Function in Aplastic Anemia
Kongsomboonvech, A. K.
Kongtim, P.
1517 - Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) Results in Higher Remission Rates over Conventional 7+3 Chemotherapy without Increased Toxicity in Newly Diagnosed Acute Myeloid Leukemia
4908 - Final Results of a Prospective Observational Study Using Budesonide, Added to Ptcy-Based Gvhd Prophylaxis, for Prevention of Acute GI Gvhd after Allogeneic Transplantation
4908 - Final Results of a Prospective Observational Study Using Budesonide, Added to Ptcy-Based Gvhd Prophylaxis, for Prevention of Acute GI Gvhd after Allogeneic Transplantation
Königs, C.
Konijnenburg, J.
Koning, R.
Konirova, E.
Konishi, Y.
488 - Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma
590 - Bone Marrow Spatial Signatures Predict Survival Outcomes and Toxicities after CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma
1895 - Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control
3279 - Early Serum Protein Clonal Dynamics Preceding Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Years before Diagnosis
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages
590 - Bone Marrow Spatial Signatures Predict Survival Outcomes and Toxicities after CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma
1895 - Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control
3279 - Early Serum Protein Clonal Dynamics Preceding Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Years before Diagnosis
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages
Konkle, B. A.
1053 - Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial
3575 - Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec
3575 - Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec
Kononov, M.
Konopleva, M.
57 - Venetoclax Combined with "7+3" Induction Chemotherapy Induces High MRD-Negative Response Rates in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy across Ages
207 - Enhancing Macrophage Mediated Phagocytosis in AML: The Complementary Mechanisms of Venetoclax and Azacitidine Combination Therapy
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
220 - Long-Term Survival Outcomes and Cytogenetic/Molecular Patterns of Relapse in Adults with FLT3-Mutated AML Receiving Frontline Triplet Therapy with a Hypomethylating Agent, Venetoclax and FLT3 Inhibitor
326 - KRAS G12D Specific Inhibitors Relieve Erythroid Differentiation Block and Modulate Inflammatory Pathways at the Single Cell Level in Myeloid Malignancies
642 - Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1-Mutated Myeloid Malignancies
830 - EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin
1389 - Decitabine-Venetoclax Treatment Reactivates Endogenous Retrovirus RNA Signaling in AML Cells and Induces T Cell Activation
1439 - Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
1515 - Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
2749 - Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
2753 - Elucidating Transcriptional Heterogeneity in Venetoclax Resistant AMLs
2760 - Anti-Leukemia Combinatorial Efficacy of ABBV155, a B7H3-BCL-XL Inhibitor Antibody-Drug Conjugate, in Combination with Venetoclax through BCL-XL/BIM and BCL-2/BIM Complex Dissociations
2766 - Transcriptomic Signature of Resistance to Decitabine/Venetoclax in AML Patients
2791 - Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma
2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results
3067 - Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients
3307 - Assessing the Performance of the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Model in a Multicultural Bronx Cohort: Implications for Monoclonal Gammopathy of Undetermined Significance (MGUS) Risk Stratification
3802 - Developments in Therapeutics and Impact on AML Survival in Older Patients: A Populational Analysis
4137 - Targeting PERK Arm of Unfolded Protein Response Helps to Eliminate Therapy-Induced Residual Senescent-like Acute Myeloid Leukemia Cells
4198 - A Phase I/II Study of Mini-Hyper-CVD, Venetoclax and Navitoclax in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
4261 - Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
4443 - Impact of Patient and Donor Factors on Successful Hematopoietic Stem Cell Transplantation for Acute T-Cell Leukemia/Lymphoma Patients in an Underserved Minority Population
4265.2 - A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)
4265.5 - A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML
- Non-transplant Treatment Approaches for High-risk TP53 Myeloid Disease
- Glutaminolysis in Myelodysplastic Syndromes/Acute Myeloid Leukemia as a Therapeutic Target
- Closing Remarks
207 - Enhancing Macrophage Mediated Phagocytosis in AML: The Complementary Mechanisms of Venetoclax and Azacitidine Combination Therapy
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
220 - Long-Term Survival Outcomes and Cytogenetic/Molecular Patterns of Relapse in Adults with FLT3-Mutated AML Receiving Frontline Triplet Therapy with a Hypomethylating Agent, Venetoclax and FLT3 Inhibitor
326 - KRAS G12D Specific Inhibitors Relieve Erythroid Differentiation Block and Modulate Inflammatory Pathways at the Single Cell Level in Myeloid Malignancies
642 - Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1-Mutated Myeloid Malignancies
830 - EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin
1389 - Decitabine-Venetoclax Treatment Reactivates Endogenous Retrovirus RNA Signaling in AML Cells and Induces T Cell Activation
1439 - Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
1515 - Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
2749 - Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
2753 - Elucidating Transcriptional Heterogeneity in Venetoclax Resistant AMLs
2760 - Anti-Leukemia Combinatorial Efficacy of ABBV155, a B7H3-BCL-XL Inhibitor Antibody-Drug Conjugate, in Combination with Venetoclax through BCL-XL/BIM and BCL-2/BIM Complex Dissociations
2766 - Transcriptomic Signature of Resistance to Decitabine/Venetoclax in AML Patients
2791 - Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma
2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results
3067 - Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients
3307 - Assessing the Performance of the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Model in a Multicultural Bronx Cohort: Implications for Monoclonal Gammopathy of Undetermined Significance (MGUS) Risk Stratification
3802 - Developments in Therapeutics and Impact on AML Survival in Older Patients: A Populational Analysis
4137 - Targeting PERK Arm of Unfolded Protein Response Helps to Eliminate Therapy-Induced Residual Senescent-like Acute Myeloid Leukemia Cells
4198 - A Phase I/II Study of Mini-Hyper-CVD, Venetoclax and Navitoclax in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
4261 - Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
4443 - Impact of Patient and Donor Factors on Successful Hematopoietic Stem Cell Transplantation for Acute T-Cell Leukemia/Lymphoma Patients in an Underserved Minority Population
4265.2 - A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)
4265.5 - A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML
- Non-transplant Treatment Approaches for High-risk TP53 Myeloid Disease
- Glutaminolysis in Myelodysplastic Syndromes/Acute Myeloid Leukemia as a Therapeutic Target
- Closing Remarks
Konstantellos, I.
Konstantinou, I.
Konstantinova, T.
3332 - The Impact of Circulating Plasma Cells on Overall Survival (OS) in Patients with Newly Diagnosed Multiple Myeloma (MM) - Results of a Multicenter Study
4614 - Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax
4614 - Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax
Kontandreopoulou, C. N.
Konto, C.
1026 - First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
3364 - Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma
3364 - Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma
Kontos, C.
Kontro, M.
1529 - Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes
1560 - Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia
2757 - Integrative Analysis of Transcriptomic and Proteomic Data Identifies Patterns of Primary Resistance to Venetoclax-Azacitidine and Reveals Targetable Vulnerabilities in Acute Myeloid Leukemia (AML)
4265 - Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study
4320 - Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML
1560 - Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia
2757 - Integrative Analysis of Transcriptomic and Proteomic Data Identifies Patterns of Primary Resistance to Venetoclax-Azacitidine and Reveals Targetable Vulnerabilities in Acute Myeloid Leukemia (AML)
4265 - Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study
4320 - Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML
Konuma, T.
Koo, A. S. M.
Koo, E.
Koo, H. H.
1595 - Gut Microbiome Composition As a Prognostic Marker in CD19-Targeting CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
3107 - Real-World Outcomes of Polatuzumab Vedotin with Bendamustine and Rituximab As Salvage and Bridge Therapy to CAR T-Cell Treatment in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
3107 - Real-World Outcomes of Polatuzumab Vedotin with Bendamustine and Rituximab As Salvage and Bridge Therapy to CAR T-Cell Treatment in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Koo, J.
2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
Koo, P.
Koo, S.
Koo-McCoy, S.
Kooiman, B.
Kook, H. W.
Kool, E. T.
Kooshesh, K. A.
Kopacz, A.
970 - A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) – Topline Results
4268 - The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia – a Report of Polish Adult Leukemia Group (PALG)
4268 - The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia – a Report of Polish Adult Leukemia Group (PALG)
Koparanis, D.
Kopmar, N. E.
523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
4209 - Extended Follow-up of Dose-Adjusted EPOCH (DA-EPOCH) Plus Inotuzumab Ozogamicin (InO) in Adults with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Safe and Effective Salvage Therapy
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
4209 - Extended Follow-up of Dose-Adjusted EPOCH (DA-EPOCH) Plus Inotuzumab Ozogamicin (InO) in Adults with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Safe and Effective Salvage Therapy
Kopp, K.
Kopp-Schneider, A.
Koppikar, P.
Koppinger, S.
Koprivnikar, J.
1448 - Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired Regimen for Adults Younger Than 50 Years of Age with Acute Lymphoblastic Leukemia (ALL), Yields High Rates of MRD Negativity, Favorable 3-Year Overall Survival Regardless of Allogeneic Stem Cell Transplant (ASCT): A Single Center Experience
4295 - Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)
4295 - Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)
Kopylova, A.
Koralkova, P.
Koranteng, E. O.
Koravou, E. E.
Korbel, J. O.
Körber, V.
Korc-Grodzicki, B.
Kordasti, S.
34 - T Cell Receptor Clonal Dynamics and Hematopoietic Recovery after Immunotherapy in Severe Aplastic Anemia
104 - Clinical Relevance of the Integrative Analysis of Gut Microbiome and Metabolomics in Myeloid Neoplasms: Correlations with Genomic Profiles, Treatment Response/Complications and Clinical Outcome
105 - Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)
301 - Treatment of Idiopathic Aplastic Anemia (AA) with Expanded Autologous Regulatory T Cells: The Tiara Phase One Trial
665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium
1788 - QRISK3: A New Marker for Thrombotic Events in Essential Thrombocythemia and Polycythemia Vera at Diagnosis and during Follow up
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
3323 - Could Clinical-Laboratory Features Recognize Functional High Risk Multiple Myeloma Patients? a Real-World Analysis
3597 - The “David Vs Goliath” Study: Application of Large Language Models (LLM) for Automatic Medical Information Retrieval from Multiple Data Sources to Accelerate Clinical and Translational Research in Hematology
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4547 - Rapid and Sustained Recovery of Cellular Immunity in Patients with Myelofibrosis on Momelotinib Therapy
4557 - Mympnvoice – a Novel Smartphone App for Monitoring Patient Reported Outcomes and Biometric Data in Patients with Myeloproliferative Neoplasms
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
104 - Clinical Relevance of the Integrative Analysis of Gut Microbiome and Metabolomics in Myeloid Neoplasms: Correlations with Genomic Profiles, Treatment Response/Complications and Clinical Outcome
105 - Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)
301 - Treatment of Idiopathic Aplastic Anemia (AA) with Expanded Autologous Regulatory T Cells: The Tiara Phase One Trial
665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium
1788 - QRISK3: A New Marker for Thrombotic Events in Essential Thrombocythemia and Polycythemia Vera at Diagnosis and during Follow up
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
3323 - Could Clinical-Laboratory Features Recognize Functional High Risk Multiple Myeloma Patients? a Real-World Analysis
3597 - The “David Vs Goliath” Study: Application of Large Language Models (LLM) for Automatic Medical Information Retrieval from Multiple Data Sources to Accelerate Clinical and Translational Research in Hematology
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4547 - Rapid and Sustained Recovery of Cellular Immunity in Patients with Myelofibrosis on Momelotinib Therapy
4557 - Mympnvoice – a Novel Smartphone App for Monitoring Patient Reported Outcomes and Biometric Data in Patients with Myeloproliferative Neoplasms
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
Kordbacheh, T.
2272 - Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada
5134 - A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada
5134 - A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada
Korde, N.
248 - Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease
671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
672 - Immune-MRD Status Informs Tumor-MRD Outcome Prognostication in Multiple Myeloma Patients on Lenalidomide Maintenance
1944 - Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)
1985 - A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
3362 - Daratumumab Versus Lenalidomide As Maintenance Therapy in Newly Diagnosed Multiple Myeloma – Interim Efficacy Results of a Randomized Clinical Trial
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis
4735 - Frailty and Outcomes after Bispecific T-Cell Engager Therapy for Patients with Relapsed/Refractory Multiple Myeloma
4850 - Manufacture of Anti-BCMA CAR T Cell Is Feasible after Salvage Autologous or Allogeneic Hematopoietic Stem Cell Transplantation
671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
672 - Immune-MRD Status Informs Tumor-MRD Outcome Prognostication in Multiple Myeloma Patients on Lenalidomide Maintenance
1944 - Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)
1985 - A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
3362 - Daratumumab Versus Lenalidomide As Maintenance Therapy in Newly Diagnosed Multiple Myeloma – Interim Efficacy Results of a Randomized Clinical Trial
4655 - Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis
4735 - Frailty and Outcomes after Bispecific T-Cell Engager Therapy for Patients with Relapsed/Refractory Multiple Myeloma
4850 - Manufacture of Anti-BCMA CAR T Cell Is Feasible after Salvage Autologous or Allogeneic Hematopoietic Stem Cell Transplantation
Kordek, D.
Kordy, K.
Koren, J.
Korenke, G. C.
Koreth, J.
379 - Heterogeneity of PD-1+regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease
917 - Mesothelin Targeting IL12-Engineered CAR Memory-like NK Cells Demonstrate Promising Efficacy in Acute Myeloid Leukemia
1041 - Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation
3500 - BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study
3538 - Impact of Consolidative Cellular Therapy with DLI or Second Transplant in Patients with AML Who Achieve Complete Remission Following Post-Transplant Relapse
4833 - Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant
4866 - Expression of HLA-B*35 Is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation
4885 - Early CMV Viral Load Burden Predicts Late Clinically Significant CMV Infections in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation
4938 - Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes
917 - Mesothelin Targeting IL12-Engineered CAR Memory-like NK Cells Demonstrate Promising Efficacy in Acute Myeloid Leukemia
1041 - Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation
3500 - BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study
3538 - Impact of Consolidative Cellular Therapy with DLI or Second Transplant in Patients with AML Who Achieve Complete Remission Following Post-Transplant Relapse
4833 - Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant
4866 - Expression of HLA-B*35 Is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation
4885 - Early CMV Viral Load Burden Predicts Late Clinically Significant CMV Infections in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation
4938 - Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes
Korfi, K.
644 - CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)
990 - Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072
3123 - BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL
4180 - Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients
4356 - Early Assessment of Circulating Tumor (ct)DNA and Analysis of TP53 mutations in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma Treated with Glofitamab Monotherapy
990 - Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072
3123 - BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL
4180 - Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients
4356 - Early Assessment of Circulating Tumor (ct)DNA and Analysis of TP53 mutations in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma Treated with Glofitamab Monotherapy
Korhonen, L.
Korhonen, M.
Kori, A. N.
656 - Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO)
2687 - Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition
2687 - Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition
Korin, L.
983 - Refining Prognostication in Peripheral T Cell Lymphoma (PTCL): A Risk-Adapted Prognostic Model for Patients with Limited-Stage PTCL
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)
Koristek, Z.
1962 - Predictive Value of Clonal Plasma Cells in Autografts Assessed By Next Generation Flow Cytometry on Pre-Transplant Bone Marrow MRD in Multiple Myeloma Patients
2806 - Central Nervous System Involvement Does Not Worsen Survival in Hematologic or Molecular Relapse of Adult Acute Lymphoblastic Leukemia Patients – Retrospective Analysis By the Czech Leukemia Study Group for Life (CELL)
2806 - Central Nervous System Involvement Does Not Worsen Survival in Hematologic or Molecular Relapse of Adult Acute Lymphoblastic Leukemia Patients – Retrospective Analysis By the Czech Leukemia Study Group for Life (CELL)
Korkmaz, F.
Korkmaz, F.
Korman, R.
1122 - Exploring N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) in Children with Sickle Cell Disease (SCD) and Vaso-Occlusive Pain Episodes (VOE)
1123 - Secretory Phospholipase A2(sPLA2) in Patients with Sickle Cell Disease (SCD) Hospitalized for Vaso-Occlusive Pain Episodes (VOE)
2518 - Procalcitonin Elevation in Children with Sickle Cell Disease (SCD) Requiring Hospitalization for Acute Vaso-Occlusive Pain (VOE)
1123 - Secretory Phospholipase A2(sPLA2) in Patients with Sickle Cell Disease (SCD) Hospitalized for Vaso-Occlusive Pain Episodes (VOE)
2518 - Procalcitonin Elevation in Children with Sickle Cell Disease (SCD) Requiring Hospitalization for Acute Vaso-Occlusive Pain (VOE)
Kornauth, C.
Kornblau, S. M.
53 - Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML
830 - EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin
1534 - Identification of Prognostic Signatures and Potential New Therapies in NPM1 Mutant Adult Acute Myeloid Leukemia Patients Using Proteomics
1837 - Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
2778 - The Mitochondrial Unfolded Protein Response (UPRmt) Is Upregulated in Acute Myeloid Leukemia (AML) and Inhibiting the UPRmt Protease, LONP1, Leads to Mitochondrial Protein Aggregation and Cell Death Selectively in AML
2896 - Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy
2912 - Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker
2942 - Proteomics-Based Approach Recognize Unique Expression Profiles in Adult Acute Monocytic/Monoblastic Leukemia: Implications for Prognostication and Drug Repurposing
3572 - Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
4601 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
830 - EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin
1534 - Identification of Prognostic Signatures and Potential New Therapies in NPM1 Mutant Adult Acute Myeloid Leukemia Patients Using Proteomics
1837 - Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies
1855 - Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL
2778 - The Mitochondrial Unfolded Protein Response (UPRmt) Is Upregulated in Acute Myeloid Leukemia (AML) and Inhibiting the UPRmt Protease, LONP1, Leads to Mitochondrial Protein Aggregation and Cell Death Selectively in AML
2896 - Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy
2912 - Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker
2942 - Proteomics-Based Approach Recognize Unique Expression Profiles in Adult Acute Monocytic/Monoblastic Leukemia: Implications for Prognostication and Drug Repurposing
3572 - Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
4601 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
Kornblith, L.
Kornblum, N.
57 - Venetoclax Combined with "7+3" Induction Chemotherapy Induces High MRD-Negative Response Rates in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy across Ages
2791 - Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma
3067 - Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients
3152 - Highly Effective Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Helps Overcome Social Determinants of Health in Medically Underserved Populations
3307 - Assessing the Performance of the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Model in a Multicultural Bronx Cohort: Implications for Monoclonal Gammopathy of Undetermined Significance (MGUS) Risk Stratification
4443 - Impact of Patient and Donor Factors on Successful Hematopoietic Stem Cell Transplantation for Acute T-Cell Leukemia/Lymphoma Patients in an Underserved Minority Population
4265.5 - A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML
2791 - Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma
3067 - Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients
3152 - Highly Effective Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Helps Overcome Social Determinants of Health in Medically Underserved Populations
3307 - Assessing the Performance of the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Model in a Multicultural Bronx Cohort: Implications for Monoclonal Gammopathy of Undetermined Significance (MGUS) Risk Stratification
4443 - Impact of Patient and Donor Factors on Successful Hematopoietic Stem Cell Transplantation for Acute T-Cell Leukemia/Lymphoma Patients in an Underserved Minority Population
4265.5 - A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML
Korolkiewicz, R.
Korsholm, L. P.
Korsos, V.
Korst, C. L.
Kort, J.
Kortüm, K. M.
284 - Balancing Treatment Intervals and Quality of Life in Multiple Myeloma Patients: Patient Perspectives and Recommendations
493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
593 - Bi-Allelic GPRC5D Alterations Provide Proliferative Advantage in Presence of Talquetamab
1952 - The CAR-Hematotox As a Risk Model to Predict Early Complications and Outcome after Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma
2007 - Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis
3267 - GPRC5D Status Impacts CD38 Expression in Multiple Myeloma
3322 - Symptomatic Progression Free Survival (SPFS): A New Endpoint for Multiple Myeloma (MM) Combining Patient-Reported Outcomes (PROs) and Progression-Free Survival (PFS)
3792d - Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement
4665 - CD31 and JAM-a Expressing Circulating Tumor Plasma Cells As Prognostic Biomarkers for Multiple Myeloma Disease
4688 - Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy
4705 - Classic Anti-Myeloma Treatments Alter Circulating Immune Cell Subsets with Potential Implications for T Cell Immunotherapies in Multiple Myeloma
4714 - Early Detection and Monitoring of Multiple Myeloma By a Blood-Based Multi-Transcript Molecular Signature
4758 - Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry
493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
593 - Bi-Allelic GPRC5D Alterations Provide Proliferative Advantage in Presence of Talquetamab
1952 - The CAR-Hematotox As a Risk Model to Predict Early Complications and Outcome after Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma
2007 - Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis
3267 - GPRC5D Status Impacts CD38 Expression in Multiple Myeloma
3322 - Symptomatic Progression Free Survival (SPFS): A New Endpoint for Multiple Myeloma (MM) Combining Patient-Reported Outcomes (PROs) and Progression-Free Survival (PFS)
3792d - Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement
4665 - CD31 and JAM-a Expressing Circulating Tumor Plasma Cells As Prognostic Biomarkers for Multiple Myeloma Disease
4688 - Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy
4705 - Classic Anti-Myeloma Treatments Alter Circulating Immune Cell Subsets with Potential Implications for T Cell Immunotherapies in Multiple Myeloma
4714 - Early Detection and Monitoring of Multiple Myeloma By a Blood-Based Multi-Transcript Molecular Signature
4758 - Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry
Kortylewski, M.
Korula, A.
647 - Rationalization of Anti-PD-1 Therapy Using Receptor Occupancy Data to Guide Drug Dosing – a Single Arm Phase II Trial Using Immunomodulation in Relapsed/Refractory Hodgkin Lymphoma
1052 - Factor VIII Expression from a Novel F8 Transgene through a Lentiviral Vector Transduced CD34+ Autologous Hematopoietic Stem Cells for Gene Therapy of Severe Hemophilia Α: Final Results from a Phase 1 Clinical Trial
2090 - Safety, Efficacy and Total Cost of Therapy of Decentralized, Point-of-Care Manufactured Anti-CD19 CAR-T Cells for Relapsed or Refractory B Cell Leukemia and Lymphoma: Results from the First Phase 1 Indian Trial (VELCART)
2150 - Lower Mycophenolic Acid Exposure in Patients Undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide/ Cyclosporine a-Based GvHD Prophylaxis – Need for Dose Intensification
3048 - Dose Optimization of Check-Point Inhibitors: A Comparison of Standard Dose and Low Dose Nivolumab in Relapsed/Refractory Hodgkin Lymphoma
3078 - Impact of Consolidation Radiotherapy in Bulky Diffuse Large B Cell Lymphoma By PET Based Response Assessment
4879 - EASIXd0 Predicts Early Transplant-Related Mortality in Patients Undergoing Haploidentical Transplantation with Post-Transplant Cyclophosphamide-Mycophenolate Mofetil-Based GvHD Prophylaxis
3055.1 - Lonah Trial: A Phase III Randomized Study of Low Dose Nivolumab Plus AVD or ABVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
1052 - Factor VIII Expression from a Novel F8 Transgene through a Lentiviral Vector Transduced CD34+ Autologous Hematopoietic Stem Cells for Gene Therapy of Severe Hemophilia Α: Final Results from a Phase 1 Clinical Trial
2090 - Safety, Efficacy and Total Cost of Therapy of Decentralized, Point-of-Care Manufactured Anti-CD19 CAR-T Cells for Relapsed or Refractory B Cell Leukemia and Lymphoma: Results from the First Phase 1 Indian Trial (VELCART)
2150 - Lower Mycophenolic Acid Exposure in Patients Undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide/ Cyclosporine a-Based GvHD Prophylaxis – Need for Dose Intensification
3048 - Dose Optimization of Check-Point Inhibitors: A Comparison of Standard Dose and Low Dose Nivolumab in Relapsed/Refractory Hodgkin Lymphoma
3078 - Impact of Consolidation Radiotherapy in Bulky Diffuse Large B Cell Lymphoma By PET Based Response Assessment
4879 - EASIXd0 Predicts Early Transplant-Related Mortality in Patients Undergoing Haploidentical Transplantation with Post-Transplant Cyclophosphamide-Mycophenolate Mofetil-Based GvHD Prophylaxis
3055.1 - Lonah Trial: A Phase III Randomized Study of Low Dose Nivolumab Plus AVD or ABVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Kosaka, Y.
Kosakoglu Shields, L.
Kosakowska, K.
Kosch, R.
Koschmeider, S.
Koschmieder, S.
406 - Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival – an Analysis By the German Study Group for MPN (GSG-MPN)
1348 - CSF3RT618I Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL)
1766 - Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) – an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
1348 - CSF3RT618I Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL)
1766 - Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) – an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
Kosciejew, S.
Kościołek-Zgódka, S.
Koseki, H.
Kosheleva, K.
Koshkina, A.
Koshy, M.
Kosinsky, Y.
Kositsky, R.
Koskenvesa, P.
Koskinen, M.
Kosmider, O.
36 - Vexas Syndrome Is a New Cause of p53-Mediated Erythroblastopenia
349 - Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial
4343 - Inflammatory Waldenström Macroglobulinemia Is Associated with Clonal Hematopoiesis: A Multicentric Cohort
349 - Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial
4343 - Inflammatory Waldenström Macroglobulinemia Is Associated with Clonal Hematopoiesis: A Multicentric Cohort
Kosmidou, A.
822 - Spatial Transcriptomics Identifies Aberrant Communication between Dendritic Cells and Leukemia Stem Cells As a Therapeutically Targetable Axis in Juvenile Myelomonocytic Leukemia
2525 - Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis
2527 - KLF5 Is a Key Regulator of IMiD-Induced Neutropenia
2525 - Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis
2527 - KLF5 Is a Key Regulator of IMiD-Induced Neutropenia
Kosnopfel, C.
Kosobud, A.
Kossinna, P.
Koster, A.
Koster, B. D.
493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
495 - Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm‑2 Studies
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
4653 - Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
495 - Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm‑2 Studies
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
4653 - Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
Koster, E. A.
Köster, J.
Koster, L.
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study
4939 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
4939 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
Koster, L.
Koster, L.
600 - Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Study on Behalf of the Chronic Malignancies Working Party of the EBMT
4949 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria – a Study on Behalf of Cmwp and Saawp of the EBMT
4949 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria – a Study on Behalf of Cmwp and Saawp of the EBMT
Koster, L.
2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
4894 - Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
4894 - Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT
Koster, M. J.
2686 - DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality
3181 - Subclassification of Erdheim-Chester Disease: Distinct Clinical and Molecular Findings between Classical and Non-Classical Forms
3910 - High Prevalence of Concomitant Autoimmunity in Patients with Rosai-Dorfman Disease
3181 - Subclassification of Erdheim-Chester Disease: Distinct Clinical and Molecular Findings between Classical and Non-Classical Forms
3910 - High Prevalence of Concomitant Autoimmunity in Patients with Rosai-Dorfman Disease
Kostic, A.
1031 - Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
4721 - Health Related Quality of Life (HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review (SLR) and Meta-Analysis
4825 - Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up
4721 - Health Related Quality of Life (HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review (SLR) and Meta-Analysis
4825 - Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up
Kostopoulos, I. V.
361 - Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study
490 - A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma
889 - Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis
1020 - Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
1083 - High Incidence of Thalassemia Traits Among Myelodysplastic Syndrome Patients May Mask Macrocytic Anemia but Not the Enhanced Proteasome Proteolytic Activity
1934 - Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)
490 - A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma
889 - Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis
1020 - Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies
1083 - High Incidence of Thalassemia Traits Among Myelodysplastic Syndrome Patients May Mask Macrocytic Anemia but Not the Enhanced Proteasome Proteolytic Activity
1934 - Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)
Kostova, V.
Kota, V. K.
221 - Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML
523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
2426 - Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium
2434 - Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States
3160 - Clinical Assessment of Cumulative Stress Via Allostatic Load in Chronic Myeloid Leukemia Patients: Implications for Treatment Outcomes
4184 - The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
5174 - Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium
523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
2426 - Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium
2434 - Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States
3160 - Clinical Assessment of Cumulative Stress Via Allostatic Load in Chronic Myeloid Leukemia Patients: Implications for Treatment Outcomes
4184 - The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
5174 - Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium
Kotani, A.
Kotay, D.
Kotb Abdrabou, A.
Kothapally Hanok, S.
Kothari, K.
Kothari, S.
976 - Metabolic Determinants of Ferroptosis in B-Cell Lymphoma
1412 - Targeting β-Catenin Protein Degradation in Refractory B-Cell Malignancies
3003 - Mechanism of Negative Feedback Regulation of Oncogenic BCR-Signaling in Mature B-Cell Lymphoma
4164 - Identification of Nuclear NAD+ Salvage As a Therapeutic Vulnerability in B-Lymphoid Malignancies
1412 - Targeting β-Catenin Protein Degradation in Refractory B-Cell Malignancies
3003 - Mechanism of Negative Feedback Regulation of Oncogenic BCR-Signaling in Mature B-Cell Lymphoma
4164 - Identification of Nuclear NAD+ Salvage As a Therapeutic Vulnerability in B-Lymphoid Malignancies
Kotini, A.
Kotlov, N.
1593 - Machine Learning-Based Approach to Improve Classification and Diagnostics of Peripheral T-Cell Lymphomas
2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study
2981 - Gene Expression-Based Classifier Reclassifies Burkitt Lymphoma, HGBL NOS, DLBCL NOS, and Double/Triple Hit Lymphomas into Subtypes with More Uniform Mutational and Microenvironment Landscapes and Treatment Response
2982 - Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma
4341 - Comprehensive Analysis of Malignant B-Cell Receptors Provides Insights into B-Cell Lymphoma Pathogenesis
4348 - Genomic and Spatial Proteomic Characterization of the Microenvironment of Diffuse Large B-Cell Lymphoma in African American Patients
4364 - Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma
2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study
2981 - Gene Expression-Based Classifier Reclassifies Burkitt Lymphoma, HGBL NOS, DLBCL NOS, and Double/Triple Hit Lymphomas into Subtypes with More Uniform Mutational and Microenvironment Landscapes and Treatment Response
2982 - Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma
4341 - Comprehensive Analysis of Malignant B-Cell Receptors Provides Insights into B-Cell Lymphoma Pathogenesis
4348 - Genomic and Spatial Proteomic Characterization of the Microenvironment of Diffuse Large B-Cell Lymphoma in African American Patients
4364 - Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma
Kotmayer, L.
Kotmayer, L.
Kotoucek, P. P.
Kotrova, M.
Kotrova, M.
Kotsianidis, I.
664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
3211 - Prevalence of Comorbidities at Diagnosis in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
3211 - Prevalence of Comorbidities at Diagnosis in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
Kotsianidis, I.
Kotsinyan, M.
Kotsiopoulou, S.
Kotsopoulou, M.
1991 - Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group
3361 - Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
3361 - Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group
4673 - Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
Kottaridis, P.
Kottke, E. W.
Kotwal, N.
Kotwal, S.
Koudijs, M. J.
1459 - Challenging Conventional Diagnostic Methods By Comprehensive Molecular Diagnostics: Results of a Nationwide Prospective Comparison in Children with Acute Lymphoblastic Leukemia
2985 - High Clinical Benefit of Diagnostic RNA Sequencing in Pediatric T-Cell Lymphoblastic Lymphoma for the Identification of Potentially Targetable Risk Groups
2985 - High Clinical Benefit of Diagnostic RNA Sequencing in Pediatric T-Cell Lymphoblastic Lymphoma for the Identification of Potentially Targetable Risk Groups
Kouides, P. A.
Koumakis, L.
Koumantakis, E.
Kountouris, P.
290 - Oxygen Gradient Ektacytometry Is Associated with Markers of Hemolysis and Inflammation in a Large Sickle Cell Disease Cohort within the GenoMed4ALL Project
794 - uRADAR: European Patients Referral Frame to Improve Access to New Drugs and Therapies in Ultra-Rare Anemia Disorders and Severe Hereditary Spherocytosis
1132 - Analysis of the Pilot Study of the International Hemoglobinopathy Research Network (INHERENT)
1138 - Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease
794 - uRADAR: European Patients Referral Frame to Improve Access to New Drugs and Therapies in Ultra-Rare Anemia Disorders and Severe Hereditary Spherocytosis
1132 - Analysis of the Pilot Study of the International Hemoglobinopathy Research Network (INHERENT)
1138 - Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease
Koura, D.
523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
2873 - A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
2873 - A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
Kouramba, A.
Kourelis, T.
83 - Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma
1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
2400 - Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
3258 - Integrated Coding and Non-Coding Transcriptional Single-Cell Atlas of Multiple Myeloma: Unraveling the Effects of Myeloma Genotype on the Bone Marrow Microenvironment
3305 - Proteomic Determinants of Renal Organ Response in AL Amyloidosis
3308 - Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients
3315 - Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia
4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
4695 - Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma
4711 - Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma
4716 - Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
5047 - Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
3309.1 - A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)
1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
2400 - Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
3258 - Integrated Coding and Non-Coding Transcriptional Single-Cell Atlas of Multiple Myeloma: Unraveling the Effects of Myeloma Genotype on the Bone Marrow Microenvironment
3305 - Proteomic Determinants of Renal Organ Response in AL Amyloidosis
3308 - Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients
3315 - Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia
4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
4695 - Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma
4711 - Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma
4716 - Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
5047 - Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
3309.1 - A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)
Kouros-Mehr, H.
Kouroukis, C. T.
Kousa, A.
259 - Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical Gvhd Models
501 - Dual-Vector-Transduction with Single-Step Magnetic Selection (Zip-sort) Increases Transgenic Payloads to Enhance CAR T Cell Activity
2010 - Regulatory T Cell Derived Trefoil Factor 1 Drives Thymic Regeneration in Allogeneic Hematopoietic Cell Transplantation
501 - Dual-Vector-Transduction with Single-Step Magnetic Selection (Zip-sort) Increases Transgenic Payloads to Enhance CAR T Cell Activity
2010 - Regulatory T Cell Derived Trefoil Factor 1 Drives Thymic Regeneration in Allogeneic Hematopoietic Cell Transplantation
Koutoulidis, V.
Koutroumpakis, E.
Kovach, A. E.
1316 - Flow Cytometric Quantitation of CD34+ Progenitors in Peripheral Blood: An Underutilized Tool in Diagnostic Evaluation of Pancytopenia
2799 - Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch
2837 - Enhanced Flow Cytometry and Next Generation Sequencing Assays for Residual B Lymphoblastic Leukemia (B-ALL) Reveal a Subset with Discordant Results Due to Leukemic Changes Post-Therapy
4183 - Initial Cerebrospinal Fluid Blast Clearance Rate in Pediatric B-Lymphoblastic Leukemia Is Associated with Overall Survival
2799 - Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch
2837 - Enhanced Flow Cytometry and Next Generation Sequencing Assays for Residual B Lymphoblastic Leukemia (B-ALL) Reveal a Subset with Discordant Results Due to Leukemic Changes Post-Therapy
4183 - Initial Cerebrospinal Fluid Blast Clearance Rate in Pediatric B-Lymphoblastic Leukemia Is Associated with Overall Survival
Kovach, A. E.
Kovach, J. D.
Kovach, M.
Kovacsovics, T.
211 - Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia
733 - Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial
733 - Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial
Kovacsovics, T. J.
1564 - Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
4324 - Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
4324 - Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
Kovalova, Z.
Kovar, P.
Kowal, S. L.
Kowalska, M. A.
185 - Antiphospholipid Syndrome (APS) Is a Platelet Factor 4 (PF4)-Centric Immunothrombotic Disorder
2528 - Why Do Peptidyl Arginine Deiminase (PAD) 4-Deficient Mice Have Improved Survival Following Cecal Ligation and Puncture (CLP) Sepsis? Implications for the Role Neutrophil Extracellular Trap (NETs) in Immune Homeostasis
2528 - Why Do Peptidyl Arginine Deiminase (PAD) 4-Deficient Mice Have Improved Survival Following Cecal Ligation and Puncture (CLP) Sepsis? Implications for the Role Neutrophil Extracellular Trap (NETs) in Immune Homeostasis
Kowalski, A.
Kowalski, K.
Kowalyk, S.
Kowitwanich, K.
Kowol, M.
Kowoll, S.
Koya, J.
Koyama, M.
Koyama, S.
Koyama, S.
Koyama, T.
Koyunlar, C.
Koziel, S.
Kozlowska, A.
Kozlowski, M.
Kozmina, M.
Kracker, S.
Kraeber-Bodéré, F.
575 - Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa
4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)
4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)
Kraft, W.
Kragh, N.
719 - Association between Hemophilia Joint Health Score and Quality of Life Using Results from the Xtend-1 Efanesoctocog Alfa Phase 3 Trial
2582 - Cost Comparison of Efanesoctocog Alfa with Existing Factor VIII Replacement Therapies for Major Surgeries in People with Severe Hemophilia a
3967 - Real-World Patterns of Additional Factor Treatment Use Among Hemophilia a Patients on Regular Prophylaxis in the United States: Results from the Picnichealth Database
2582 - Cost Comparison of Efanesoctocog Alfa with Existing Factor VIII Replacement Therapies for Major Surgeries in People with Severe Hemophilia a
3967 - Real-World Patterns of Additional Factor Treatment Use Among Hemophilia a Patients on Regular Prophylaxis in the United States: Results from the Picnichealth Database
Krainer, J.
Kraitem, H.
Krajewska, K.
Krali, O.
Kramer, A.
Kramer, A. M.
69 - CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up
96 - Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
679 - Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL
911 - CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
2064 - CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma
96 - Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
679 - Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL
911 - CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
2064 - CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma
Kramer, A. N.
Kramer, M.
Kramer, M. H.
1333 - Recurrent Amplification of Chromosome 7 in Murine AML with Dnmt3aR878H and Npm1cA Mutations Identifies Gab2 As a Possible Therapeutic Target in AML
2066 - Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients with CD7+ T-Cell Non-Hodgkin Lymphoma
4100 - VISTA As a Mediator of Immune Suppression in AML Initiated By DNMT3A and NPM1 mutations
2066 - Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients with CD7+ T-Cell Non-Hodgkin Lymphoma
4100 - VISTA As a Mediator of Immune Suppression in AML Initiated By DNMT3A and NPM1 mutations
Krammer, F.
Krampera, M.
3131 - Outcomes of CAR T-Cells Therapy in High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas: A Weighted Comparison Analysis from CAR-T SIE Study
4786 - High Ferritin and C-Reactive Protein Levels Result in Poor Clinical Outcome in R/R Large B-Cell Lymphoma Patients Despite Significant Anti-CD19 CAR-T Cell In Vivo Expansion
4797 - Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study
4786 - High Ferritin and C-Reactive Protein Levels Result in Poor Clinical Outcome in R/R Large B-Cell Lymphoma Patients Despite Significant Anti-CD19 CAR-T Cell In Vivo Expansion
4797 - Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study
Krampf, M. R.
194 - Disease Correction of a Diamond-Blackfan Anemia Mouse Model Using Non-Genotoxic Conditioning and Hematopoietic Stem Cell Transplantation
2015 - Evaluation of Bone Marrow in Fanconi Anemia Patients Treated with Briquilimab Antibody-Based Conditioning and TCRαβ+ T-Cell/CD19+ B-Cell Depleted Haploidentical Grafts
4095 - Robust Immune Reconstitution in Fanconi Anemia Mice Post in Utero Hematopoietic Stem Cell Transplantation
2015 - Evaluation of Bone Marrow in Fanconi Anemia Patients Treated with Briquilimab Antibody-Based Conditioning and TCRαβ+ T-Cell/CD19+ B-Cell Depleted Haploidentical Grafts
4095 - Robust Immune Reconstitution in Fanconi Anemia Mice Post in Utero Hematopoietic Stem Cell Transplantation
Kransdorf, E.
Kraskouskas, K. E.
Krasnow, N.
Krauel, K.
Kraus, S.
Krause, K.
Krause, S. W.
776 - Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
1527.1 - Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
1527.1 - Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial
Krause, T.
Krauz, I. E.
Krava, E.
296 - Mechanical Thromboprophylaxis and Hospital-Acquired Venous Thromboembolism: A Report from the Children’s Healthcare Advances in Thrombosis Consortium
4010 - Insights and Characteristics of Pediatric Central Venous Catheter Malfunction and Catheter-Associated Deep Vein Thrombosis: A Subanalysis of the Circle Study
4010 - Insights and Characteristics of Pediatric Central Venous Catheter Malfunction and Catheter-Associated Deep Vein Thrombosis: A Subanalysis of the Circle Study
Kravets, L.
Krawczuk-Rybak, M.
Krawczyk, J.
494 - Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
733 - Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial
733 - Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial
Krawiec, K.
2854 - The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)
4268 - The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia – a Report of Polish Adult Leukemia Group (PALG)
4268 - The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia – a Report of Polish Adult Leukemia Group (PALG)
Krayem, B.
Kregar, L.
Kreiniz, N.
Kreisberg, H.
Kreissl, S.
Kreitman, R. J.
Krejcik, Z.
Kremer Hovinga, J. A.
718 - Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study
4003 - Daratumumab for Refractory and Frequently Relapsing Immune Thrombotic Thrombocytopenic Purpura – a Case Series with Long-Term Follow-up
4003 - Daratumumab for Refractory and Frequently Relapsing Immune Thrombotic Thrombocytopenic Purpura – a Case Series with Long-Term Follow-up
Kremers, S.
Kremlev, A.
Kremyanskaya, M.
243 - TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms
656 - Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO)
2798 - Relative Influence of Socioeconomic and Biological Determinants of Outcomes in Adult Acute Lymphoblastic Leukemia
4559 - Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
656 - Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO)
2798 - Relative Influence of Socioeconomic and Biological Determinants of Outcomes in Adult Acute Lymphoblastic Leukemia
4559 - Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
Krengel, P.
Krenitsky, P.
Krenova, Z.
Kret, E. J.
Kretschmann, S.
Kretschmer, L.
Kretz, C.
Kretzschmar, W.
Kreutz, M.
Kreuz, M.
Kreuzer, K. A.
Kreuzer, K. A.
Krevvata, M.
362 - Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
494 - Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
675 - Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups
494 - Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
675 - Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups
Kreychman, Y.
Krhovska, P.
Kribs, R.
Kricheldorf, K.
406 - Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival – an Analysis By the German Study Group for MPN (GSG-MPN)
4082 - The Impact of Body Mass Index (BMI) in Patients with Aplastic Anemia Receiving Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG) on Outcome, Response and Relapse Rate
4082 - The Impact of Body Mass Index (BMI) in Patients with Aplastic Anemia Receiving Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG) on Outcome, Response and Relapse Rate
Krichevsky, S.
Krickau, T.
Kridel, R.
1606 - Shallow Whole Genome Sequencing of Circulating Tumor DNA Is Predictive of Outcome in Diffuse Large B-Cell Lymphoma
1695 - Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy
2272 - Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada
2352 - Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance
3082 - Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis
3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada
4385 - Multiome Single Cell Analyses Identify a Distinct CD8+ T Cell Phenotype Linked to Treatment Response in PTLD
4469 - Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy
5134 - A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada
4422.2 - Golseek-2: A Phase 2 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma
1695 - Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy
2272 - Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada
2352 - Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance
3082 - Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis
3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada
4385 - Multiome Single Cell Analyses Identify a Distinct CD8+ T Cell Phenotype Linked to Treatment Response in PTLD
4469 - Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy
5134 - A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada
4422.2 - Golseek-2: A Phase 2 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma
Krieger, E.
Kriegova, E.
Krigsfeld, G. S.
2178 - Single-Agent Ibrutinib Versus Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and del(17p)
3742 - Association Between Dose Reduction and Duration of Therapy in Patients Receiving Ibrutinib or Acalabrutinib for Chronic Lymphocytic Leukemia: A Medical Chart Review Study
4615 - Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up
3742 - Association Between Dose Reduction and Duration of Therapy in Patients Receiving Ibrutinib or Acalabrutinib for Chronic Lymphocytic Leukemia: A Medical Chart Review Study
4615 - Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up
Krimmel, T.
470 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
472 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
472 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
Krishna, N.
Krishnadasan, R.
Krishnamoorthy, G.
Krishnamurthy, H.
Krishnamurthy, P.
120 - Prospective Cohort Study of Non-COVID Infection in Patients with AML/MDS Undergoing Treatment: Implications for Practice
944 - Clonal Haematopoiesis with TP53 Mutations Exhibits Abnormal Erythropoiesis and Erythroid Metabolic Stress
1332 - A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41-Mutant Myeloid Neoplasia
944 - Clonal Haematopoiesis with TP53 Mutations Exhibits Abnormal Erythropoiesis and Erythroid Metabolic Stress
1332 - A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41-Mutant Myeloid Neoplasia
Krishnamurthy, P.
Krishnamurti, L.
601 - Deciding between Multiple Curative Options in Sickle Cell Disease: Cost-Effectiveness of Non-Myeloablative/Reduced Intensity Conditioning Haploidentical Allo-HSCT Vs Gene Therapy Vs Standard of Care in Adult Patients with Sickle Cell Disease
1063 - Predictors of Graft Failure Beyond 24 Months Following Hematopoietic Stem Cell Transplantation for Sickle Cell Disease
2302 - Pre-Transplant Liver Fibrosis Predicts Poor Overall Survival Following Hematopoietic Stem Cell Transplantation for Sickle Cell Disease
2304 - Age at Hematopoietic Cell Transplantation Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Patients with Sickle Cell Disease
3681 - Large Scale Community-Based Sickle Cell Surveillance in an Aboriginal Population from Western India
3899 - Sickle Pain-Related Impact (SPiRIt): A Prospective Study of Impact of Chronic Pain in Sickle Cell Disease
5007 - Prediction of Event Free Survival in Hematopoietic Cell Transplantation: A Machine Learning Clustering and Proximity Analysis
1063 - Predictors of Graft Failure Beyond 24 Months Following Hematopoietic Stem Cell Transplantation for Sickle Cell Disease
2302 - Pre-Transplant Liver Fibrosis Predicts Poor Overall Survival Following Hematopoietic Stem Cell Transplantation for Sickle Cell Disease
2304 - Age at Hematopoietic Cell Transplantation Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Patients with Sickle Cell Disease
3681 - Large Scale Community-Based Sickle Cell Surveillance in an Aboriginal Population from Western India
3899 - Sickle Pain-Related Impact (SPiRIt): A Prospective Study of Impact of Chronic Pain in Sickle Cell Disease
5007 - Prediction of Event Free Survival in Hematopoietic Cell Transplantation: A Machine Learning Clustering and Proximity Analysis
Krishnan, A.
Krishnan, A. Y.
81 - 24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
1021 - Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies
1941 - The Microbiome and Clinical Outcome Among Patients with Multiple Myeloma (MM) Following CD38-Directed Antibody Treatment
3368 - Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium
4734 - Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study
2000.2 - A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
1021 - Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies
1941 - The Microbiome and Clinical Outcome Among Patients with Multiple Myeloma (MM) Following CD38-Directed Antibody Treatment
3368 - Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium
4734 - Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study
2000.2 - A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Krishnan, A.
Krishnan, I.
Krishnan, N.
Krishnan, S.
Krishnan, S.
644 - CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)
4180 - Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients
4180 - Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients
Krishnan, V.
Krishnaswamy, S.
Kristanto, P.
Kristiansen, M. H.
Kristiansen, T. A.
Kristinsson, S. Y.
1015 - Differential Detection of Clonal Bone Marrow Plasma Cells in IgA Vs. IgG Monoclonal Gammopathy of Undetermined Significance and Its Association with Disease Progression
1857 - Incidence of Infections and Survival Outcomes in Patients with Multiple Myeloma and Chronic Lymphocytic Leukemia in Sweden: A Nationwide Population-Based Study of More Than 15,000 Patients
3306 - Implementing Revised Reference Intervals for Free Light Chains Improves Risk Stratification of Monoclonal Gammopathy of Undetermined Significance
1857 - Incidence of Infections and Survival Outcomes in Patients with Multiple Myeloma and Chronic Lymphocytic Leukemia in Sweden: A Nationwide Population-Based Study of More Than 15,000 Patients
3306 - Implementing Revised Reference Intervals for Free Light Chains Improves Risk Stratification of Monoclonal Gammopathy of Undetermined Significance
Kristo, F.
1662 - Patient-Reported Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classical Hodgkin Lymphoma Treated with BrECADD and eBEACOPP in the HD21 Trial
2346 - Estimation of Health State Utility Values for Patients Undergoing First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the HD21 Trial
4426 - Impact of Treatment-Related Morbidity on Health-Related Quality of Life in Patients with Advanced-Stage Classical Hodgkin Lymphoma Receiving Multiagent Therapy: Findings from the HD21 Study
2346 - Estimation of Health State Utility Values for Patients Undergoing First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the HD21 Trial
4426 - Impact of Treatment-Related Morbidity on Health-Related Quality of Life in Patients with Advanced-Stage Classical Hodgkin Lymphoma Receiving Multiagent Therapy: Findings from the HD21 Study
Kriukov, K.
Krivenko, A.
Krivisky, A.
Kriwacki, R. W.
Kroeger, N.
2073 - CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple Sclerosis
3547 - Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation
3571 - Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission
3547 - Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation
3571 - Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission
Kroeger, N.
2003 - Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma
3560 - Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
4940 - Reconstructing Skeletal Homeostasis through Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis
3560 - Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
4940 - Reconstructing Skeletal Homeostasis through Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis
Kroesen, B. J.
Kroeze, E.
Kroger, B.
Kröger, N.
245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
505 - Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation from Unrelated and Matched Sibling Donors in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT
508 - Younger Haploidentical Versus Older Matched Sibling Donors in Acute Lymphoblastic Leukemia: A Study from the ALWP of EBMT
607 - Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT
693 - No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
708 - Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
2161 - Comparative Safety and Efficacy of Posttransplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Cardiovascular Comorbidity Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission from Unrelated Donors: A Retrospective Pair-Match Analysis of EBMT ALWP
2185 - Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party
2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
3554 - Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
3559 - Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis
3570 - Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT
4315 - In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP
4895 - Separation of Gvl Effects from GvHD with Ptcy-Based Gvhd Prophylaxis in Mmud Transplantation: A Study from the ALWP of the EBMT
4939 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
4949 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria – a Study on Behalf of Cmwp and Saawp of the EBMT
505 - Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation from Unrelated and Matched Sibling Donors in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT
508 - Younger Haploidentical Versus Older Matched Sibling Donors in Acute Lymphoblastic Leukemia: A Study from the ALWP of EBMT
607 - Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT
693 - No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
708 - Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
2161 - Comparative Safety and Efficacy of Posttransplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Cardiovascular Comorbidity Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission from Unrelated Donors: A Retrospective Pair-Match Analysis of EBMT ALWP
2185 - Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party
2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
3554 - Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
3559 - Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis
3570 - Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT
4315 - In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP
4895 - Separation of Gvl Effects from GvHD with Ptcy-Based Gvhd Prophylaxis in Mmud Transplantation: A Study from the ALWP of the EBMT
4939 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
4949 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria – a Study on Behalf of Cmwp and Saawp of the EBMT
Krohl, P.
Krohn, S.
Krokhotin, A.
Krol, G. D.
Kromer, H.
Kronfield, C.
Kronke, J.
Krönke, J.
53 - Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
2007 - Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
2007 - Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis
Kroog, G. S.
3265 - Characterization of Linvoseltamab’s BCMA Binding Epitope and Efficacy Against BCMA Mutations in Relapsed/Refractory Multiple Myeloma
3283 - A CD38xCD28 Costimulatory Bispecific Antibody Demonstrates Potent Preclinical Combinatorial Activity with a BCMAxCD3 T Cell-Engager
3310 - Soluble BCMA Dynamics in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1
3369 - Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study
3283 - A CD38xCD28 Costimulatory Bispecific Antibody Demonstrates Potent Preclinical Combinatorial Activity with a BCMAxCD3 T Cell-Engager
3310 - Soluble BCMA Dynamics in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1
3369 - Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study
Kropp, E. M.
Kroschinsky, F. P.
Krouse, A. E.
Kruah, B.
800 - The Amyloidogenic Transthyretin V122I Variant Increase Severity of Cardiac Phenotype and Mortality in Sickle Cell Disease
2491 - Mitapivat-Induced Improvements in RBC Deformability and Membrane Integrity in Patients with Sickle Cell Disease Are Sustained during Extended Therapy
1143.1 - A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with Stable Sickle Cell Disease: Trial in Progress
2491 - Mitapivat-Induced Improvements in RBC Deformability and Membrane Integrity in Patients with Sickle Cell Disease Are Sustained during Extended Therapy
1143.1 - A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with Stable Sickle Cell Disease: Trial in Progress
Kruczkowska-Tarantowicz, K.
2854 - The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)
4268 - The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia – a Report of Polish Adult Leukemia Group (PALG)
4268 - The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia – a Report of Polish Adult Leukemia Group (PALG)
Krueger, M.
Krug, U.
Krüger, W. H.
Kruip, M. J.
129 - Postpartum Hemorrhage in Hemophilia a and B Carriers after Enhanced Prophylactic Clotting Factor Suppletion: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
1208 - The Influence of Postpartum Hemorrhage on the Quality of Life Among Pregnant Hemophilia a and B Carriers: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
2595 - Postpartum Hemorrhage in Women with Von Willebrand Disease after Enhanced Prophylactic Clotting Factor Suppletion: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
2601 - The Influence of Postpartum Hemorrhage on Patient Reported Outcomes Among Women with Von Willebrand Disease: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
1208 - The Influence of Postpartum Hemorrhage on the Quality of Life Among Pregnant Hemophilia a and B Carriers: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
2595 - Postpartum Hemorrhage in Women with Von Willebrand Disease after Enhanced Prophylactic Clotting Factor Suppletion: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
2601 - The Influence of Postpartum Hemorrhage on Patient Reported Outcomes Among Women with Von Willebrand Disease: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)
Krull, A. A.
Krull, J.
Krull, K. R.
Krum, B.
Krumb, E.
Krumholz, H. M.
Kruppa, N.
1374 - The PTPN2/PTPN1 Inhibitor Abbv-CLS-484 Augments Immune Responses Against Leukemic Blasts and Impedes Leukemia Cell Proliferation in AML Alone and in Combination with Venetoclax
1397 - CD39 Is Predominantly Expressed in Adverse AML Patients and Blockade By a New Anti-CD39 Nanobody Increases Lysis of AML Blasts
1397 - CD39 Is Predominantly Expressed in Adverse AML Patients and Blockade By a New Anti-CD39 Nanobody Increases Lysis of AML Blasts
Kruse-Jarres, R.
3580 - Improved Joint Health in the Phase 3 HOPE-B Trial of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B over 36 Months of Follow up
3965 - Assessment of Annual Rate Changes of Intraarticular Tissue Measurements in Hemophilic Joints Experiencing Acute Bleeding Using the Joint Activity Damage Exam (JADE) Ultrasound Protocol
- Lifespan Hematology
3965 - Assessment of Annual Rate Changes of Intraarticular Tissue Measurements in Hemophilic Joints Experiencing Acute Bleeding Using the Joint Activity Damage Exam (JADE) Ultrasound Protocol
- Lifespan Hematology
Kruta, J.
Kryachok, I.
1626 - High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma
1634 - Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study
4614 - Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax
1634 - Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Follicular Lymphoma: Results from the Phase 2 Bellwave-003 Study
4614 - Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax
Krystal, E.
Krzisch, D.
Krzykalla, J.
Krzyzanowski, D.
Ksanznak, K.
Ksenzova, T.
Ktena, Y. P.
Ku, J. J.
Ku, M.
582 - A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics
2990 - Evaluation of Anti-Tumor Activity and Impact on T Cell Activation of Glofitamab in Combination with Gemcitabine and Oxaliplatin (Glofit-GemOx)
3255 - Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study
4407 - Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study
5132 - Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study
3042.1 - Mosunetuzumab and Zanubrutinib in Relapsed/Refractory Follicular Lymphoma Patients (MOZART): A Phase II, Chemo-Free Trial from Fondazione Italiana Linfomi (FIL)
2990 - Evaluation of Anti-Tumor Activity and Impact on T Cell Activation of Glofitamab in Combination with Gemcitabine and Oxaliplatin (Glofit-GemOx)
3255 - Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study
4407 - Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study
5132 - Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study
3042.1 - Mosunetuzumab and Zanubrutinib in Relapsed/Refractory Follicular Lymphoma Patients (MOZART): A Phase II, Chemo-Free Trial from Fondazione Italiana Linfomi (FIL)
Kuang, P.
Kuang, Z.
682 - CD19 CAR T-Cell Therapy in Refractory Autoimmune Hemolytic Anemia
2307 - Delayed Physical Growth and Related Factors in Pediatric Patients with Transfusion-Dependent Thalassemia
2697 - Anti-CD38 Monoclonal Antibody Is a Salvage Regimen in Relapsed/Refractory Aplastic Anemia
4029 - Daratumumab Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia: A Pilot Trail
4961 - Deciphering Hematopoietic Reconstitution Dynamics of Lentiviral Vector HBBT87Q-Engineered Hematopoietic Stem Cells Gene Therapy for β-Thalassemia Patients
2307 - Delayed Physical Growth and Related Factors in Pediatric Patients with Transfusion-Dependent Thalassemia
2697 - Anti-CD38 Monoclonal Antibody Is a Salvage Regimen in Relapsed/Refractory Aplastic Anemia
4029 - Daratumumab Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia: A Pilot Trail
4961 - Deciphering Hematopoietic Reconstitution Dynamics of Lentiviral Vector HBBT87Q-Engineered Hematopoietic Stem Cells Gene Therapy for β-Thalassemia Patients
Kubaczka, C.
Kuball, J.
112 - “Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
607 - Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT
2333 - Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT
3456 - Impact of Fludarabine Dosage on Outcomes in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy: A Retrospective Study on Behalf of the Ctiwp of the EBMT
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
4907 - The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party
4945 - Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification – an EBMT ALWP Study
607 - Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT
2333 - Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT
3456 - Impact of Fludarabine Dosage on Outcomes in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy: A Retrospective Study on Behalf of the Ctiwp of the EBMT
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
4907 - The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party
4945 - Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification – an EBMT ALWP Study
Kubasch, A. S.
666 - Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
1845 - Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1del5q): Outcomes and Response to Treatment
3207 - Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial
3221 - Targeting of Various Inflammatory Circuits Does Not Ameliorate Ineffective Hematopoiesis: Results of the Lucas and Canfire Studies Investigating IRAK4 or IL-1β Blockade to Target Anemia in Lower-Risk MDS
4989 - An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
1845 - Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1del5q): Outcomes and Response to Treatment
3207 - Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial
3221 - Targeting of Various Inflammatory Circuits Does Not Ameliorate Ineffective Hematopoiesis: Results of the Lucas and Canfire Studies Investigating IRAK4 or IL-1β Blockade to Target Anemia in Lower-Risk MDS
4989 - An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia
Kubicki, T.
Kubicki, T.
Kübler, K.
Kubota, N.
Kubota, Y.
666 - Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))
1328 - Genomic Landscape of Germline RUNX1 variants in Adult Myeloid Neoplasia According to Functional Impact
2224 - Unraveling Immunogenomic Features Germane to Pathobiology of Myelodysplastic Syndromes
2920 - Distinct Phenotypes of Myeloid Neoplasia Associated with Truncating C-CBL Mutations
2943 - Geno-Transcriptomic Topography of Clonal Drivers in Trisomy 8 Myeloid Malignancies
3199 - Could Somatic Gene Rescue Explain Frequency of Compound Heterozygous and Concurrent Receptor Tyrosine Kinase Mutations in Hematological Diseases?
4104 - Telomere Content Diversity in Myeloid Neoplasia Could Inform on Differential Sensitivity to Telomerase Inhibitors
1328 - Genomic Landscape of Germline RUNX1 variants in Adult Myeloid Neoplasia According to Functional Impact
2224 - Unraveling Immunogenomic Features Germane to Pathobiology of Myelodysplastic Syndromes
2920 - Distinct Phenotypes of Myeloid Neoplasia Associated with Truncating C-CBL Mutations
2943 - Geno-Transcriptomic Topography of Clonal Drivers in Trisomy 8 Myeloid Malignancies
3199 - Could Somatic Gene Rescue Explain Frequency of Compound Heterozygous and Concurrent Receptor Tyrosine Kinase Mutations in Hematological Diseases?
4104 - Telomere Content Diversity in Myeloid Neoplasia Could Inform on Differential Sensitivity to Telomerase Inhibitors
Kubuki, Y.
Kucharczuk, C. R.
Kuchenbauer, F.
733 - Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial
2919 - Survival Outcomes for Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML-MRC) in a Real-World, Retrospective Cohort Receiving Intensive Chemotherapy
2954 - Presence of Leukemia-Related Basophils and Mast Cells with Atypical Immunophenotype during Induction Should Not be Interpreted As Measurable Residual Disease in Children with Acute Myeloid Leukemia with RUNX1::RUNX1T1
3276 - Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma
4070 - Dissecting the Interactions between Leukemic Cells and the Aging Bone Marrow Niche
2919 - Survival Outcomes for Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML-MRC) in a Real-World, Retrospective Cohort Receiving Intensive Chemotherapy
2954 - Presence of Leukemia-Related Basophils and Mast Cells with Atypical Immunophenotype during Induction Should Not be Interpreted As Measurable Residual Disease in Children with Acute Myeloid Leukemia with RUNX1::RUNX1T1
3276 - Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma
4070 - Dissecting the Interactions between Leukemic Cells and the Aging Bone Marrow Niche
Kuchibhatla, M.
Kuchkova, O.
Kuchler, R. L.
Küchler, S.
Kuchma, G.
Kucia, M.
1421 - Meta-Analysis of Complete Remission Rates Following First-Line Salvage Treatment after Anti-CD19 CAR-T Failure in Adult Patients with Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia
4034 - The Pro-Mobilizing Effects of UDP-Glucose—P2Y14 Purinergic Receptor Signaling Are Explained By Promoting Membrane Lipid Raft Formation to Optimize Hspcs' Responsiveness to Chemoattractants—a Potential Strategy to Optimize Hematopoietic Transplantation and Improve Transplant Outcomes
4034 - The Pro-Mobilizing Effects of UDP-Glucose—P2Y14 Purinergic Receptor Signaling Are Explained By Promoting Membrane Lipid Raft Formation to Optimize Hspcs' Responsiveness to Chemoattractants—a Potential Strategy to Optimize Hematopoietic Transplantation and Improve Transplant Outcomes
Kucine, N.
Kücüktas, F. M.
Kuczmarski, T. M.
Kudalkar, R.
Kudela, D.
Kuderer, N. M.
Kudo, K.
Kudryashova, O.
Kuebler, J.
Kuehn, J. C.
856 - Modulation of the Tumor Microenvironment By CCL19 in Primary CNS Lymphomas
1583 - Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid
4374 - The Effect of Ibrutinib on the Myeloid Cell Compartment in Central Nervous System Lymphoma Slice Cultures
1583 - Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid
4374 - The Effect of Ibrutinib on the Myeloid Cell Compartment in Central Nervous System Lymphoma Slice Cultures
Kuehne, T.
Kuelp, M.
Kufe, D.
Kufrin, V.
Kugler, E.
727 - Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features
837 - Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse
1427 - Evaluating the Safety of Tyrosine Kinase Inhibitor Discontinuation in Adult Patients with Ph+ ALL Not Undergoing Allogeneic Transplant
1472 - Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax
2857 - Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT-Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic Mastocytosis
2861 - Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission
3572 - Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax
4198 - A Phase I/II Study of Mini-Hyper-CVD, Venetoclax and Navitoclax in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
837 - Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse
1427 - Evaluating the Safety of Tyrosine Kinase Inhibitor Discontinuation in Adult Patients with Ph+ ALL Not Undergoing Allogeneic Transplant
1472 - Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax
2857 - Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT-Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic Mastocytosis
2861 - Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission
3572 - Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax
4198 - A Phase I/II Study of Mini-Hyper-CVD, Venetoclax and Navitoclax in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Kuhlman, W.
Kühn, M.
Kühn, M. W.
Kuhnl, A.
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
607 - Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT
2342 - Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK
3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications
607 - Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT
2342 - Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK
3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications
Kuhr, F.
Kui, N.
Kuiatse, I.
Kuijpers, T. W.
Kuiper, R. P.
Kuiper, R.
Kuipers, M. T.
93 - Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
1747 - Population-Based External Validation of the CAR-Hematotox Score to Predict CAR T Cell Related Toxicity and Outcome in R/R LBCL Patients
1747 - Population-Based External Validation of the CAR-Hematotox Score to Predict CAR T Cell Related Toxicity and Outcome in R/R LBCL Patients
Kujawa, T.
Kuker, R.
337 - Loncastuximab Tesirine with Rituximab Induces Robust and Durable Complete Metabolic Responses in High-Risk Relapsed/Refractory Follicular Lymphoma
1622 - Epcoritamab with R-CHOP Overcomes Poor Risk Features of High Total Metabolic Tumor Volume in High-Risk Large B-Cell Lymphoma
3032 - Limited Duration Loncastuximab Tesirine Induces a High Rate of Complete Responses in Patients with Relapsed/Refractory Marginal Zone Lymphoma - Report of First Planned Interim Futility Analysis of a Multicenter Phase II Study
4423 - Association of Body Composition Factors and Toxicity in Patients with Advanced Stage Hodgkin Lymphoma Receiving BV-AVD
1622 - Epcoritamab with R-CHOP Overcomes Poor Risk Features of High Total Metabolic Tumor Volume in High-Risk Large B-Cell Lymphoma
3032 - Limited Duration Loncastuximab Tesirine Induces a High Rate of Complete Responses in Patients with Relapsed/Refractory Marginal Zone Lymphoma - Report of First Planned Interim Futility Analysis of a Multicenter Phase II Study
4423 - Association of Body Composition Factors and Toxicity in Patients with Advanced Stage Hodgkin Lymphoma Receiving BV-AVD
Kukreti, V.
1606 - Shallow Whole Genome Sequencing of Circulating Tumor DNA Is Predictive of Outcome in Diffuse Large B-Cell Lymphoma
1695 - Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy
1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1954 - Analysis of Chip Mutations Pre-and Post-Transplant in Multiple Myeloma (MM): Expanded Results from a Prospective Longitudinal Study
1956 - Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies
2272 - Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada
2352 - Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance
3082 - Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis
3376 - Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)
3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada
3787 - Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin
4469 - Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy
4690 - Handgrip Strength – Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma
5134 - A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada
- Systems Based Hematology
1695 - Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy
1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1954 - Analysis of Chip Mutations Pre-and Post-Transplant in Multiple Myeloma (MM): Expanded Results from a Prospective Longitudinal Study
1956 - Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies
2272 - Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada
2352 - Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance
3082 - Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis
3376 - Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)
3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada
3787 - Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin
4469 - Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy
4690 - Handgrip Strength – Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma
5134 - A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada
- Systems Based Hematology
Kukuyan, A. M.
Kulagin, A.
Kulagin, A.
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
693 - No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
2182 - Analysis of Outcomes after Second Allogeneic Stem Cell Transplant in Relapsed Acute Myeloid Leukaemia in Children: A Study from the EBMT Pediatric Diseases Working Party
2190 - Peripheral Blood Stem Cell Versus Bone Marrow Graft for Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT
2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
3497 - Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)
4939 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
693 - No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT
2182 - Analysis of Outcomes after Second Allogeneic Stem Cell Transplant in Relapsed Acute Myeloid Leukaemia in Children: A Study from the EBMT Pediatric Diseases Working Party
2190 - Peripheral Blood Stem Cell Versus Bone Marrow Graft for Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT
2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
3497 - Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)
4939 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
Kulander, M.
Kulasekaran, M.
1265 - Cardiovascular Outcome of Heart Failure Patients with Iron Deficiency Anemia Who Received Iron Infusion Vs Red Blood Cell Transfusion: Analysis from a Nationwide Trinetx Database
3098 - Factors Associated with Palliative Care Utilization Among Patients with Post-Transplant Lymphoproliferative Disease. a Retrospective Analysis of the National Inpatient Sample Database
3098 - Factors Associated with Palliative Care Utilization Among Patients with Post-Transplant Lymphoproliferative Disease. a Retrospective Analysis of the National Inpatient Sample Database
Kulasekararaj, A. G.
33 - Dynamics of Oligoclonal Hematopoiesis in Severe Aplastic Anemia Patients Undergoing Immunosuppressive Treatment: Longitudinal Somatic Mutation Analysis from the EBMT Race Trial
301 - Treatment of Idiopathic Aplastic Anemia (AA) with Expanded Autologous Regulatory T Cells: The Tiara Phase One Trial
302 - Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study
305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
1313 - Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab
1323 - Phase III COMMODORE 2 and 1 Trials: Characterization of Breakthrough Hemolysis Events in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab or Eculizumab
1332 - A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41-Mutant Myeloid Neoplasia
2321 - The Association of Anemia and Patient Reported Outcomes in the New Era of PNH Treatment
2692 - Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial
3706 - The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry: Highlights of the Data from the First Three Years
4076 - Aplastic Anemia in the Elderly: Treatment Patterns and Outcomes from an International Observational Study
4078 - Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Ravulizumab
4079 - Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY-PNH and APPOINT-PNH Trials
4087 - The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Randomized Phase III APPLY-PNH Trial
301 - Treatment of Idiopathic Aplastic Anemia (AA) with Expanded Autologous Regulatory T Cells: The Tiara Phase One Trial
302 - Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study
305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
1313 - Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab
1323 - Phase III COMMODORE 2 and 1 Trials: Characterization of Breakthrough Hemolysis Events in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab or Eculizumab
1332 - A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41-Mutant Myeloid Neoplasia
2321 - The Association of Anemia and Patient Reported Outcomes in the New Era of PNH Treatment
2692 - Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial
3706 - The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry: Highlights of the Data from the First Three Years
4076 - Aplastic Anemia in the Elderly: Treatment Patterns and Outcomes from an International Observational Study
4078 - Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Ravulizumab
4079 - Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY-PNH and APPOINT-PNH Trials
4087 - The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Randomized Phase III APPLY-PNH Trial
Kulesha, A.
Kulidjian, A.
Kulkarni, P. P.
Kulkarni, R.
Kulkarni, S.
Kulkarni, S.
Kulkarni, U.
647 - Rationalization of Anti-PD-1 Therapy Using Receptor Occupancy Data to Guide Drug Dosing – a Single Arm Phase II Trial Using Immunomodulation in Relapsed/Refractory Hodgkin Lymphoma
1052 - Factor VIII Expression from a Novel F8 Transgene through a Lentiviral Vector Transduced CD34+ Autologous Hematopoietic Stem Cells for Gene Therapy of Severe Hemophilia Α: Final Results from a Phase 1 Clinical Trial
2090 - Safety, Efficacy and Total Cost of Therapy of Decentralized, Point-of-Care Manufactured Anti-CD19 CAR-T Cells for Relapsed or Refractory B Cell Leukemia and Lymphoma: Results from the First Phase 1 Indian Trial (VELCART)
2150 - Lower Mycophenolic Acid Exposure in Patients Undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide/ Cyclosporine a-Based GvHD Prophylaxis – Need for Dose Intensification
3048 - Dose Optimization of Check-Point Inhibitors: A Comparison of Standard Dose and Low Dose Nivolumab in Relapsed/Refractory Hodgkin Lymphoma
3078 - Impact of Consolidation Radiotherapy in Bulky Diffuse Large B Cell Lymphoma By PET Based Response Assessment
4879 - EASIXd0 Predicts Early Transplant-Related Mortality in Patients Undergoing Haploidentical Transplantation with Post-Transplant Cyclophosphamide-Mycophenolate Mofetil-Based GvHD Prophylaxis
3055.1 - Lonah Trial: A Phase III Randomized Study of Low Dose Nivolumab Plus AVD or ABVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
1052 - Factor VIII Expression from a Novel F8 Transgene through a Lentiviral Vector Transduced CD34+ Autologous Hematopoietic Stem Cells for Gene Therapy of Severe Hemophilia Α: Final Results from a Phase 1 Clinical Trial
2090 - Safety, Efficacy and Total Cost of Therapy of Decentralized, Point-of-Care Manufactured Anti-CD19 CAR-T Cells for Relapsed or Refractory B Cell Leukemia and Lymphoma: Results from the First Phase 1 Indian Trial (VELCART)
2150 - Lower Mycophenolic Acid Exposure in Patients Undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide/ Cyclosporine a-Based GvHD Prophylaxis – Need for Dose Intensification
3048 - Dose Optimization of Check-Point Inhibitors: A Comparison of Standard Dose and Low Dose Nivolumab in Relapsed/Refractory Hodgkin Lymphoma
3078 - Impact of Consolidation Radiotherapy in Bulky Diffuse Large B Cell Lymphoma By PET Based Response Assessment
4879 - EASIXd0 Predicts Early Transplant-Related Mortality in Patients Undergoing Haploidentical Transplantation with Post-Transplant Cyclophosphamide-Mycophenolate Mofetil-Based GvHD Prophylaxis
3055.1 - Lonah Trial: A Phase III Randomized Study of Low Dose Nivolumab Plus AVD or ABVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Kulke, M.
Kull, M.
708 - Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
1901 - Functional and Molecular Analyses Reveal Impaired HSPCs in Multiple Myeloma Patients Post-Induction
1901 - Functional and Molecular Analyses Reveal Impaired HSPCs in Multiple Myeloma Patients Post-Induction
Kulothungan, P.
Kulozik, A. E.
314 - Role of Stem-like Cells in Chemotherapy Resistance and Relapse in Pediatric T Cell Acute Lymphoblastic Leukemia (T-ALL)
730 - Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy
794 - uRADAR: European Patients Referral Frame to Improve Access to New Drugs and Therapies in Ultra-Rare Anemia Disorders and Severe Hereditary Spherocytosis
2194 - Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia
730 - Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy
794 - uRADAR: European Patients Referral Frame to Improve Access to New Drugs and Therapies in Ultra-Rare Anemia Disorders and Severe Hereditary Spherocytosis
2194 - Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia
Kulp, S. B.
Kulshrestha, A.
Kulzhanova, G.
Kuma, A. B. A.
Kumagai, T.
Kumagai, Y.
Kumar, A.
Kumar, A.
Kumar, A.
Kumar, A.
Kumar, A.
234 - A Single-Cell Atlas of Classical Mantle Cell Lymphoma Reveals Paired Tumor-Immune Malignant States Correlating with Prognosis
238 - Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis
340 - Single-Agent Mosunetuzumab Produces High Complete Response Rates in Patients with Newly Diagnosed Follicular Lymphoma: Primary Analysis of the Mithic-FL1 Trial
463 - Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma
569 - Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin
1010 - Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)
1707 - High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease
1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
2336 - Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
3053 - Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma
4346 - Molecular Features Are Associated with Disease Stage in Diffuse Large B-Cell Lymphoma and Reveal Heterogeneity in Patient Outcomes
4393 - Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma
4429 - Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis
4434 - Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
4451 - Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases
4474 - A Prospective Geriatric Assessment (GA) Study Predicting Toxicities in Older Adults (OA) with Non-Hodgkin Lymphoma (NHL): Timed up and Go Test (TUG) Time Emerges As a Functional Vital Sign
4485 - Sequential R-CHOP/(R)-ICE and Dose-Adjusted EPOCH-R Are Both Appropriate Frontline Treatments for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Retrospective Analysis
5097 - Impact of Novel Therapies (NTs) on Real-World (RW) Clinical Outcomes of Patients (pts) with Relapsed/Refractory (RR) Mantle-Cell Lymphoma (MCL) By Race/Ethnicity and TP53 Mutation Status
238 - Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis
340 - Single-Agent Mosunetuzumab Produces High Complete Response Rates in Patients with Newly Diagnosed Follicular Lymphoma: Primary Analysis of the Mithic-FL1 Trial
463 - Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma
569 - Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin
1010 - Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)
1707 - High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease
1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
2336 - Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
3053 - Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma
4346 - Molecular Features Are Associated with Disease Stage in Diffuse Large B-Cell Lymphoma and Reveal Heterogeneity in Patient Outcomes
4393 - Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma
4429 - Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis
4434 - Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
4451 - Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases
4474 - A Prospective Geriatric Assessment (GA) Study Predicting Toxicities in Older Adults (OA) with Non-Hodgkin Lymphoma (NHL): Timed up and Go Test (TUG) Time Emerges As a Functional Vital Sign
4485 - Sequential R-CHOP/(R)-ICE and Dose-Adjusted EPOCH-R Are Both Appropriate Frontline Treatments for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Retrospective Analysis
5097 - Impact of Novel Therapies (NTs) on Real-World (RW) Clinical Outcomes of Patients (pts) with Relapsed/Refractory (RR) Mantle-Cell Lymphoma (MCL) By Race/Ethnicity and TP53 Mutation Status
Kumar, A. J.
Kumar, A.
Kumar, A. D.
2083 - Late Polyclonal P-BCMA-101 CAR-T Cell Re-Expansion and Rapid Complete Response in a Patient with Relapsed Multiple Myeloma Treated with One Cycle of Talquetamab, More Than 3 Years after CAR-T Infusion
2397 - Real Word Autologous Transplant Utilization and Outcomes By Race and Ethnicity
4712 - Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience
4758 - Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry
2397 - Real Word Autologous Transplant Utilization and Outcomes By Race and Ethnicity
4712 - Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience
4758 - Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry
Kumar, A.
Kumar, B.
Kumar, E. A.
Kumar, H.
Kumar, J.
3028 - Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety Outcomes for Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for the Treatment of Third-Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
3651 - Cost Consequence and Time Toxicity Model for the Treatment of Third-Line or Later (3L+) Follicular Lymphoma (FL) Using Advanced Therapies: A Comparison of Lisocabtagene Maraleucel (liso-cel) with Mosunetuzumab
4387 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up
3651 - Cost Consequence and Time Toxicity Model for the Treatment of Third-Line or Later (3L+) Follicular Lymphoma (FL) Using Advanced Therapies: A Comparison of Lisocabtagene Maraleucel (liso-cel) with Mosunetuzumab
4387 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up
Kumar, K.
Kumar, P.
Kumar, R.
687 - Survival and Engraftment Post Allogeneic Hematopoietic Stem Cell Transplantation: ABO Mismatch Matters in RIC
2151 - The Effect of Smoking and Pre-Transplant Pulmonary Comorbidity on the Incidence of Lung Graft Versus Host Disease and Post Transplant Outcomes
2183 - Expanding the Donor Pool, the Number of Antigen Mismatches Has No Impact in the Outcomes of Haploidentical Stem Cell Transplantation with Peripheral Blood Stem Cells and Dual T Cell Depletion
3938 - Randomised Controlled Trial of High Dose Dexamethasone and Methylprednisolone in Immune Thrombocytopenia (HDMI Trial)
4863 - Strength to Endure: Superiority of MAC over RIC in Patients <65 Years Undergoing Stem Cell Transplantation Using ATG-Ptcy-CSA for Gvhd Prophylaxis
4865 - Haploidentical and Mismatched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Cohort Study
4883 - Tolerability and Efficacy of Post-Transplant Cyclophosphamide in Older Adults Undergoing Matched Sibling Donor Allogeneic Transplantation: A Retrospective Analysis
4896 - Monocytes Matter: Impact of Monocyte Recovery on Allogeneic Hematopoietic Stem Cell Transplant Outcomes with Post-Transplantation Cyclophosphamide As Graft Versus Host Disease Prophylaxis
4899 - Identification of High-Risk Patients and Establishment of a Clinical Prediction Model for Frontline Steroid Failure in Chronic Graft-Versus-Host-Disease
2151 - The Effect of Smoking and Pre-Transplant Pulmonary Comorbidity on the Incidence of Lung Graft Versus Host Disease and Post Transplant Outcomes
2183 - Expanding the Donor Pool, the Number of Antigen Mismatches Has No Impact in the Outcomes of Haploidentical Stem Cell Transplantation with Peripheral Blood Stem Cells and Dual T Cell Depletion
3938 - Randomised Controlled Trial of High Dose Dexamethasone and Methylprednisolone in Immune Thrombocytopenia (HDMI Trial)
4863 - Strength to Endure: Superiority of MAC over RIC in Patients <65 Years Undergoing Stem Cell Transplantation Using ATG-Ptcy-CSA for Gvhd Prophylaxis
4865 - Haploidentical and Mismatched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Cohort Study
4883 - Tolerability and Efficacy of Post-Transplant Cyclophosphamide in Older Adults Undergoing Matched Sibling Donor Allogeneic Transplantation: A Retrospective Analysis
4896 - Monocytes Matter: Impact of Monocyte Recovery on Allogeneic Hematopoietic Stem Cell Transplant Outcomes with Post-Transplantation Cyclophosphamide As Graft Versus Host Disease Prophylaxis
4899 - Identification of High-Risk Patients and Establishment of a Clinical Prediction Model for Frontline Steroid Failure in Chronic Graft-Versus-Host-Disease
Kumar, R.
Kumar, R.
Kumar, R.
Kumar, S. S.
Kumar, S.
81 - 24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702
83 - Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma
249 - Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax
287 - Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
784 - Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience
1880 - Single-Cell Spatial Proteomic Characterization of Clonal Plasma Cell and Immune Cell Metabolism within the Bone Marrow Microenvironment in High-Risk Smoldering Multiple Myeloma and Its Association with Progression to Multiple Myeloma
1916 - MGUS Prevalence in Special Populations: Insights from a Large-Scale Community Study from Rural India (IMAGe-002B Study)
1945 - Development of a Three-Gene-Based Proliferation Score (3GPS) to Predict Proliferation Index in Newly Diagnosed Multiple Myeloma
1951 - Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry
1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease
1972 - Initial Results from the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
1985 - A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
1994 - Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
2372 - Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy
2393 - Feasibility and Implementation of the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
2400 - Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
2744 - The Mutational Landscape of Extramedullary Multiple Myeloma Reveals Novel Biologic Insights and Potential Therapeutic Targets for Exploration
3263 - Preclinical Development of a Novel Pan-RAS Inhibitor Against Relapsed/Refractory Multiple Myeloma
3305 - Proteomic Determinants of Renal Organ Response in AL Amyloidosis
3308 - Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients
3319 - A Comparative Study of Plasma Cell Detection By Peripheral Smear and Peripheral Blood Flow Cytometry
3340 - Presence of Circulating Tumor Cells on Peripheral Blood Flow Cytometry at Best Response Predicts Overall Survival in Multiple Myeloma
3770 - Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study – Interim Results
3792e - Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network
3996 - Platelet-Activating Anti-PF4 Antibodies in MGUS Patients with Thrombosis
4635 - The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma
4695 - Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma
4711 - Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma
4716 - Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
4732 - Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study
5047 - Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)
4757.1 - Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1–4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody
- What Is the Ideal Approach – Doublet, Triplet or Quadruplet(s)?
- Pushing Data Frontiers: How Artificial Intelligence and Molecular Data can Facilitate Translational Research in the Network
83 - Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma
249 - Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax
287 - Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy
592 - Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
784 - Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience
1880 - Single-Cell Spatial Proteomic Characterization of Clonal Plasma Cell and Immune Cell Metabolism within the Bone Marrow Microenvironment in High-Risk Smoldering Multiple Myeloma and Its Association with Progression to Multiple Myeloma
1916 - MGUS Prevalence in Special Populations: Insights from a Large-Scale Community Study from Rural India (IMAGe-002B Study)
1945 - Development of a Three-Gene-Based Proliferation Score (3GPS) to Predict Proliferation Index in Newly Diagnosed Multiple Myeloma
1951 - Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry
1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease
1972 - Initial Results from the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
1985 - A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
1994 - Exposure-Response (ER) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Optimal Step-up Dose (SUD) Selection to Improve Cytokine Release Syndrome (CRS) Safety Profile of Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
2372 - Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy
2393 - Feasibility and Implementation of the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
2400 - Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
2744 - The Mutational Landscape of Extramedullary Multiple Myeloma Reveals Novel Biologic Insights and Potential Therapeutic Targets for Exploration
3263 - Preclinical Development of a Novel Pan-RAS Inhibitor Against Relapsed/Refractory Multiple Myeloma
3305 - Proteomic Determinants of Renal Organ Response in AL Amyloidosis
3308 - Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients
3319 - A Comparative Study of Plasma Cell Detection By Peripheral Smear and Peripheral Blood Flow Cytometry
3340 - Presence of Circulating Tumor Cells on Peripheral Blood Flow Cytometry at Best Response Predicts Overall Survival in Multiple Myeloma
3770 - Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study – Interim Results
3792e - Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network
3996 - Platelet-Activating Anti-PF4 Antibodies in MGUS Patients with Thrombosis
4635 - The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma
4695 - Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma
4711 - Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma
4716 - Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
4732 - Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study
5047 - Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)
4757.1 - Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1–4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody
- What Is the Ideal Approach – Doublet, Triplet or Quadruplet(s)?
- Pushing Data Frontiers: How Artificial Intelligence and Molecular Data can Facilitate Translational Research in the Network
Kumar, S.
Kumar, S.
Kumar, S.
Kumar, S.
Kumar, S.
Kumar, S.
Kumar, S.
Kumar, S.
Kumar, V.
Kumar, V.
Kumar, V.
Kumaran, M. V.
280 - Strategies to Optimize Overutilization of Provider-Ordered Peripheral Blood Smear Review in an University Hospital Setting
523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
2402 - Impact of Social Vulnerability Index and Travel Distance on Access to Chimeric Antigen Receptor T-Cell Therapy
3074 - Cutaneous Involvement By Peripheral T-Cell Lymphoma: Incidence, Characteristics, Treatment Trends, and Outcomes in the United States (2000-2021)
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
2402 - Impact of Social Vulnerability Index and Travel Distance on Access to Chimeric Antigen Receptor T-Cell Therapy
3074 - Cutaneous Involvement By Peripheral T-Cell Lymphoma: Incidence, Characteristics, Treatment Trends, and Outcomes in the United States (2000-2021)
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
Kumari, N.
1617 - Golcadomide Extends Survival of Lymphoma GEMM Mice in Combination with a CD20xCD3 T-Cell Bispecific through Increased T-Cell Activation and Infiltration
2523 - Degradation of Ikaros Induces Neutropenia through Altered Transcriptional Programming across Multiple Stages of Neutrophil Development and Maturation
2523 - Degradation of Ikaros Induces Neutropenia through Altered Transcriptional Programming across Multiple Stages of Neutrophil Development and Maturation
Kumari, R.
Kumari, R.
Kume, K.
45 - Cell Growth Trajectories of B-Cell Lymphomas Are Defined By Oscillations between MYC- and BCL6-Dependent States
632 - PKCδ-Mediated Phosphorylation of CD25 Initiates Feedback Control of Oncogenic Tyrosine Kinases in Acute Lymphoblastic Leukemia
3003 - Mechanism of Negative Feedback Regulation of Oncogenic BCR-Signaling in Mature B-Cell Lymphoma
4125 - Identification of High-Efficiency β-Catenin Protein Degradation As Critical Vulnerability in B-Cell Malignancies
4164 - Identification of Nuclear NAD+ Salvage As a Therapeutic Vulnerability in B-Lymphoid Malignancies
632 - PKCδ-Mediated Phosphorylation of CD25 Initiates Feedback Control of Oncogenic Tyrosine Kinases in Acute Lymphoblastic Leukemia
3003 - Mechanism of Negative Feedback Regulation of Oncogenic BCR-Signaling in Mature B-Cell Lymphoma
4125 - Identification of High-Efficiency β-Catenin Protein Degradation As Critical Vulnerability in B-Cell Malignancies
4164 - Identification of Nuclear NAD+ Salvage As a Therapeutic Vulnerability in B-Lymphoid Malignancies
Kummer, S.
Kumode, T.
867 - Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
4475 - A Multicenter, Prospective, Observational Study of Pola-R-CHP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (POLASTAR): A Preliminary Analysis
4475 - A Multicenter, Prospective, Observational Study of Pola-R-CHP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (POLASTAR): A Preliminary Analysis
Kumskova, M.
Kumta, J.
Kumwenda, P.
Kunadt, D.
776 - Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation
2948 - HLA‑DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD
3392 - FLT3-ITD Driven CMTM6 Expression Contributes to Immune Escape of Acute Myeloid Leukemia
2948 - HLA‑DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD
3392 - FLT3-ITD Driven CMTM6 Expression Contributes to Immune Escape of Acute Myeloid Leukemia
Kundaje, A.
Kunden, R.
Kundrat, D.
Kundu, N.
Kundu, R.
1477 - Epidemiological Trends in Incidence, Death and Associated Risk Factors of Leukemia 1990-2021 and Projection to 2040
1969 - Epidemiological Trends in Incidence, Death and Associated Risk Factors of Multiple Myeloma 1990-2021 and Projection to 2040
5059 - Analysis of Factors Influencing Enrollment Success in Hematology Malignancy Cancer Clinical Trials (2008-2023)
1969 - Epidemiological Trends in Incidence, Death and Associated Risk Factors of Multiple Myeloma 1990-2021 and Projection to 2040
5059 - Analysis of Factors Influencing Enrollment Success in Hematology Malignancy Cancer Clinical Trials (2008-2023)
Kunes, R.
Kunhipurayil, S.
Kunieda, H.
Kunihiro, C.
Kunimoto, H.
Kunisada, K.
Kunisaki, Y.
Künkele-Langer, A.
Kuno, M.
2162 - Novel Insights into Predictors, Optimized Treatments, and Prognosis Factors for Virus-Induced Hemorrhagic Cystitis Post-Hematopoietic Stem Cell Transplantation: A Single-Institution Study of 427 Japanese Patients
2189 - Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL
3485 - What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes
3508 - Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation
4920 - Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status
2189 - Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL
3485 - What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes
3508 - Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation
4920 - Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status
Künstner, A.
631 - IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
1348 - CSF3RT618I Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL)
1348 - CSF3RT618I Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL)
Künstner, A.
Kunz, J. B.
Künzl, S.
Kuo, D. J.
Kuo, K. H.
409 - ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia
512 - Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
1118 - The Utility of Maternal Placental Growth Factor (PlGF) for Prediction of Pre-Eclampsia in Pregnancies Complicated By Sickle Cell Disease
2475 - Improvement of Iron Overload Parameters in Patients with Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Data from the Phase 3b Long-Term Rollover Study Following the BELIEVE Trial
2509 - Evaluating the Effect of Hydroxyurea on Fertility in Individuals Identifying As Women
3696 - Clinical Monitoring Practices Among Adult Patients with Pyruvate Kinase Deficiency Who Have Never Been Transfused
3831 - Satisfy: A Eurobloodnet Multicenter, Single-Arm Phase 2 Trial of Mitapivat in Adult Patients with Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II – Results from the 8-Week Dose-Escalation Period
4954 - Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease
5068 - Validitation of the Rowland Universal Dementia Assessment Scale (RUDAS) for the Detection of Cognitive Impairment Among Adults with Sickle Cell Disease
512 - Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
1118 - The Utility of Maternal Placental Growth Factor (PlGF) for Prediction of Pre-Eclampsia in Pregnancies Complicated By Sickle Cell Disease
2475 - Improvement of Iron Overload Parameters in Patients with Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Data from the Phase 3b Long-Term Rollover Study Following the BELIEVE Trial
2509 - Evaluating the Effect of Hydroxyurea on Fertility in Individuals Identifying As Women
3696 - Clinical Monitoring Practices Among Adult Patients with Pyruvate Kinase Deficiency Who Have Never Been Transfused
3831 - Satisfy: A Eurobloodnet Multicenter, Single-Arm Phase 2 Trial of Mitapivat in Adult Patients with Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II – Results from the 8-Week Dose-Escalation Period
4954 - Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease
5068 - Validitation of the Rowland Universal Dementia Assessment Scale (RUDAS) for the Detection of Cognitive Impairment Among Adults with Sickle Cell Disease
Kuo, M. C.
Kupcova, K.
Kupesiz, O. A.
2136 - Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
2184 - Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party
2184 - Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party
Kupf, S.
Kupfer, G. M.
Kurasawa, M.
Kuriakose, P.
Kurian, B.
Kurian, S.
Kurita, N.
Kurlander, J. E.
Kurlapski, M.
Kurniawan, N.
Kurnick, M.
Kuroda, J.
338 - Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study
4178 - The Anti-Myeloma Efficacy of TAS0612, a Triple Inhibitor of RSK, AKT, and S6K, and Itssynergistic Combination with Venetoclax in Multiple Myeloma Irrespective of Cytogeneticabnormalities
4472 - Trends and Outcomes of Hematopoietic Stem Cell Transplantation for Malignant Lymphoma in Japan between 2006 and 2021
4743 - MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
4178 - The Anti-Myeloma Efficacy of TAS0612, a Triple Inhibitor of RSK, AKT, and S6K, and Itssynergistic Combination with Venetoclax in Multiple Myeloma Irrespective of Cytogeneticabnormalities
4472 - Trends and Outcomes of Hematopoietic Stem Cell Transplantation for Malignant Lymphoma in Japan between 2006 and 2021
4743 - MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Kuroda, Y.
Kurokawa, M.
Kurokawa, M.
Kuroki, A.
Kurosawa, S.
Kurowska, A.
Kurowska-Stolarska, M.
Kurre, P.
168 - TNFα Plays Essential Role in Resolution of Anemia of Inflammation in Tnfαko Mice Treated with Heat-Killed Brucella Abortus
2021 - CCR2 Cooperatively Regulates Hematopoietic Stem Cell Homing to the Bone Marrow
2202 - In Utero mRNA Lipid Nanoparticle Delivery in a Murine Model of Fanconi Anemia
2691 - Outcomes of Immunosuppressive Therapy in Children Less Than Three Years of Age with Idiopathic Severe Aplastic Anemia: A North American Collaboration
4069 - Metabolic Rewiring of AML-Experienced Hematopoietic Stem and Progenitor Cells
2021 - CCR2 Cooperatively Regulates Hematopoietic Stem Cell Homing to the Bone Marrow
2202 - In Utero mRNA Lipid Nanoparticle Delivery in a Murine Model of Fanconi Anemia
2691 - Outcomes of Immunosuppressive Therapy in Children Less Than Three Years of Age with Idiopathic Severe Aplastic Anemia: A North American Collaboration
4069 - Metabolic Rewiring of AML-Experienced Hematopoietic Stem and Progenitor Cells
Kurth, E.
Kurtoglu, M.
Kurtova, A.
Kurtz, D.
72 - Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study
96 - Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
565 - Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma
648 - Non-Invasive Characterization and Early Detection of Post-Transplant Lymphoproliferative Disorders
651 - Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL
853 - Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling
1583 - Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid
2223 - Direct Method for Estimating the Fraction of T and B/Plasma Cell-Derived DNA
2955 - Circulating Tumor DNA (ctDNA) Enables Superior and Universal Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) Highly Predictive of Relapse Free and Overall Survival
3410 - Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study
4357 - Anatomic Genetic Heterogeneity Is Uncovered By Concurrent Cell-Free DNA and Tissue Profiling and Predicts Treatment Resistance in Diffuse Large B-Cell Lymphoma
4846 - Indolent CD8+ CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma
96 - Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
565 - Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma
648 - Non-Invasive Characterization and Early Detection of Post-Transplant Lymphoproliferative Disorders
651 - Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL
853 - Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling
1583 - Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid
2223 - Direct Method for Estimating the Fraction of T and B/Plasma Cell-Derived DNA
2955 - Circulating Tumor DNA (ctDNA) Enables Superior and Universal Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) Highly Predictive of Relapse Free and Overall Survival
3410 - Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study
4357 - Anatomic Genetic Heterogeneity Is Uncovered By Concurrent Cell-Free DNA and Tissue Profiling and Predicts Treatment Resistance in Diffuse Large B-Cell Lymphoma
4846 - Indolent CD8+ CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma
Kurtz, J.
Kurtz, S. E.
62 - Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML
271 - Mapping the Drug Combination Landscape for AML: An Integrative Ex Vivo Functional and Computational Approach
1498 - Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients
1566 - Combination with Palbociclib Overcomes Venetoclax Resistance Mechanisms and Outperforms Single Agent Efficacy in Acute Myeloid Leukemia
271 - Mapping the Drug Combination Landscape for AML: An Integrative Ex Vivo Functional and Computational Approach
1498 - Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients
1566 - Combination with Palbociclib Overcomes Venetoclax Resistance Mechanisms and Outperforms Single Agent Efficacy in Acute Myeloid Leukemia
Kurtzberg, J.
Kurup, A. R.
Kuruvilla, J.
1411 - Investigating the Metabolic Underpinnings of Venetoclax Resistance in DLBCL
1606 - Shallow Whole Genome Sequencing of Circulating Tumor DNA Is Predictive of Outcome in Diffuse Large B-Cell Lymphoma
1645 - Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II
1646 - Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma
1695 - Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy
2272 - Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada
2352 - Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance
3082 - Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis
3092 - Outcomes and Predictors of Survival for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Large Population-Based Analysis
3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada
4179 - Metabolic and Cell Cycle Proteins As Novel Targets of Selinexor Activity in Diffuse Large B Cell Lymphoma
4385 - Multiome Single Cell Analyses Identify a Distinct CD8+ T Cell Phenotype Linked to Treatment Response in PTLD
4387 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up
4407 - Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study
4469 - Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy
5134 - A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada
1606 - Shallow Whole Genome Sequencing of Circulating Tumor DNA Is Predictive of Outcome in Diffuse Large B-Cell Lymphoma
1645 - Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II
1646 - Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma
1695 - Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy
2272 - Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada
2352 - Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance
3082 - Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis
3092 - Outcomes and Predictors of Survival for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Large Population-Based Analysis
3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada
4179 - Metabolic and Cell Cycle Proteins As Novel Targets of Selinexor Activity in Diffuse Large B Cell Lymphoma
4385 - Multiome Single Cell Analyses Identify a Distinct CD8+ T Cell Phenotype Linked to Treatment Response in PTLD
4387 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up
4407 - Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study
4469 - Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy
5134 - A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada
Kurzhals, A.
Kusch, C.
Kushner, J.
Kusne, Y.
440 - Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome
2686 - DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality
2771 - Preclinical Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Chronic Myelomonocytic Leukemia
3183 - Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41MT Germline Predisposition Syndrome
3218 - PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations
- Therapy Related Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome
2686 - DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality
2771 - Preclinical Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Chronic Myelomonocytic Leukemia
3183 - Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41MT Germline Predisposition Syndrome
3218 - PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations
- Therapy Related Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome
Kuster, B.
Kusuda, M.
Kusurkar, S.
Kuter, D. J.
5 - Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)
710 - A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3
2552 - Improved Health-Related quality of Life (HRQoL) with Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib Vs Placebo in Adults with Previously Treated Immune Thrombocytopenia (ITP): Phase 3 Luna 3 Multicenter Study
2562 - Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-Fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-Mediated Diseases
3836 - Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study
3944 - Clinical Burden of Illness in Patients with Persistent or Chronic Primary Immune Thrombocytopenia Treated with Advanced Therapies in the United States
710 - A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3
2552 - Improved Health-Related quality of Life (HRQoL) with Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib Vs Placebo in Adults with Previously Treated Immune Thrombocytopenia (ITP): Phase 3 Luna 3 Multicenter Study
2562 - Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-Fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-Mediated Diseases
3836 - Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study
3944 - Clinical Burden of Illness in Patients with Persistent or Chronic Primary Immune Thrombocytopenia Treated with Advanced Therapies in the United States
Kutilina, A.
Kutlar, A.
Kutluk, T.
Kutner, N.
Kutny, M. A.
967 - A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group
4233 - Molecular Features, Treatments and Outcomes for Pediatric AML Patients from APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial
4233 - Molecular Features, Treatments and Outcomes for Pediatric AML Patients from APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial
Kutsch, N.
1714 - Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL
1859 - Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial
3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial
1859 - Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial
3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial
Kutyna, M.
1304 - Impact of Chronic Inflammation and Cytotoxic Therapy on Bone Marrow Microenvironment of Patients with Autoimmune Rheumatic Diseases and Myeloid Neoplasms
1817 - High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine
3196 - CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4596 - Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure
4928 - Clonal Architecture of Donor-Derived Leukemia/Clonal Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplant
1817 - High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine
3196 - CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4596 - Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure
4928 - Clonal Architecture of Donor-Derived Leukemia/Clonal Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplant
Kuusanmäki, H.
329 - Genomic Subtypes of AML Define Sensitivity to NK Cell Cytotoxicity
1560 - Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia
2757 - Integrative Analysis of Transcriptomic and Proteomic Data Identifies Patterns of Primary Resistance to Venetoclax-Azacitidine and Reveals Targetable Vulnerabilities in Acute Myeloid Leukemia (AML)
4320 - Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML
1560 - Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia
2757 - Integrative Analysis of Transcriptomic and Proteomic Data Identifies Patterns of Primary Resistance to Venetoclax-Azacitidine and Reveals Targetable Vulnerabilities in Acute Myeloid Leukemia (AML)
4320 - Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML
Kuwatsuka, Y.
2121 - Kinetics of Recipients with Thrombocytopenia and Its Impact on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study
2588 - Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors: 96-Week Interim Analysis of the AKATSUKI Study
2588 - Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors: 96-Week Interim Analysis of the AKATSUKI Study
Kuykendall, A. T.
245 - Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
481 - A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia
998 - Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF)
1004 - CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?
1046 - Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes
1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
1520 - A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2415 - Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience
3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis
3215 - Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies
3217 - Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes
3228 - IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)
3804 - Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States
4270 - Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
4332 - Prospective Evaluation of the Impact of Measurable Residual Disease (MRD) By Error Corrected Next-Generation Sequencing (NGS) with CPX-351 in Acute Myeloid Leukemia (AML)
4559 - Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
4561 - Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes
4578 - Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin
4589 - The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS
5190 - Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas
1808.2 - POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
3147.1 - A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)
4569.2 - A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm
481 - A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia
998 - Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF)
1004 - CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?
1046 - Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes
1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
1520 - A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2415 - Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience
3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis
3215 - Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies
3217 - Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes
3228 - IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)
3804 - Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States
4270 - Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
4332 - Prospective Evaluation of the Impact of Measurable Residual Disease (MRD) By Error Corrected Next-Generation Sequencing (NGS) with CPX-351 in Acute Myeloid Leukemia (AML)
4559 - Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
4561 - Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes
4578 - Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin
4589 - The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS
5190 - Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas
1808.2 - POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
3147.1 - A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)
4569.2 - A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm
Kuypers, N.
Kuzma, M.
Kuznetsov, S.
Kuznetsova, A.
Kuznetsova, E.
Kuznetsova, O.
Kuznicki, L.
Kwag, D.
4220 - Impact of Concurrent IKZF1 and CDKN2 Deletions on Prognostic Outcomes in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation
4892 - Feasibility of TBI-Augmented Reduced Toxicity Conditioning Regimen with ATG/Ptcy Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia
4892 - Feasibility of TBI-Augmented Reduced Toxicity Conditioning Regimen with ATG/Ptcy Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia
Kwak, J. Y.
1636 - Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry
3101 - Durability of Complete Responses in Patients from the ECHELON-3 Study
3101 - Durability of Complete Responses in Patients from the ECHELON-3 Study
Kwak, J. E.
Kwak, L. W.
3127 - Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease
1742.1 - A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
1742.1 - A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Kwak, T.
Kwan, A.
1645 - Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II
1646 - Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma
4407 - Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study
1646 - Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma
4407 - Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study
Kwang, A.
Kwiatek, M.
4411 - Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study
1742.2 - Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma
1742.2 - Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma
Kwiatkowski, J. L.
511 - An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel
512 - Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
1064 - Defining the Impacts of Iron Overload in Children Receiving Hematopoietic Stem Cell Transplantation for Non-Malignant Hematologic Disorders: A Multicenter Analysis
2194 - Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia
2504 - Hydroxyurea Initiation and Occurrence of Cerebrovascular Outcomes in Sickle Cell Disease
- Hematopoietic Cell Transplantation Versus Gene Therapy for Hemoglobinopathies
512 - Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
1064 - Defining the Impacts of Iron Overload in Children Receiving Hematopoietic Stem Cell Transplantation for Non-Malignant Hematologic Disorders: A Multicenter Analysis
2194 - Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia
2504 - Hydroxyurea Initiation and Occurrence of Cerebrovascular Outcomes in Sickle Cell Disease
- Hematopoietic Cell Transplantation Versus Gene Therapy for Hemoglobinopathies
Kwiatkowsky, L.
3756 - Symptoms Detection Among Patients with Lymphoid Malignancies (LM) Using Electronic Patient-Reported Outcomes (ePROs) in Community Hematology-Oncology Clinics
5046 - Electronic Patient-Reported Outcome (ePRO) Symptom Monitoring for Relapsed/Refractory Multiple Myeloma in Community Settings, Focusing on Bispecific Antibody Therapy
5046 - Electronic Patient-Reported Outcome (ePRO) Symptom Monitoring for Relapsed/Refractory Multiple Myeloma in Community Settings, Focusing on Bispecific Antibody Therapy
Kwok, C.
Kwok, M.
Kwok, M.
Kwok, T. H.
Kwon, D.
Kwon, M.
67 - Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update
471 - Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients
2044 - Molecular Tumor Burden and Clonal Evolution As Factors Associated with Early Progression in Large B-Cell Lymphomas Treated with CAR-T Therapy
2113 - Predictive Value of Liver Sitffness Measurement for Early Diagnosis of Veno-Occlusive Disease and Final Stem-Cell Outcomes
2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
3414 - Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate
3565 - Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)
4872 - At-Home Allogeneic Stem Cell Transplantation: A Single Centre Experience
4889 - Outcomes of Allogeneic Transplantation with Clofarabine and Post-Transplant Cyclophosphamide-Based Conditioning in Patients with Very High-Risk Acute Myeloid Leukemia
4942 - Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party
471 - Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients
2044 - Molecular Tumor Burden and Clonal Evolution As Factors Associated with Early Progression in Large B-Cell Lymphomas Treated with CAR-T Therapy
2113 - Predictive Value of Liver Sitffness Measurement for Early Diagnosis of Veno-Occlusive Disease and Final Stem-Cell Outcomes
2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
3414 - Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate
3565 - Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)
4872 - At-Home Allogeneic Stem Cell Transplantation: A Single Centre Experience
4889 - Outcomes of Allogeneic Transplantation with Clofarabine and Post-Transplant Cyclophosphamide-Based Conditioning in Patients with Very High-Risk Acute Myeloid Leukemia
4942 - Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party
Kwon, M. C.
Kwon, O.
Kwon, S. S.
Kwong, Y. L.
3678 - Modified Delphi Process to Develop Best Practice Recommendations for Myelofibrosis Management in Routine Clinical Practice in the Asia-Pacific Region (The APAC-MF Alliance)
4444 - A Phase II Prospective Study Evaluating an L-Asparaginase Regimen, Simple, in Newly Diagnosed Extranodal NK/T Cell Lymphoma
4444 - A Phase II Prospective Study Evaluating an L-Asparaginase Regimen, Simple, in Newly Diagnosed Extranodal NK/T Cell Lymphoma
Ky, B.
698 - Late Venous Thromboembolic Events in Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort Study
967 - A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group
967 - A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group
Kyasa, S. B.
Kyle, R. A.
83 - Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma
1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease
3315 - Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma
1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease
3315 - Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma
Kyman, S.
Kyogoku, Y.
Kyriakakis, G.
Kyriakidis, G.
Kyriakopoulou, D.
Kyriakou, C.
749 - Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
1654 - Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical
1960 - Automated Body Composition Analyses Reveal Significant Associations with Mortality in Myeloma Patients Following Immunotherapy with Bispecific Antibodies
3023 - Focal Symptomatic Bone Involvement with Waldenström’s Macroglobulinaemia and Non-IgM Lymphoplasmacytic Lymphoma
3027 - Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
1654 - Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical
1960 - Automated Body Composition Analyses Reveal Significant Associations with Mortality in Myeloma Patients Following Immunotherapy with Bispecific Antibodies
3023 - Focal Symptomatic Bone Involvement with Waldenström’s Macroglobulinaemia and Non-IgM Lymphoplasmacytic Lymphoma
3027 - Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Kyriakou, C.
Kyrou, D.
Kyrtsonis, M. C.
Kytölä, S.
2757 - Integrative Analysis of Transcriptomic and Proteomic Data Identifies Patterns of Primary Resistance to Venetoclax-Azacitidine and Reveals Targetable Vulnerabilities in Acute Myeloid Leukemia (AML)
4320 - Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML
4320 - Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML
Kyvsgaard, E. R.